

國立台灣大學生物資源暨農業學院動物科學技術學系

碩士論文

Department of Animal Science and Technology  
College of Bioresources and Agriculture

National Taiwan University

Master thesis

探討冬蟲夏草菌絲體於硫代乙醯胺誘導肝損傷下護肝功效

Hepatoprotection of *Ophiocordyceps sinensis* mycelium

against thioacetamide-induced liver fibrosis

吳奕賢

Samuel Yi-Hsieng Wu

指導教授：陳億乘 博士

邱智賢 博士

Advisor: Yi-Chen Chen, Ph.D.


Chih-Hsien Chiu, Ph.D.

中華民國一百零三年八月

August, 2014








## 謝誌

本試驗的進行首先要感謝泰宗生技股份有限公司，在計畫經費和原料上的幫助。沒有這些樣本原料的前備作業，這個研究是沒有辦法進行的。另外，也期待他們能夠參考此研究之結果，進一步開發助益人類健康的相關產品。

碩士班一路走來，旁人看似崎嶇辛苦的路途，但是我卻由衷的感謝 神讓我充分的學習到寶貴的人生功課。一張文憑，對某些人來說是一個謀生的工具，或是飛向未來夢想的魔毯；對我而言，它是記錄了我人生經歷的相簿。碩士班期間我學到謙卑、忍耐、負責任的人生道理，也嘗試對人用愛心說誠實話，發自內心的去關心並教導學弟妹，我認為這些都是大學部時沒有想過的。另外最重要的，就是訓練自我的毅力，這對從小就善於放棄的我是一個相當的突破，不論是要額外找家教、深夜趕實驗等等，雖然最後結果並不是盡善盡美，我靠著那加給我力量的主，堅持到最後了！當然，我絕對不是獨自一人度過這些種種難關，所以我要在這裡向這些人表達我微不足道的敬意和感謝。有些人滿在意謝誌的順序，但是學生只是將相近的內容分段書寫，大家就饒了我吧！

首先，我要感謝的是從大學部一來栽培我的邱智賢老師，以及在碩士班中給我許多學習機會的陳億乘老師。兩位老師著實是帶著提攜後輩的熱誠來教導我，不但對於未來方向的規劃慷慨地分享自身經驗，在各樣事物中重點式的訓練讓我受益良多，學術研究上，做事情的方法、實驗室管理等等，老師們貫徹為人勤奮、精明、認分的指導原則。更感謝的是，兩位老師更是體諒我的家庭狀況，常常在各方面幫補許多。能夠遇見兩位老師，我相信這是上帝給我的祝福。另外，我特別要感謝系上的劉逸軒老師，因為老師給我上了一堂很重要的人生課程，讓我能夠尋回正確的學習態度，才不至於成為社會中想像有名無實、自我感覺良好的台大學生。當然，系上每位師長都是對我呵護備至，你們的鼓勵和教訓我都一一銘記在心，但篇幅有限，在此聊表心意，還望師長們不要責怪。

接下來我要感謝曾經陪伴和幫助我的所有學長姐、同學和學弟妹。其實我個人資質並不是很好，修課的成績也不盡理想，完全不是典型的台大生類型。當初只是帶著一股



傻勁，想要跟學長姐好好學習，他們不厭其煩的教導讓我至今難忘，甚至是陪我做實驗到深夜，熬夜幫我看我選的論文和報告，我認為這是我之所以日後想要走向教職的初因。這些學長姐大部分已經畢業了，包括：叡豐學長、玲玲學姊、逸帆學長、俊淵學長、孟傑學長、貝蘿學姊、致均學姊、嘉莉學姊、怡伶學姊、宜岑學姊、阿伯學長等。至於同學和學弟妹，則是跟我一起度過碩士班的好夥伴，有些也許已經工作，有一些轉跑道，但是互相幫助鼓勵當中，彼此也成長很多，包括：立盈、柏歲、珮瑄、家昇、林真、怡甄、家慈、皓倫、耀霖、壯嵩、丁毅、智淞、采潔、柏如、思筠、鈺軒等。非常感謝大家的幫助和陪伴，雖然大部分的人已經各奔東西，也不知何時再相見，但是我在這裡要由衷的祝福大家，願 神賜福你們。

最後，我要感謝我的親人和好友。最感謝的是辛苦的母親，自從父親過世之後，因為孩子都在外地求學，我本人也因為諸多因素沒有常常回家，母親一個人忍受寂寞也要忙著賺錢，肩負許多的壓力，但卻未曾跟我抱怨過，也總是表達對我的支持，總是跟我說：「你已經是大人了！我相信你會處理好這一切的...」對於她的付出、諒解和信任，我真的沒辦法再給她更多的感謝。另外要感謝「台大倍加團契」的弟兄，因為我跟他們就像家人一樣，一起住，一起學習聖經，整個碩士班期間，也為他們帶來許多麻煩，最後我還要感謝他們時時為我禱告，叫我莫忘初衷。

其實，整本論文最令我感到欣慰的部分就是致謝，也許我的研究之路還有相當長的距離要走，也許我博士班會換一個完全不一樣的題目，但是這些感謝的事情，我會一輩子記得，想到大家曾經對我的種種，我就有更多的動力走這個看似漫長的旅程。再次感謝所有幫助和陪伴我的人，謝謝你們。

吳奕賢

謹誌於 台大動科研究所加工館 306 室電腦前 民國一百零三年七月



# CONTENTS



## CHAPTER

PAGE

Abstract (Chinese Ver.)

Abstract (English Ver.)

I.	Introduction.....	1
II.	Literature review.....	2
2.1	<i>Ophiocordyceps sinensis</i> : treasure ancient medicine in scientific research.....	2
2.1.1	Synopsis and current marketing situation.....	2
2.1.2	Collection to the submerged-fermented production.....	7
2.1.3	Potential medical and nutraceutical applications.....	9
2.2	Bioactive ingredients of OS and their known functions.....	11
2.2.1	Nucleosides, bases and their analogues.....	11
2.2.2	Proteins, peptides and amino acids.....	16
2.2.3	Carbohydrates.....	19
2.2.4	Fatty acids and sterols.....	20
2.3	Hepatotoxic thioacetamide in animal model.....	24
2.3.1	Animal model for liver injury.....	24



2.3.2	Synopsis of thioacetamide.....	29
2.3.3	Pathophysiological effect of thioacetamide.....	29
2.4	Hepatic fibrogenesis.....	33
2.4.1	Fibrogenesis and clinical research.....	33
2.4.2	Liver injury and inflammation.....	34
2.4.3	Hepatic stellate cell activation and its molecular mechanism.....	43
2.4.4	TLR4 signaling in the liver injury and hepatic fibrogenesis.....	44
2.4.5	The role of TGF- $\beta$ signaling in liver fibrosis.....	46
III.	Materials & methods.....	49
3.1	Chemicals.....	49
3.2	Animals and treatments.....	49
3.3	Sample collection.....	50
3.4	Serum biochemical value analyses.....	51
3.5	Preparation of liver homogenate.....	51
3.6	Liver lipid analyses.....	51
3.7	Antioxidative capability analyses.....	53
3.7.1	Thiobarbituric acid reactive substances (TBARS).....	53
3.7.2	Glutathione (GSH).....	53

3.7.3	Trolox equivalent antioxidant capacity (TEAC).....	54
3.7.4	Superoxide dismutase (SOD).....	55
3.7.5	Catalase (CAT).....	55
3.7.6	Glutathione peroxidase (GPx).....	56
3.8	Inflammatory cytokine analysis.....	57
3.9	Histopathological sections and staining.....	57
3.10	Collagen assay.....	62
3.11	Real-time polymerase chain reaction (Realtime-PCR).....	63
3.12	Immunohistochemistry (IHC).....	65
IV.	Results.....	67
4.1	Effects of OS mycelium on growth performance of rats.....	67
4.2	Effects of OS mycelium on serum and liver lipid.....	67
4.3	Effects of OS mycelium on antioxidative capacity of livers.....	68
4.4	Effects of OS mycelium on liver damage.....	68
4.5	Protective mechanism by OS supplementation.....	69
V.	Discussion.....	71
VI.	Conclusion.....	77
	References.....	91



Appendix..... 120




## LIST OF FIGURES



<b>NO.</b>	<b>TITLE</b>	<b>PAGE</b>
II -1	Habitat range and appearance of <i>Ophiocordyceps sinensis</i> .....	4
II -2	Classification of <i>Cordyceps</i> and clavicipitaceous fungi.....	5
II -3	Flow chart of OSM production.....	8
II -4	Typical HPLC chromatogram of OS and OSM extracted by ambient temperature water extraction and boiling water extraction.....	12
II -5	Phosphatidylcholine biosynthesis via the Kennedy pathway.....	15
II -6	Metabolic pathway and pathophysiological effect of thioacetamide.....	32
II -7	The mortality and incidence of liver cancer worldwide .....	36
II -8	The prevalence of liver cancer in different countries.....	37
II -9	Leading causes of lethal cancer categories in Taiwan.....	38
II -10	The leading causes of death within 2001 and 2012 in Taiwan.....	39
II -11	The pathological process of liver injury to hepatocellular carcinoma...	40
II -12	Major responsive hepatic cells to fibrosis.....	41
II -13	Members of ROS and their generated pathway in antioxidativ system.....	42
II -14	Pathway of hepatic stellate cell activation.....	47

II -15	TLR4 and TGF- $\beta$ related pathway in liver fibrosis.....	48
III -1	Experimental design of this study.....	50
III -2	The Criteria of METAVIR fibrosis staging system.....	60
IV -1	Body weight changes of experimental rats during the feeding period...	79
IV -2	Serum triglyceride, cholesterol, AST, and ALT levels of serum.....	82
IV -3	Masson's trichrome staining for liver tissues.....	84
IV -4	HE staining for liver tissues.....	85
IV -5	Immunohistochemistry analysis: $\alpha$ SMA protein expression.....	86
IV -6	TGF- $\beta$ related genes expression.....	87
IV -7	TLR4 related genes expression.....	88
IV -8	Hepatic fibrosis related genes expression.....	89
IV -9	Immunohistochemistry analysis: NF $\kappa$ B protein expression.....	90
VI -1	Conclusive illustration for this study.....	78



## LIST OF TABLES



NO.	TITLE	PAGE
II -1	Medically or nutritionally related effects of various <i>Cordyceps</i> taxa.....	6
II -2	Amino acid levels in OS and OSM.....	18
II -3	The contents of ten fatty acids and four sterols in OS and OSM.....	23
II -4	Main AHF animal models in different species.....	28
II -5	International histology activity index (HAI) score.....	61
III -1	Primer sequences and PCR product size for Realtime-PCR.....	64
III -2	Product sheets of antibody for IHC.....	66
III -3	Average food and water intakes, organ sizes, serum albumin and liver lipids.....	80
IV -1	Antioxidative capacity and enzymatic activities of liver tissues.....	81
IV -2	Liver collagen and cytokine contents.....	83
V -1	The hepatoprotective effects in different treatments.....	72

## LIST OF SUPPLEMENT



NO.	TITLE	PAGE
1	List of major chemicals and their structures found in OS.....	120



## 中文摘要



肝纖維化 (liver fibrosis) 源於慢性肝損傷，這會使肝星狀細胞活化並分泌胞外基質 (Extracellular matrix, ECM)。在組織學上，肝纖維化過去被認為是被動而不可逆的過程，但 1970 年代之臨床報告指出該病症具有可逆的潛力，目前則以損傷與癒合模式看待此類病症。

本研究設計參考衛福部公告之護肝功能評估方法來探討人工培養之冬蟲夏草菌絲體 (*Ophiocordyceps sinensis* mycelium, OSM) 對於硫代乙醯胺 (thioacetamide, TAA) 誘導下肝纖維化與慢性肝損傷之保護作用。試驗之結果證實：冬蟲夏草菌絲體粉末在以 TAA 誘導大鼠之模式中可藉由改善肝臟脂質恆定而減少脂肪堆積，並提高其抗氧化能力，減緩因 TAA 造成的肝損傷。實驗結果中指出經 TAA 處理之大鼠補充 OSM，可以降低肝臟大小 ( $p < 0.05$ ) 及血液生化值中的 AST 和 ALT ( $p < 0.05$ )；TAA 所造成的低血脂現象亦顯著地回復 ( $p < 0.05$ )，且肝組織中脂質氧化程度 (TBARS) 減少，抗氧化能力 (TEAC、SOD、CAT、GPx) 顯著的上升 ( $p < 0.05$ )；在發炎相關細胞激素 (TNF- $\alpha$  and IL-1 $\beta$ ) 與肝臟組織中所含的 collagen 含量則是顯著的降低 ( $p < 0.05$ )，並在組織病理切片的結果中發現處理組能夠有效的減緩 ( $p < 0.05$ ) 纖維的產生並且減少 ( $p < 0.05$ ) 發炎之區域。透過分子生物學之分析，OSM 的護肝機制主要是藉由抑制 ( $p < 0.05$ ) 轉化生長因子 (TGF- $\beta$ ) 以及第四型類鐸受體 (TLR4) 相關之路徑，進而抑制 ( $p < 0.05$ ) 核因子活化 B 細胞  $\kappa$  輕鏈增強子 (NF $\kappa$ B) 之活化，最後該轉錄因子下游之發炎 (COX2) 與纖維化 (Coll $\alpha$ 、 $\alpha$ SMA) 相關之訊號也有顯著 ( $p < 0.05$ ) 的降低。透過免疫染色分析，OSM 可以顯著減少 ( $p < 0.05$ ) 肝臟星狀細胞活化之訊號  $\alpha$ SMA。本研究結果證實冬蟲夏草菌絲體之補充可以有效地減緩硫代乙醯胺誘導之肝損傷。

**關鍵字：**肝纖維化、硫代乙醯胺、冬蟲夏草菌絲體。

## ABSTRACT



Chronic liver diseases result in persisting inflammation, progressive fibrogenesis and chronic activation of the wound healing response. This study was to exam the protective activity of compound TCM-808FB which is mycelium of *Ophiocordyceps sinensis* (OSM) via a wistar rat model. Although rats were induced by injecting thioacetamide ( $\text{CH}_3\text{C}(\text{S})\text{NH}_2$ , TAA), oral OSM administration improved ( $p < 0.05$ ) the hypolipemia and lipid accumulation in livers. Meanwhile, the smaller ( $p < 0.05$ ) liver sizes as well as lower ( $p < 0.05$ ) serum alanine transaminase (AST) and asparatate transaminase (ALT) values showed its potential for relieving from the fibrosis symptom. Moreover, the results of cytokine assays, liver collagen assay and pathological section supported previous hypothesis. Besides, the OSM administration also enhanced ( $p < 0.05$ ) liver antioxidant capacities (GSH, TEAC, SOD, CAT and GPx) and decreased ( $p < 0.05$ ) lipid peroxidation (TBARS), and alleviated liver damage against TAA. As a result, we found an evidence that the protective effect of OSM against hepatic fibrosis may be via downregulations ( $p < 0.05$ ) of TGF- $\beta$  and TLR4 pathways while OSM also decreased ( $p < 0.05$ ) the expression of NF $\kappa$ B which further decreased ( $p < 0.05$ ) the expressions of fibrotic and inflammatory genes (i.e.,  $\alpha$ SMA, Col1 $\alpha$ , COX2). Therefore, OSM showed preventive effects on the development of TAA-induced hepatic fibrosis.

**Key words:** liver fibrosis, thioacetamide, *Ophiocordyceps sinensis* mycelium.


## I. INTRODUCTION



In 1993, the year of summer Olympic game, *Ophiocordyceps sinensis* (Renamed from *Cordyceps sinensis* in 2007) first gained a worldwide attention when it was revealed that several Chinese laureates included it in diets during their training program. Although it lacked scientific supportings at that time, it prompted the curiosity to research. Nowadays, it is still difficult to apply in therapeutic usages or supplementation due to its rareness and expensiveness. Hence, most of studies have focused on isolating, identifying and cultivating the OSM, while finding the bioactive compound consequently. Many bioactive compounds were found, but the beneficial mechanisms of them are still unclear.

In Taiwan, the liver related disease is prevalent (MOHW, 2013) due to a westernized diet, enviromental pollution, alcoholic habitual drinking, etc. While the functional products of hepatoprotection, called a hepatoprotectant, are popular in the market, the bioactivity of OSM attracts more and more scientific attention. According to previous studies of OSM, although it performs many bioactive functions, such as immunomodulatory, anti-inflammatory, anti-apoptotic, anti-hypertensive, anti-hyperglycaemic, neuroprotective, etc., the mechanism of hepatoprotective effect in TAA-induced liver fibrosis is still unknown. Therefore, this investigation would indicate the modulation of signal cascade in livers of TAA-treated rats under OSM consumption.

## II. LITERATURE REVIEW



### 2.1 *Ophiocordyceps sinensis*: treasure ancient medicine in scientific researches

#### 2.1.1 Synopsis and current marketing situation

*Ophiocordyceps sinensis* (*O. sinensis*; OS) that is a kind of fungi that parasitizes larvae of ghost moths (*hepialus armoricanus*) or other *Lepidoptera* (Wang & Yao, 2011), it distributes above 3000 m altitude in southwest China, Tibet, north India, and so on (Li *et al.*, 2011; Figure II-1). Officially, this species was first described by Mile Berkeley in 1843 as *Sphaeria sinensis*. This species had transferred into different genus twice (Saccardo, 1878; Sung *et al.*, 2007) because of analytical technique progressing. The scientific name's etymology was from the Latin *cord* "club", *ceps* "head", and *sinensis* "from china".

It is thousand years for usage of OS as herbal medicine in china. The first ancient records in Tang dynasty (618-907 AD), called "Yue-wang-yao-zhen" (月王藥診), mentioned its protective effect of lung-related diseases. Until the Qing dynasty (1644-1912 AD), a scholar, Yi-luo Wu, experted on handling of chinese herbal materials, and in his representative writings, Ben-cao-cong-xin (本草從新), it mentioned the integrated functions of this "mild" material, including, pro-sexual

activity, asthma and chronic lung-related diseases cure, cardiac functions promotion, immune modulation, chronic renal disease prevention, anti-hypertensive, etc.

Although there is no liver-related record, modern scientist proclaimed its hepatoprotective effect by many scientific evidences.

In a comparison with OS, there are diverse insect-parasitic fungi (*Ophiocordyceps sinensis*, *Cordyceps militaris*, *Elaphocordyceps ophioglossoides*, *Cordyceps pruinosa*; Figure II-2) as health food and herbal medicine (Table II-1). The most famous one of them is *C. militaris*, which is similar but cheaper than OS.

Although it had been proclaimed that *C. militaris* performs multi pharmacological functions in many scientific studies early, the publics still believe subjectively that legendary unimaginable functions of OS are unrevealed. Hence, it is still worthy to be a potential product for medicinal or nutraceutical studies in commercial viewpoint.

Nowadays, because the economic power of China is raising and the worldwide market demand is increasing (Cooper and Chang, 2001), the price of wild OS may be US\$ 20,000 to 40,000 per kg in an international market and even higher (Sharma, 2004). However, over-harvesing in some wild habitats has been made recently (Sharma, 2004). However, OS is still extremely treasured making cultured mycelium a ray of light to those in need.




Figure II-1. Habitat range and appearance of *Ophiocordyceps sinensis*. (A) The appearance of OS fruit body that is a yellow-brown stick, and it still remain the image of larva. (B) OS distributes Asia areas where are above 3000 m altitude in southwest China, Tibet, and north India. This figure was modified from Buenz *et al.* (2005). The picture of OS is from online resource: [http://www.johnsunmushroom.com/epro\\_show.asp?ProID=110](http://www.johnsunmushroom.com/epro_show.asp?ProID=110) and [http://www.bibliotecapleyades.net/ciencia/ciencia\\_industryhealthiermedica53.htm](http://www.bibliotecapleyades.net/ciencia/ciencia_industryhealthiermedica53.htm).




Figure II-2. Classification of *Cordyceps* and *clavicipitaceous* fungi. Bootstrap proportions (ML-BP) are obtained in maximum likelihood analyses and shown above corresponding nodes for  $\geq 70\%$ . Internodes that are supported with both bootstrap proportions (ML-BP  $\geq 70\%$ ) and posterior probabilities (PP  $\geq 0.95$ ) are considered strongly supported and drawn in a thicker line. Portions of the tree in grey rectangular boxes indicate nomenclatural changes of *Cordyceps* (Sung *et al.*, 2007).





Table II-1. Medically or nutritionally related effects of various *Cordyceps* taxa (or preparations)

Purported effect / Taxon	<i>O. sinensis</i>	<i>C. militaris</i>	<i>E. ophioglossoides</i>	<i>C. pruinosa</i>
Immunomodulatory	(Zhang <i>et al.</i> , 2005)	(Sone <i>et al.</i> , 1985)		
Anti-inflammatory	(Liu <i>et al.</i> , 2011)	(Yu <i>et al.</i> , 2004)		(Kim <i>et al.</i> , 2003)
Anti-tumor /anti-cancer	(Yang <i>et al.</i> , 2005)	(Lin & Chiang, 2008)	(Ohmori <i>et al.</i> , 1986)	
Anti-apoptotic	(Buenz <i>et al.</i> , 2004)			
Mitogenic		(Jung <i>et al.</i> , 2007)		
Pro-sexual	(Huang <i>et al.</i> , 2004)			
Nephroprotective	(Lin <i>et al.</i> , 1999)	(Wu <i>et al.</i> , 2000)		
Hepatoprotective	(Gong <i>et al.</i> , 2000) (Liu & Shen, 2003)			
Anti-Hypertensive	(Chiou <i>et al.</i> , 2000)			
Anti-hyperglycaemic	(Li <i>et al.</i> , 2006)	(Young <i>et al.</i> , 2001)		
Anti-atherosclerotic	(Yamaguchi <i>et al.</i> , 2000)			
Hematological		(Jung <i>et al.</i> , 2007)	(Ikeda <i>et al.</i> , 1993)	
Anti-ageing /antioxidant	(Hui <i>et al.</i> , 2006)	(Yu <i>et al.</i> , 2007)	(Jin <i>et al.</i> , 2004)	
Neuroprotective		(Lee <i>et al.</i> , 2011)		
Anti-fungal		(Wang and Yao, 2011)	(Kneifel <i>et al.</i> , 1977)	
Anti-bacterial		(Ahn <i>et al.</i> , 2000)	(Kneifel <i>et al.</i> , 1977)	
Anti-fibrotic	(Peng <i>et al.</i> , 2013)	(Nan <i>et al.</i> , 2001)		
Anti-HIV		(Mueller <i>et al.</i> , 1991)		
Anti-invasion	(Kuo <i>et al.</i> , 2005)			



### 2.1.2 Collection to the submerged-fermented production



As mentioned, wild OS is over-harvested and expensive; hence, it is not enough to develop the wide-spread daily supplements or nutraceuticals for people in need. Unsurprisingly, there had already been few kind of procedure for cultivated production (Figure II-3). Liquid or submerged fermentation is usually a preferred system for efficient production in mycelial cultures because the condition of cultures could be manipulated and optimized for various fungi. Shashidhar *et al.* (2013) mentioned: “Initial attempts to develop an efficient technology for cultivation of fruiting bodies became futile, but solid state and submerged fermentations remained widely used for the production of OS mycelia biomass and components.” Since different micro-environmental factors may influence the production of biomass, the end products of two fermentation systems may be various. In many cases, two cultivated systems are cut both ways, but the comparative analysis in OS mycelia production is still awaited.

In 2006, Lo *et al.* proclaimed that both extracts from wild and cultivated mycelia of OS have direct and potent bioactivities. Furthermore, cultivated mycelia may have stronger activities in results of some scientific reports (Dong and Yao, 2008). According to the aforementioned, no matter what dimensions we focus on, the cultivated mycelia of OS are the most appropriate research subject for further medical or nutraceutical application.





Figure II-3 Flow chart of OSM production. By improvement of biotechnology The producer found that cultivated method of OS. First, they collected fresh sample from natural habitat, and confirmed by genome sequencing because one wild OS is consisted of variant fungi. Moreover, OS was isolated, purified, and confirmed. After all, they produced mycelium via liquid or submerged fermentation. The last, dried and grounded to become OSM product.

### 2.1.3 Potential medical and nutraceutical applications



As the ancient-wisdoms, the benefits of OS to human beings had been proven by scientists, and OSM also become a current subject in many studies and researches. After searching, the results are as followings:

immunomodulation (Sheng *et al.*, 2011), anti-inflammation (Chiou and Lin, 2012), anti-fatigue (Kumar *et al.*, 2011), anti-fibrosis (Pan *et al.*, 2013), anti-tumor (Kubo *et al.*, 2010), antioxidation and cardiovascular (Yan *et al.*, 2013), and hepatic protection (Peng *et al.*, 2013).

The evidence for exercise-endurance promotion and anti-fatigue activities of OS is well known. Current study demonstrated that it is mediated by upregulation of metabolic regulators, such as AMPK, PGC-1, and PPAR in skeletal muscle (Kumar *et al.*, 2011); furthermore, it was found to elevate ATP level in liver tissue (Manabe *et al.*, 1996&2000). Recently, Wu *et al.* (2014) proclaimed that cordycepin, which is one of major nucleotides in OS, could activate AMPK in HepG2, and decreasing intracellular lipid accumulation significantly. Qiet *et al.* (*In press*) also found Cordymin, which is a kind of peptide from OS, ameliorated the osteopenia and restored the circulating blood glucose and insulin level in diabetic rats. These results provide a strong evidence that OS can affect metabolism.

Sheng *et al.* (2011) found polysaccharides from OSM activated the immunocytes and promoted cytokines expressions. Wang *et al.* (2012) reported that peptide of OSM had a neuroprotective effect in the ischemic brain via inhibiting an inflammation, and it also increased antioxidant activities. Moreover, the anti-inflammatory effect of OSM is not only presenting in brain but also in airway tissues (Chiou and Lin, 2012). Besides, Yan *et al.* (2013) also confirmed

that OSM supplementation would maintain cardiovascular function against an ischemic-reperfusion injury. Furthermore, they demonstrated that OS regulates specific markers of oxidative stress and ameliorates cardiovascular injury.

Last but not least, the previous research showed that the polysaccharides of the OSM have been demonstrated to ameliorate liver fibrosis against CCl<sub>4</sub>-induction in rats (Peng *et al.*, 2013). Furthermore, the anti-fibrotic effects have been proved to be associated with its down-regulation on hepatic stellate cells (HSCs) activation by modulating protein expression and matrix metalloproteinase (MMP) activities (Peng *et al.*, 2013). In addition, its anti-fibrotic effect was also found in renal injury model (Pan *et al.*, 2013). Kubo *et al.* (2010) proclaimed that the OSM possesses an anti-metastatic activity by inhibiting the HGF-accelerated tumor invasiveness in mouse hepatic melanoma. To sum up, the fermented OSM are the potential phyto-materials for medicines and nutraceuticals indeed.

## 2.2 Bioactive ingredients of OS and their function



### 2.2.1 Nucleoside, bases and their analogues

Nucleotides are one of the major components in *Cordyceps*. There are more than 20 nucleotides and analogs discovered in wild and cultivated OS nowadays (Supplement 1). Although it could not explain all efficacies of OS, nucleotides are widely recognized as one of the bioactive components. Furthermore, there is a significantly different quantification of nucleotides between various preparations of samples, but slight qualitative change is in HPLC-DAD analysis (Figure II-4). Five nucleotides, i.e. uridine, inosine, guanosine, adenosine and cordycepin are the majors in OS. And these nucleotides can be degraded to others or further through specific enzyme into their bases and/or related compound in wild or cultivated OS. The change pathway of nucleosides in OS was suggested as follows (Zhao *et al.*, 2013):

- (1). AMP → adenosine → inosine → hypoxanthine (wild OS)
- (2). AMP → adenosine → adenine (cultivated OS)
- (3). GMP → guanosine → suanine (wild and cultivated OS)
- (4). UMP → uridine → uracil (wild and cultivated OS)

Before it goes to details, it is obvious that the investigation of relationship between nucleotide and liver function is still banal except the adenosine, Although most of studies focus on brain disease and neuronprotection, there are still some inspired results for further discussion in this study.





Figure II-4. Typical HPLC chromatogram of OS (left) and OSM (right) extracted by ambient temperature water extraction (ATWE) and boiling water extraction (BWE). U, uridine; I, inosine; G, guanosine; A, adenosine and C, cordycepin. (Yang & Li, 2008)

The uridine, cytidines, and their respective bases contribute to brain phosphatidylcholine and phosphatidylethanolamine synthesis via the Kennedy pathway (Figure II-5). In Kennedy pathway, the biosynthesis of PC, a crucial factor for the function of neuronal membrane, requires a cytidine nucleotide, which is involved in the rate-limiting step (Kennedy and Weiss, 1956). By some indirect evidences, an addition of uridine to cultivated medium *in vitro* or chronic dietary supplement *in vivo* may modulate such membrane-dependant processes as neurotransmitter release (Wang *et al.*, 2005) and neurite outgrowth (Pooler *et al.*, 2005; Wang *et al.*, 2005). As for uridine, it involves in many metabolic, i.e., glycogen synthesis, lipid and carbohydrate metabolism pathway in brain. Hence, the *in vitro* protection of uridine on astrocytes which under

immunostimulation and glucose deprivation was proved, and the protective effect may be via metabolic modulation (Choi *et al.*, 2006). Meanwhile, uridine also has been demonstrated to be anti-inflammatory and protective in lung tissues (Evaldsson *et al.*, 2007).



Of all nucleotide content, Guanosine, a neuronprotective element, is the highest in some investigations (Li *et al.*, 2011). Oleskovicz *et al.*(2008) reported that guanosine performed neuroprotective effect on an oxygen-glucose deprivation. Also guanosine was demonstrated to present anticonvulsant and amnesic effects in rodent models (Soares *et al.*, 2004; Vinadé *et al.*, 2004). Moreover, guanosine is protective against mitochondrial oxidative stress *in vitro*, and the disruption is due to the pathway related to PI3K, Akt, GSK-3 $\beta$  and induction of antioxidative enzyme HO-1 (Dal-Cim *et al.*, 2012).

Adenosine is a constitutive metabolite of all cells, and it is involved in key pathways such as nucleic acid base synthesis, amino acid and other cellular metabolic status. In addition, it not only exerted a range of generally beneficial effects in the heart and vessels (Olsson & Pearson, 1990; Shryock & Belardinelli, 1997) but also played an important role to the immuno-activity of macrophage along with reactive oxygen. Besides, adenosine was reported to have functions in liver according to Chiang *et al.* (2013). Adenosine-2A-receptor antagonist prevented and reversed fibrosis in ethanol-exacerbated liver fibrosis model. They indicated that a treatment of A2A receptor antagonist alleviated the liver injury index, hepatic stellate cells (HSC) activation, fibrosis, and dysregulated angiogenesis.

Unlike the other nucleotides as mentioned above, cordycepin was initially extracted from fungi of genus *Cordyceps*. As the previous investigations, the

ability of cordycepin to reduce total cholesterol and triglycerides content through AMPK activation *in vitro* was obvious, and its *in vivo* preventive effect on hyperlipidemia model was also proved (Guo *et al.*, 2010). Moreover, AMPK had been widely reported to play an important role in insulin signaling (Sriwijitkamol *et al.*, 2006; Fullerton & Steinberg, 2010).

Among studies of Jeong *et al.* (2010), Ren *et al.* (2012), and Jung *et al.* (2010) cordycepin significantly attenuated the release of inflammatory mediators, i.e., NO, PGE2, TNF- $\alpha$ , IL-1 $\beta$ , phosphorylated Akt and MAPKs. Ramesh *et al.* (2012) indicated that the administration of cordycepin protects the liver, kidneys, heart, and lungs of aged rats from oxidative stress by enhancing the activities of enzymatic and non-enzymatic antioxidants. Cha *et al.* (2013) also showed that a hepatoprotective effect in alcohol-induced model was attributed to cordycepin, and it could increase the activities of alcohol-metabolizing enzymes and decrease the liver injury.






Figure II-5. Phosphatidylcholine biosynthesis via the Kennedy pathway. In rats, plasma cytidine is the major circulating pyrimidine, and however, in gerbils and humans, the primary circulating pyrimidine is uridine. Only small amounts of circulating cytidine are converted to brain CTP, since the rat blood–brain barrier (BBB) lacks a high-affinity transporter for cytidine; uridine, in contrast, readily enters the brain via a high-affinity transporter (CNT2) yielding UTP which is then converted to CTP by CTP synthase. This CTP reacts with phosphocholine to form endogenous CDP-choline, which then combines with diacylglycerol (DAG) to form PC (Cansev, 2006).


## 2.2.2 Proteins, peptides, and amino acids

To compare with other bioactive ingredients, proteins, peptides and other related analogues were overlooked in the past. Approximate 20 species (Supplement 1 ), i.e., cordyheptapeptide A/B, cicadeptin I/II, cyclosporin, cordycedipeptide A, cordysin A-E, etc. were found, but their own bioactivity are still unclear .

Cyclosporin was proved its bioactivity in 1990s. Hozumi *et al.* (1994) proclaimed the elongation of hair-existing phase via lengthening the growing phase of the hair cycle in treated animal. Moreover, Adhirai and Selvam (1997) indicated it would enhance retention of oxalate in hyperoxaluria, which is mediated through the altered antioxidant defensive system. Now cyclosporin is widely used in organ transplantation by its immunosuppressive effect to prevent rejection in clinicals (Nakayasu *et al.*, 1990).

Cordymin, which was found in early time, obtains the limelight these years because Qi *et al.* (*In press*) proclaimed that cordymin from OS retarded the diabetic osteopenia in the rat model, and also restored the normal circulating blood biochemical levels. The results suggested that cordymin may indirectly recover the function of pancreatic  $\beta$ -cells.

Besides, OS contains many functional amino acids (Table II-2), for example: glutamic acid (Glu), aspartic acid (Asp), alanine (Ala), arginine (Arg) etc. Saiga *et al.* (2003) demonstrated that the composition with more acidic amino acids (Glu and Asp) or histidine could promote the antioxidative capacity and decrease the levels of lipid peroxidation because of the  $\text{COO}^-$  groups, which are electrophilic which bind to free radicals (Kang *et al.*, 2012). Moreover, Glu supplementation protected hepatic function against fatty liver disease via



enhancing the glucagon in plasma, decreasing the ratio of insulin/glucagon, and increasing the output of triglyceride (Greenfield *et al.*, 2009). On the other hand, it is proclaimed that alanine-additional diet results in stimulations of insulin secretion, glucose metabolism, and energy expenditure, hence it may be protective in type II diabetes (Brennan *et al.*, 2002). Arg was confirmed to be multi-functional supplementary in immunomodulation (Popvic *et al.*, 2007), anti-hypertension (Gokce, 2004) etc. A recent study insisted that it is beneficial by taking the multi-amino-acid formula, which comprises Glu, Ala, His, Leu, and Lys, to suppress weight gain and lipid accumulation through enhancing energy expenditure in high-fat-diet treatment (Kobayashi *et al.*, 2009).


Table II-2. Amino acid levels in OS and OSM

Amino acid composition (%)	natural OS		cultivated OSM	
	Corpus	Fruiting body	Mycelium	Supernatant of broth
Aspartic acid	1.70a	1.84a	1.05ab	0.31c
Threonine	0.86a	0.83a	0.65a	0.05c
Serine	0.77a	0.78a	0.49b	0.04c
Glutamic acid	2.64a	2.66a	1.12a	0.48b
Proline	1.13a	0.95a	0.72a	-
Glycine	0.82a	0.73ab	0.58ab	0.09c
Alanine	1.02a	0.95a	0.75a	0.05b
Valine	0.98a	0.80a	0.63b	0.06c
Methionine	0.26a	0.18a	0.18a	0.02b
Isoleucine	0.81a	0.53b	0.44ab	0.05c
Leucine	1.30a	0.95a	0.69ab	0.06d
Tyrosine	0.89a	0.67ab	0.31b	0.02c
Phenylalanine	0.96a	0.61b	0.50bc	0.04d
Histidine	1.07a	1.13a	0.28ab	0.02c
Lysine	1.38a	1.15a	0.80a	0.08b
Arginine	1.53a	1.60a	0.04ab	0.05b
Total	18.1a	16.4a	9.23b	1.42d

\*Means with different letters in the same row are significantly different ( $p < 0.05$ ).

\*\*modified from Hsu *et al.* (2002)

### 2.2.3 Carbohydrate



Categories of carbohydrates in OS are mainly mannitol, trehalose, and polysaccharides (Supplement 1). Mannitol is a kind of phytochemicals that is unassimilable and stable in animal, and hence, it increase the osmotic pressure and micturition against edema and some renal disorders. The efficacy of mannitol to decrease intracranial pressures leads to its widespread use in neurosurgery (Wani *et al.*, 2008). Xiao *et al.* (2013) found dietary mannitol increased absorption and retention of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  in bone through fermentation of mannitol in large intestine. Regarding the benefits of trehalose, Rodríguez-Navarro *et al.* (2010) demonstrated that it is protective in taupathies and parkinsonism, which performed higher metabolic and oxidative stress activity in cerebral regions. Arai *et al.* (2010) also found that trehalose intake would suppress adipocyte hypertrophy under high-fat-diet induced obesity, and it could mitigate insulin resistance by decreasing insulin secretion and downregulating the mRNA of MCP-1.

Polysaccharides, which were larger amount (3-8%) than other ingredients, were regarded as the most possible bioactive compounds but they structurally diversified (Yue *et al.*, 2012). Cheung *et al.* (2009) isolated and identified a kind of polysaccharide, Cordysinocan, from cultured OS. Futhermore, it activated immune responses in cultured T-lymphocytes and macrophages via cytokine induction and downstream signaling cascade. Although many investigations mentioned and emphasized those carbohydrate compounds in discussion, the isolation of each certain bioactive compound and those functional tests are still awaiting.

#### 2.2.4 Fatty acids and sterols

Fatty acids were required nutrients for organisms, and recently some of them were proven to be critical in certain physiological functions (Yang *et al.*, 2013; Koba and Yanagita, 2013). OS only contains few kinds of fatty acids (Table II-3), i.e., palmitic acid, linoleic acid, and oleic acid, and also sterols like ergosterol and  $\beta$ -sitosterol (Table II-3), showed beneficial effects to human health (Zhu *et al.*, 2014; Wong *et al.*, 2013)


Conjugated linoleic acid (CLA) is a well-studied representative natural conjugated fatty acid (Koba and Yanagita, *In press*). CLA showed the anticarcinogenic effect (Ip *et al.*, 1991; Ip *et al.*, 1994), antiobesity (Park *et al.*, 1997; Pariza *et al.*, 2001), antidiabetic effect (Riserus *et al.*, 2002; Moloney *et al.*, 2004), and antihypertensive property (Inoue *et al.*, 2004). Until now, the one of most possible mechanisms in each beneficial effect was due to a modulation of peroxisome proliferator-activated receptors (PPARs) related pathway, which had been proven to regulate  $\beta$ -oxidation and other lipid metabolic genes (Inoue *et al.*, 2006; Wang *et al.*, 2006). It was shown that CLA was as an activator of PPAR $\alpha$  (Moya-Camarena *et al.*, 1999) and PPAR $\gamma$  (Houseknecht *et al.*, 1998).

Oleic acid (OA) and human  $\alpha$ -lactalbumin ( $\alpha$ -LA) form a complex, named HAMLET, which was indicated to have a selective apoptotic activity (Mossberg *et al.*, 2010) and be a possible cancer therapy (Ho Cs *et al.*, 2012). Recently, it was mentioned that OA is an active compound in HAMLET-like complex to kill tumor cells, and the dynamic system of protein/OA molar ratio is critical in the biological properties of this complex; in other words, the solubility and aggregation state of the fatty acid significantly affect the stability of the complex and consequently its toxicity (Spolaore *et al.*, 2010). The effects of

cellular processes that were shared between OA and HAMLET are membrane perturbation (Niazy, 1997; Engelbrecht *et al.*, 2011), apoptosis (Yu *et al.*, 2008; Maris *et al.*, 2011), mitochondrial function (Köhler *et al.*, 2001), cell adhesion (Trulsson *et al.*, 2011), Glycolysis (Stewart and Balkely, 2000; Wilson *et al.*, 2003).

Palmitic acid (PA) is also a kind of unsaturated fatty acids that were demonstrated to activate PPARs depends on their various sizes and double bonds (Poulsen *et al.*, 2012; Schup and Lazar, 2010). Bolsoni-Lopes *et al.* (2013) showed that PA significantly increased PPAR $\alpha$  binding to its DNA consensus sequence (PPRE), concomitant with the activation of lipolysis *in vitro* and *in vivo*. However, PA is not as effective as CLA aforementioned. In addition, former investigation showed that PA increased the release of cholecystokinin (CCK) from STC-1 cells (Tanaka *et al.*, 2008). Yang *et al.* (2013) indicated that dietary PA suppressed appetite via releasing appetite-related hormones in male rats.

Dietary phytosterols were also proven to inhibit the growth and metastasis of human breast cancer cells in mice (Awad *et al.*, 2008). Among those phytosterols,  $\beta$ -sitosterol (StS) and Ergosterol (ErS) are rich in OS relatively (Table II-3). Although the molecular mechanism should be further investigated, Russo *et al.* (2010) proclaimed that ErS peroxide and its derivatives attenuated the growth of human prostate cancer cells and partially triggered an apoptotic process. Zhu *et al.* (2014) found ErS peroxide may prevent the renal fibrosis against TGF- $\beta$ 1 induced activation of fibroblasts *in vitro*. For  $\beta$ -sitosterol (StS), Awad *et al.* (1996) indicated that StS inhibits cell growth as compared to cholesterol or non-sterol medium, and they inferred that the signal transduction



pathway may involve membrane phospholipids. Recently, Wong *et al.* (2013) showed that StS enhanced glutathione redox cycling via modulating mitochondrial reactive oxygen species (ROS). Furthermore, Valerio *et al.* (2013) provided strong evidences to show that StS modulated Toll-like receptor 4 (TLR4) expression and intracellular MyD88-dependent pathway activation in macrophages. TLR4 pathway is also known to be highly related to chronic liver diseases (Soares *et al.*, 2010), especially hepatic fibrosis (Guo and Friedman, 2010). First and last, phytosterols may be another targeting bioactive compound for further hepatoprotective investigation.





Table II-3. The contents of ten fatty acids and four sterols in OS and OSM

	Smaples	LA	MA	PtA	PoA	PA	LoA	OA	SA	DA	LiA	ChS	ErS	CaS	StS
NOS	Sichuan	17.6	36.7	35.5	220.7	1469.5	2896.5	3978.0	800.7	35.9	52.6	88.2	134.3	+	103.6
	Qinghai	+	21.5	23.8	218.7	1760.0	2854.1	3943.6	609.2	33.1	47.9	69.3	108.0	+	105.1
	Tibeta	14.0	47.1	34.3	613.7	3842.4	6012.3	11517.6	1238.6	38.7	52.9	82.5	120.3	+	95.9
	Tibet2	+	26.8	30.2	245.9	2050.2	3581.0	5869.4	1269.2	38.9	55.4	68.8	89.7	+	78.1
CCOS	Wanfeng	+	14.7	19.1	98.3	98.3	2155.2	1471.9	1445.1	232.1	145.6	-	642.1	12.6	208.7
	Hebei	+	16.4	19.3	36.3	36.3	2561.2	895.7	2275.6	149.2	99.5	24.1	541.7	15.1	157.2
	Huadong	+	14.9	61.5	162.8	162.8	4549.2	749.3	1297.1	34.6	57.3	37.1	318.6	34.4	75.6
	Jiangxi	17.6	13.7	10.5	65.4	65.4	1780.2	909.6	799.2	48.3	59.7	+	212.0	+	164.4
	Anhui	21.9	40.3	82.9	968.3	968.3	13653.7	4182.0	3308.5	177.2	135.7	-	111.2	+	65.8
CCCM	Xiankang	31.6	23.8	89.5	77.9	77.9	2508.7	668.1	1237.2	33.3	47.5	+	273.2	+	-
	Quanxin	26.8	14.5	36.6	66.4	66.4	2132.0	386.6	621.1	35.7	51.9	-	306.6	+	-
	Guobao	+	+	133.6	75.8	75.8	1922.8	317.2	690.2	53.8	+	+	187.0	-	-
	HKUST	+	+	133.0	72.8	72.8	2564.4	442.8	803.8	60.4	95.8	+	205.2	-	+
	Aoli	18.3	36.4	31.2	233.2	233.2	1269.3	5148.2	3428.3	69.7	60.4	78.8	93.7	+	73.7
COS	C550542	+	+	-	-	-	726.8	442.1	483.9	+	48.8	-	145.2	+	51.6
	C550562	+	+	-	57.5	57.5	1020.3	332.2	295.5	+	48.2	-	397.1	+	49.8
	C550677	20.8	+	+	74.1	74.1	1052.8	604.2	762.6	36.8	60.4	-	514.5	+	-
	LCT	+	-	-	37.7	37.7	718.0	176.0	208.8	26.8	+	-	259.9	-	-

\*LA, lauric; MA, myristic acid; PtA, pentadecanoic acid; PA, palmitoleic acid; LoA, linoleic acid; SA, stearic acid; DA, docosanoic acid; LiA, lignoceric acid; ChS, cholesterol; ErS, ergosterol; CaS, campesterol; StS,  $\beta$ -sitosterol; NOS, natural OS; CCOS, commercial cultured OS; CCCM, commercial cultured *C. militaris*; COS, self-cultured OS; LCT, isolated from the caterpillar of OS from Qinghai province.

\*\*modified from Yang *et al.* (2009a)


## 2.3 Hepatotoxic thioacetamide in animal model

Detoxification/drug metabolism is one of the important physiological functions of the liver. If the injury signals were overloaded in liver tissues, the toxic effect will trigger downstream signal and influence the normal liver functions as following sections. The thioacetamide is one of well-known liver-specific toxin in hepatopathological researches.

### 2.3.1 Animal model for liver injury


Animal models for hepatopathological research are greatly contributive, and it successfully advances the clinical, therapeutic techniques for human beings. Tuñón *et al.* (2009) stated the importance of animal models clearly as he following: “Although a number of clinical trials testing different liver assist devices are under way, these systems alone have no significant effect on patient survival and are only regarded as an useful approach to bridge patients with AHF to liver transplantation. As a result, reproducible experimental animal models resembling the clinical conditions are still needed”. The most common models are based on surgical methods, nutrient imbalance, viral infection, and chemical induction.

Surgical procedures are including total/partial hepatectomy, complete/transient devascularization. Every clinical surgery mimics the certain pathophysiological symptoms (e.g., irritative regeneration, ischemia, hypertension, cholestasis.). For hepatectomy, Mann *et al.* (1921) found that liver injury occurred when it is under stressful liver regeneration on dogs, and it has been successfully developed in various animal species (Table II-4). Furthermore, the previous studies demonstrated highly regenerative property in rodent models



while the upper limit for liver resection for rat and mice are almost up to 95% and 90% respectively (He *et al.*, 2003; Makino *et al.*, 2005). Clinically, this model is equivalent to massive liver damage due to liver trauma or a primary graft failure (Van de Kerkhove *et al.*, 2004), and its main application was to study hepatic regeneration in the absence of toxin elimination, circulating inflammatory factors, and hepatotoxin-induced liver injury (Eguchi *et al.*, 1997). Next, devascularization was highly related to architectural and physiological properties of liver because it included occlusion of hepatic artery, bile duct, and/or accessory hepatic vessels (Ytrebø *et al.*, 2002; Nakazawa *et al.*, 2002). In this model, the inflammation and oxidative stress also occurred due to toxicity of endogenous bile acid (Kosters and Karpen, 2010; Allen *et al.*, 2011; O'Brien *et al.*, 2013) or ischemic/reperfused signals (Kireev *et al.*, 2013; Meimei *et al.*, 2014). Devascularization was more useful for studying of ischemia related effects, sterile inflammation, endogenous toxic effects, and antioxidant in liver (Van Golen *et al.*, 2012; Van Golen *et al.*, 2013).

Besides, methionine-choline deficient diet (MCD) also induced liver injuries. Bostrom-Westphal *et al.* (2003) observed that frequent hypermethioninemia and hyperhomocystinemia are proven that homocysteine-methionine pathway plays a critical role in liver metabolic function; hence, MCD had become a standard nutritional rodent model for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) (Yamaguchi *et al.*, 2007; Jorgacevic *et al.*, 2013; Itagaki *et al.*, 2013). Because the MCD model was malnutrition and toxic effect due to homocysteine accumulation (Boldyrev, 2009), it increased generation of ROS by both CYP2E1 and CYP4A enzymes (Ip *et al.*, 2003), and it also induced the expression of




inflammatory pathway (Mu *et al.*, 2010). In other ways, choline-deficiency not only impaired very low-density lipoprotein (VLDL) secretion (Rinella *et al.*, 2008) but also reduced the availability and generation of methionine (Zeisel *et al.*, 1991). Comparison with other NASH or NAFLD models, it involves oxidative injury, lipid metabolism, and proinflammatory cytokines (Jorgacevic *et al.*, 2013; Koek *et al.*, 2011) but not insulin resistance (Rinella and Green, 2004), so it remains a useful tool for delineating the mechanism of lipid-related liver injury from other diseases of metabolic syndrome.

Despite that viral hepatitis is a main cause of liver injury in many countries, viral infected model via infective agent has been unsuccessful. The only useful models are transgenic mice overexpressing virus B protein (HBV) or infected with MHV-3 (Ando *et al.*, 1993; Ding *et al.*, 1997), but these models display limitations in pathophysiological procedures which compare to human clinical researches (Newsome *et al.*, 2000; Rahman and Hodgson, 2000). Recently, Tuñón *et al.* (2011) described a new animal model of liver injury, especially in fulminant hepatic failure, using experimental infection of rabbits with rabbit hemorrhagic disease virus (RHDV). Furthermore, RHDV-infected rabbits have successfully represented a number of pathophysiological and biochemical features to human (Tuñón *et al.*, 2003; Sánchez-Campos *et al.*, 2004).

Chemicals (Table II-4) such as acetaminophen, carbon tetrachloride (CCl<sub>4</sub>), ethanol, and thioacetamide (TAA) etc. may respectively reproduce a number of important clinical characteristics (e.g., hypoglycemia, encephalopathy, and increased serum hepatic enzymes), but not completely represent them all in single certain model (Newsome *et al.*, 2000). Among all hepatotoxins, ethanol-induced model is quite different from others because it involves the

hepatic lipid accumulation additionally (Reddy and Rao, 2006). Therefore, ethanol-induced model is aimed at emulating clinical alcoholic fatty liver disease (AFLD).



Others, acetaminophen is a commonly used drug which causes dose-dependent hepatotoxic effect, and overdoses would switch the saturated normal pathway into cytochrome P-450 related pathway to form N-acetyl-p-bezoquinoneimine which induces cell damage (Sakai *et al.*, 1992). However, lacking of standardization of acetaminophen administration may be the problem for its reproducibility (Newsome *et al.*, 2000; Terblanche and Hickman, 1991).

Another, CCl<sub>4</sub> is the most common hepatotoxin of liver injured models (Slater, 1981), and it once was used as a solvent, degreaser, and cleaner both for industrial and home use until some studies proclaimed the toxicity and carcinogenicity of it. The effect of CCl<sub>4</sub>-induced toxicity depends on species, treating dose and duration, and observing time, so the pathophysiological procedures are amalgamated including loss of Ca<sup>2+</sup> storage, impairment of lipid homeostasis, release of various cytokines, apoptotic events, even fatty degeneration, fibrosis, cirrhosis, and cancer (Weber *et al.*, 2003). Generally, CCl<sub>4</sub> induced models does not correspond to certain liver disease but generate comprehensive damages in hepatic tissues; therefore, it is often used to exam the hepatoprotective effect of nutraceuticals or some clinical drugs. Recently, the CCl<sub>4</sub> induced models have been gradually replaced with the TAA-induced model because of its poor reproducibility, extrahepatic toxicity, hypertoxicity to either operators or animals, and small time window before death (Tuñón *et al.* 2009).

Table II-4. Main AHF animal models in different species

Animal models	species	Advantage/disadvantages
<i>Surgical</i>		
Total/partial hepatectomy	Pig, dog, rabbit, rat, mouse	Hepatic encephalopathy; reproducible/ no reversibility; no long-term survival
Total/partial devascularization	Pig, dog, rabbit, rat	Hepatic encephalopathy; reproducible/ no reversibility; no long-term survival
<i>Chemical</i>		
Acetaminophen	Pig, dog, rabbit, rat, mouse	Hepatic encephalopathy; no hazard/ non-reproducible; variable interval between damage and death; species and age variability
Amanitin	Pig	Hepatic encephalopathy; specific toxic effects; large animal
Azoxymethane	Mouse	Hepatic encephalopathy; reproducible/ small size; hazard
Carbon tetrachloride	Pig, rabbit, rat, mouse	Hepatic encephalopathy/ non-reproducibility; extrahepatic toxicity; small time window before death
Concanavalin A	Rat, mouse	Hepatic encephalopathy/ small size
Galactosamine	Pig, dog, rabbit, rat, mouse	Hepatic encephalopathy; biochemical markers/ non-reproducible; hazard; variable interval between damage and death; species differences
Lipopolysaccharide	Rat, mouse	Hepatic encephalopathy; reproducible/ no reversibility; small size; hazard; small time window before death
Thioacetamide	Rabbit, rat, mouse	Hepatic encephalopathy; reproducible; large time window before death/ hazard
<i>Viral</i>		
Rabbit hemorrhagic disease	Rabbit	Hepatic encephalopathy; reproducible; no hazard

(Tuñón *et al.*, 2009)


### 2.3.2 Synopsis of thioacetamide

Like most of hepatoxins, TAA was metabolized through CYP2E1 pathway, and its metabolites were proven harmful to livers. In the past, TAA had been widely used as an organic solvent in the textile, leather, and paper industries. It was as a catalyst in the vulcanization of Buna-Rubber reaction, or as a stabilizer of motor fuel, even as a fungicide. From 1981 to 1983, National Institute for Occupational Safety and Health surveyed its toxic effect on 786 workers under exposure in United States (National Toxicology Program, 2000). Nowadays, TAA has been an inducer of hepatic fibrosis (Ljubuncic *et al.*, 2005; Kang *et al.*, 2008).

Although TAA also generates comprehensive damage as CCl<sub>4</sub>, the toxic effect is not quite intense and severe as aforementioned, and the time window is longer for operation. Most importantly, it has better reproducibility (Tuñón *et al.* 2009). Many results support that experimental fibrosis/cirrhosis induced model via TAA shares a number of metabolic and histological alterations with those found in the human disease (Mangipudy *et al.*, 1995), i.e., apoptosis, periportal inflammatory cell infiltration (Ledda-Columbano *et al.*, 1991), scar formation (Pérez *et al.*, 2002), oxidative stress related damage (Bruck *et al.*, 2004), and DNA strand breaks (Yogalakshimi *et al.*, 2010). In conclusion, TAA models is the most appropriate experimental fibrosis models for this study that is related to common hepatoprotective effects.

### 2.3.3 Pathophysiological effect of thioacetamide


In 2005, Ljubuncic *et al.* (2005) reported that liver hepatic hypertrophy and lighter body weight were observed in TAA treated Sprague-Dawley rats, and it



was proclaimed that the symptom was caused by toxic metabolite of TAA, which was distinguished from high-fat diet model, non-alcoholic-fatty-liver model and other inducing factors related with obesity (Yang *et al.*, 2009b). As haloalkanes is, the toxicity of TAA is metabolites not the compound itself. It has been demonstrated that flavin-containing monooxygenase (FMO) and CYP2E1 are required enzymes for the bioactivation of TAA and TAA-induced hepatotoxicity in both rat and mouse models (Sanz *et al.*, 2002; Kang *et al.*, 2008). Meanwhile, TAA is metabolized into further adducts through them (Figure II-6) (Porter and Neal, 1978; Porter *et al.*, 1979), forming covalent-binding with other intracellular molecules were followed and an oxidative stress was induced (Bruck *et al.*, 2004; Tunez *et al.*, 2005). Until Chilakapati *et al.* (2005) had clarified the metabolism pathway and toxicity of TAA and its metabolites *in vivo*, it showed the mechanism to explain the characteristic of TAA intoxication. The evidences indicated that both of the first and the second step of TAA metabolic are saturable so that it lacks dose-response after reaching threshold; moreover, the TAA and TASO were eliminated in the urine under two different doses within 24h.

Reactive metabolites, which can covalently bind to cellular macromolecules, induced oxidative stress directly and indirectly (Witzmann *et al.*, 1996; Okuyama *et al.*, 2003; Pallottini *et al.*, 2006). Due to the detoxification of TAA, the ROS production was followed by lipid peroxidation, glutathione depletion and reduction in SH-thiol groups (Pallottini *et al.*, 2006). Recently it had found an endogenous multifunctional protein called thioredoxin (TRX) with redox-activity in livers, and TRX is also a stress-inducible protein that is enhanced by various types of stresses (e.g., viral infection, ultraviolet





light, X-ray irradiation, and hydrogen peroxide) (Nakamura *et al.*, 1997). In TAA intoxicated mice, it showed that TRX-binding protein 2 (TBP2) could be a potent regulator of not only lipid metabolism but also innate immunity in livers (Okuyama *et al.*, 2008). Although TRX and TBP2 are indicated to involve the redox pathway in injured livers, it still needs an advanced investigation to clarify the detailed mechanism.

Calcium is another key factor that responds to the TAA intoxication. The mobilization of  $\text{Ca}^{2+}$  from intracellular stores was observed (Diez-Fernandez *et al.*, 1996). The TAA administration inhibited ATP-dependent  $\text{Ca}^{2+}$  sequestration by a direct influence on the endoplasmic reticulum  $\text{Ca}^{2+}$  pump *in vivo*, and elevated the cytosolic  $\text{Ca}^{2+}$  (Diez-Fernandez *et al.*, 1996). Cytosolic  $\text{Ca}^{2+}$  was an important second messenger related to many cell biological procedures in many tissues even in livers (Orrenius *et al.*, 2003; Gaspers and Thomas, 2005; Fracchia *et al.*, 2013).

Moreover, both ROS and calcium homeostasis were determined to activate multiple mechanisms related to cell damage or proliferation (Brookes *et al.*, 2004). Mitochondria are not only for ATP synthesis but also play the key role for initiating cell apoptotic signals (Kass, 2006; De David *et al.*, 2011) when increased ROS formation and disruption of calcium homeostasis occurred (Bernardi *et al.*, 2001). It was also reported that some direct cell damage induced the cell necrosis and triggered the inflammatory response (Okuyama *et al.*, 2003; Laleman *et al.*, 2006; Shirai *et al.*, 2013). To summarize the above perspectives, the TAA intoxication results in cell death via direct and indirect pathways, which trigger the further inflammation.




Figure II-6. Metabolic pathway and pathophysiological effect of thioacetamide. Hydrophilic TAA is diffusing into cell plasma via channel, and goes by enzymatic system (purple) within some organelles (blue). Finally, the metabolites (orange) will cause the liver injury. The sign of ER and MIC were abbreviated for Endoplasmic Reticulum and Microsome. The meanings of showing number are as following, 1: Thioacetamide, TAA. 2: Thioacetamide S-oxide, TASO. 3 and 4: Thioacetamide S, S-dioxide, TASO<sub>2</sub> (unstable). 5: Acetyl sulfenic acid. 6: Acetamide (stable). 7: Amidine adducts (stable). 8: Amide derivatives (stable). ①: cytochrome P450 2E1/CYP2E1 and flavin-containing monooxygenase/FMO enzymatic system on ER or MIC. (modified from Hajovsky, 2012)

## 2.4 Hepatic fibrogenesis




### 2.4.1 Fibrogenesis and clinical research

According to a report by the International Agency for Research on Cancer in 2012, liver cancer is the second ranking of death causes among cancer categories worldwide, and it is the fifth most common cancer in male (554,000 cases, 7.5% of the total) and the ninth in women (228,000 cases, 3.4%). Besides, it is a huge problem of the eastern Asia, especially China (Figure II-7 & Figure II-8). Similarly, liver cancer was ranked first or second for cancer-related deaths within these five years in Taiwan (MOHW, 2012; Figure II-9). Furthermore, liver cancer is highly related to chronic liver diseases (CLDs), and the aetiology results in persisting inflammation, progressive fibrogenesis and chronic activation of the wound healing response (Povero *et al.* 2010). Overall, liver related diseases become a big issue in modern Taiwan society (Figure II-10).

Liver fibrosis (Figure II-11) is characterised by an excessive accumulation of extracellular matrix (ECM) proteins such as collagen, which mainly secreted by myofibroblast-like hepatic stellate cells (HSCs; also called activated HSCs). Since Hutterer and Rubin (1964) had proclaimed that terminal liver fibrosis is reversible on clinical reports, scientists had looked for a key to reduce liver fibrosis by decreasing ECM degradation and normalizing the HSCs' activation through damage-healing model until now.


According to a Bataller and Brenner (2005), the review article mentioned that the cause of liver fibrosis is due to the chronic liver damage, which may activate HSCs to become myofibroblast-like/ECM-secretion-capable cells. Although ECM deposition is proved to be acute protective response against live



damage generally (Lee and Friedman, 2010), the overloads of it, so called fibrotic scar, still leads to a conversion of the normal structure in hepatic tissues to regenerative nodules (liver cirrhosis) finally. Liver cirrhosis accompanies with liver dysfunction due to resistance of blood flows (hepatic portal hypertension), and the aforementioned progresses are irreversible (Schuppan and Afdhal, 2008). Therefore, liver therapy always focuses on fibrotic liver period. Nowadays medical technology is highly developed, but the crux that is present therapeutic drugs for liver fibrosis has many side-effects (i.e., extrahepatic toxicity, poor effectiveness to all type of liver fibrosis). Hence, many edible phytochemicals catch researcher's eye.

#### **2.4.2 Liver injury and inflammation**

Fibrosis is a wound-healing response that engages a range of cell types (Figure II-12) and mediators against liver injury. The oxidative stress and active molecule attacking are regarded as primary and direct factors among them, especially drug induced hepatic injury and fibrosis (Kaplowitz *et al.*, 2002). There are two classic pathways to generate ROS (members are shown as Figure II-13) in injured tissues: an induction of cytochrome P450 2E1 (Castillo *et al.*, 1992; Chitturi and Farrell, 2001), and lipid peroxidation (Paorla and Robino, 2001; Jaeschke, 2006). Oxidative stress may not only affect mitochondrial function but also enhance apoptosis via members of the TNF superfamily (e.g., TNFR1/2, FasL, DR4/5) (Shakibael *et al.*, 2005), which activate redox-sensitive kinases and transcription factors (e.g., AP-1, NF- $\kappa$ B.) (Kaplowitz and Tsukamoto, 1996; Czaja, 2002). An otherwise effect is that covalent binding between active metabolites and intracellular molecules directly attacks proteins,



lipids or nucleic acids within targeting cells (Jaeschke *et al.*, 2002; Jaeschke *et al.*, 2003; Kaplowitz and Tsukamoto, 1996), and it may cause metabolic disruption, ion dysregulation, mitochondrial and cellular swelling, activation of degradative enzymes, and necrosis finally (Proskuryakov *et al.*, 2003; Arends *et al.*, 1994).

An apoptosis-necrosis switch was found related to intracellular ATP concentration and NO signal in hepatic cells (Leist *et al.*, 1997; Nicotera and Melino, 2004). This suggests that they share common event in different types of cell death during an early injury response. Although the inflammatory pathway of necrosis has not been identified, Jaeschke (2002) proclaimed that apoptosis of parenchymal cells is no longer consequence of liver injury, but rather as an important inflammatory stimulus that activates HSCs. Hence, the inflammation is the key role to amplify of local direct damage into fibrosis via activating transcription of cytokines, chemokines, and adhesion molecules (e.g., TNF- $\alpha$ , IL-1 $\beta$ , and IL6) (Bataller and Brenner, 2005; Henderson and Iredale, 2007).

Estimated numbers (thousands)	Men			Women			Both sexes		
	Cases	Deaths	5-year prev.	Cases	Deaths	5-year prev.	Cases	Deaths	5-year prev.
World	554	521	453	228	224	180	782	746	633
More developed regions	92	80	112	42	43	51	134	123	164
Less developed regions	462	441	341	186	182	129	648	622	469
WHO Africa region (AFRO)	25	24	17	14	13	9	39	37	26
WHO Americas region (PAHO)	40	35	35	23	23	18	63	58	53
WHO East Mediterranean region (EMRO)	20	19	12	10	9	6	29	28	18
WHO Europe region (EURO)	47	44	42	23	25	20	71	69	61
WHO South-East Asia region (SEARO)	55	52	33	25	24	15	80	77	48
WHO Western Pacific region (WPRO)	368	347	314	133	129	112	501	477	426
IARC membership (24 countries)	120	104	135	56	55	60	176	159	195
United States of America	23	17	21	8	7	7	30	24	27
China	293	282	220	101	101	71	395	383	291
India	17	17	8	10	10	5	27	27	13
European Union (EU-28)	36	32	33	16	17	14	52	48	47

## International Agency for Research on Cancer




Figure II-7. The mortality and incidence of liver cancer worldwide. Liver cancer is largely a problem of the less developed regions where 83% (50% in China alone) of the estimated 782,000 new cancer cases worldwide occurred in 2012. It is the fifth most common cancer in men and the ninth in women. In men, the regions of high incidence are Eastern and South-Eastern Asia. Intermediate rates occur in Southern Europe (9.5) and Northern America (9.3) and the lowest rates are in Northern Europe (4.6) and South-Central Asia (3.7). In women, the rates are generally much lower, the highest being in Eastern Asia and Western Africa (10.2 and 8.1 respectively), the lowest in Northern Europe (1.9) and Micronesia (1.6). Liver cancer is the second most common cause of death from cancer worldwide, estimated to be responsible for nearly 746,000 deaths in 2012 (9.1% of the total). The prognosis for liver cancer is very poor, and as such the geographical patterns in incidence and mortality are similar. (IARC, 2012)

# International Agency for Research on Cancer




Figure II-8. The prevalence of liver cancer in different country for men. The prevalence of liver cancer in east asia is higher than other area obviously. Estimated age-standardised rates (World) per 100,000. This figure is modified from IARC (2012).




Figure II-9. Leading causes of death in cancer categories in Taiwan. (MOHW, 2012)






Figure II-10. The leading causes of death at 2001 and 2012 in Taiwan. (MOHW, 2012)




Figure II-11. The pathological process of liver injury to hepatocellular carcinoma. Liver fibrosis is characterised by an excessive accumulation of extracellular matrix proteins such under injury, and the ECM was mainly secreted by myofibroblast-like hepatic stellate cells (i.e., activated Kupffer cell, activated HSCs). The accumulated fibers will form the fibrotic scar, which will disrupt the blood flow and cause the destruction of liver. Finally, sever injury and fibrogenesis may turn into Cirrhosis (hepatic nodules and integrated fibrotic scar), and maybe hepatocellular carcinoma. Fortunately, the fibrogenesis is reverserable.




Figure II-12. Major responsive hepatic cells to fibrosis. Liver mass were mainly consisted by four kinds of hepatic cell, including: hepatocyte, endothelial cell, Kupfer cell and stellate cell. It is about 80% of live mass that is contributed to hepatocytes, which hold the critical role of hepatic metabolism, detoxification, urea formation, and sythesis of bile acid. Endothelial cells are the architectural supporter, because it will form the barrier bwtween sinusoid and space of Disse. In the sinusoid, Kupffer cells (Ito cell, fat-storing cell, perisinusoidal cell), the hepatic macrophage, will clean the fragments of dead cells and microorganisms, and it also can secrete defending cytokines. The last but not least, stellate cells (10% of liver mass) modulate the balance of extracellular matrix in liver, vitamin A storage, and hepatocyte growth factor in the space of Disse.




Figure II-13. Members of ROS and their generated pathway in antioxidative system. The antioxidative system is divided into two categories, antioxidant (orange) and antioxidative enzymes (blue). All the players in this pathway turn the harmful molecules such as ROS (red) into oxygen and water. The numbers indicate different antioxidative enzymes as following, ①: superoxide dismutase (SOD); ②: Catalase (CAT); ③: Glutathione reductase (GR); ④: Glutathione peroxidase (GPx).

### 2.4.3 Hepatic stellate cell activation and its molecular mechanism

Initial events of HSC activation are occurring on a background of progressive changes (e.g., paracrine and autocrine signals) in the surrounding ECM within the sub-endothelial space of Disse. By literatures reviewing, we found three steps of this progressive changes including: 1) changing the membrane receptors, altering matrix signals, and migrating through adhesion disassembly (Yang *et al.*, 2003; Melton *et al.*, 2007). 2) Activating cellular MMPs to release growth factors (Schuppan *et al.*, 1998; 2001). 3) Enhancing density of ECM (Wells, 2008). However, the reason that triggers HSCs activation is still unclear.

Although the opinions of regulatory pathway for HSCs activation are widely divided (Figure II-14), the Toll-like receptors (TLRs) related signals were involved, because those compelling pathways of injury were recently uncovered for innate immune signaling in liver. Paik *et al.* (2003) found that bacterial lipopolysaccharide (LPS) responsive receptors, TLR4, were unsurprisingly identified on Kupffer cells (specialized macrophages located in the liver), but also on HSCs unexpectedly. Moreover, although TLR4 signaling is essential for pathogen induced inflammation in macrophages (Hua *et al.*, 2007), many scientists indicated that TLR4 signaling in HSCs was not only triggered by LPS but also possibly endogenous ligands such as called damage-associated molecular patterns (DAMPs), which includes low molecular-weight hyaluronic acid (Taylor *et al.*, 2004; Jiang *et al.*, 2005), free fatty acids (Lee *et al.*, 2001), fibrinogen (Smiley *et al.*, 2001), fibronectin (Okamura *et al.*, 2001), heat shock proteins (HSPs) 60/70 (Chen *et al.*, 2004; Ohashi *et al.*, 2000), and high mobility group box (HMGB) 1 (Park *et al.*, 2004); furthermore, damage signals and intact

ECM degradation also activated TLR4 too *in vivo* (Brunn *et al.*, 2005).


Therefore, Friedman (2008) recommended that the TLR4 signal in HSCs may be more important than that in Kupffer cells in eliciting a fibrogenic response.

Activated human HSCs express TLR4 and its essential co-receptors (CD14 and MD2), and they have intact TLR4 signaling and regulate the downstream signal to induce proinflammatory features, such as upregulation of chemokines (CCL2, CCL3, and CCL4), adhesion molecules (Vascular cell adhesion molecule 1, VCAM-1; intercellular cell adhesion molecule 1, ICAM-1; E-selectin), and profibrogenic features including the increasing of TGF- $\beta$  signaling (Seki *et al.*, 2007; Paik *et al.*, 2003; Schwabe *et al.*, 2006). Under TLR4 signals, an otherwise effect is that anti-apoptosis signal was provoked, and it promoted HSCs' survivals (Guo *et al.*, 2009).

#### **2.4.4 TLR4 signaling in the liver injury and hepatic fibrogenesis**

TLRs mediate a tightly integrate signal transduction cascade conveying downstream signals that control transcription (Figure II-15). As De Creus *et al.* (2005) and Zarembler *et al* (2002) proclaimed, the mRNA of TLR4 and its signaling molecules were very low in healthy livers in comparison to other organs, and it contributed to the high tolerance of the liver to LPS from intestinal microbiota. The LPS is elevated in experimental models of hepatic fibrosis and in patients with cirrhosis (Seki *et al.*, 2007; Chan *et al.*, 1997), and it may be due to changes in intestinal motility and microbiota, mucosal integrity (Wiest and Garcia-Tsao, 2005). Generously, hepatic fibrosis contributes to a failure of the intestinal mucosal barrier, and causes increase LPS levels in liver.

In liver, TLR4 is not only expressed in HSCs and Kupffer cells but both the



hepatocytes and non-parenchymal cells (NPCs), and they all display a cell-specific activation pattern to TLR ligands (Chan *et al.*, 1997). Hepatocytes make up 70-85% of the liver cytoplasmic mass, so it is important to understand this kind of TLR4-responsive cells. Hepatocytes play an irreplaceable role in liver metabolism and detoxification, and they also remove the intercellular LPS via absorbing from systemic circulation and secreting into the bile (Scott *et al.*, 2009; Scott and Billiar, 2008). Moreover, the LPS uptake is through CD14-TLR4-MD2-dependent mechanism, and it is mediated by MAPK activation (Scott *et al.*, 2009; Scott and Billiar, 2008), stimulating hepatocytes to produce IL-6 and TNF- $\alpha$  via the TLR4-NF $\kappa$ B-dependent signaling (Galloway *et al.*, 2008). Obviously, TLR4-induced hepatocytes build a specific microenvironment for other cells to undergo fibrogenesis.

As Guo and Friedman (2010) mentioned, the downstream factors regulated by TLR4 signaling could divide into three parts. First, the TLR4 signal is as a causative factor of innate immune response, because it increases the expression of pro-inflammatory cytokines (TNF- $\alpha$ , IL-1, IL-6), chemotactic cytokines (monocyte chemotactic protein 1, MCP-1; macrophage migration inhibitory factor, MIF), pro-inflammatory proteins (inducible nitric oxide synthase, iNOS), ROS, adhesion molecules (ICAM-1, VCAM-1), and other effectors (cyclooxygenase 2, COX-2). Second, the TLR4 signal regulates cell-cycle progression and the apoptotic threshold via related proteins (e.g., cyclin D, Bcl-2, and Bcl-xL). Third, the TLR4 signal activates the HSCs that may interact to classic TGF- $\beta$  signal. The overall evidents showed that TLR4 signaling may be the linkage of inflammation and HSC activation in hepatic fibrogenesis progressing.

#### 2.4.5 The role of TGF- $\beta$ signaling in liver fibrosis

TGF- $\beta$  related pathway is the classic target in variant-organ fibrosis all along such as renal cells (Gentle *et al.*, 2013), pancreatic cells (Brandl *et al.*, 2013), colonic cells (Grau *et al.*, 2006), osteoclasts (Gingery *et al.*, 2008), and astrocytes (Hsieh *et al.*, 2010) *in vitro*. In liver, although scientists had found the relationship among HSCs activation, proliferation, and existence of TGF- $\beta$  proteins for much long time (Saile *et al.*, 2001), the up-regulator of them is still unclear.

Peng *et al.* (2013) reported that the anti-fibrotic effect was presented by suppressing the TGF- $\beta$ 1/Smad signaling in OS-polysaccharide-fed rats, moreover, it also inhibite the activation of HSCs, recovering the balance of MMPs and tissue inhibitor of metalloproteinases (TIMPs), which cotrol the ECM degradation so that it may also regulate the TLR4 signals. At the same year, Salama *et al.* (2013) found a kind of phytochemicals could protect liver in TAA-induced rats, and it suppress the expression of NF $\kappa$ B protein and decrease the apoptotic protein. In fact, Bitzer *et al.* (2000) had revealed the relevance between TGF- $\beta$  signal and NF $\kappa$ B protein in fibroblasts *in vitro*.As aforementioned, TLR4 signaling pathway may interact with TGF- $\beta$  signaling in HSCs (Guo and Friedman, 2010). NF $\kappa$ B may be the cross point resumptively (Figure II-15).






Figure II-14. Pathways of hepatic stellate cell activation. Features of stellate cell activation can be distinguished between those that stimulate initiation and those that contribute to perpetuation. Initiation is provoked by soluble stimuli that include oxidant stress signals (reactive oxygen intermediates), apoptotic bodies, lipopolysaccharide (LPS), and paracrine stimuli from neighboring cell types including hepatic macrophages (Kupffer cells), sinusoidal endothelium, and hepatocytes. Perpetuation follows, characterized by a number of specific phenotypic changes including proliferation, contractility, fibrogenesis, altered matrix degradation, chemotaxis, and inflammatory signaling. FGF, fibroblast growth factor; ET-1, endothelin-1; NK, natural killer; NO, nitric oxide; MT, membrane type. (Friedman, 2008)




Figure II-15. TLR4 and TGF-β related pathway in liver fibrosis.

### III. MATERIALS AND METHODS



#### 3.1 Chemicals

TAA were purchased from Sigma-Aldrich (St. Louis, MO, USA). As a chemical inducer for hepatic fibrosis, TAA was dissolved in sterile phosphate-buffered saline (PBS). The *Ophiocordyceps sinensis* mycelium (OSM) powder (TCM-808FB<sup>®</sup>), which contains 10% polysaccharide and 0.25% adenosine, was kindly provided by the TCM Biotech International Corp. (Taipei, Taiwan). According to the composition analysis of TCM-808FB, the dry matter mass is 72.82%.

#### 3.2 Animal and treatments

A total of 48 male Wistar rats (6 weeks old) weighting between 250-300 g were used in this study, and they were obtained from BioLASCO Taiwan Co., Ltd (Taipei, Taiwan). In animal room, every two rats were housed in one cage under the condition of 22±2°C, approximately 60-80% relative humidity, and 12-h light-dark cycle. Otherwise, the diet and water were *ad libitum* for them.

All rats were acclimatized for one week prior to the experimental treating (Figure III-1). Rats were randomly divided into 4 groups: 1) Control: saline (i.p.) and pure water (gavage); 2) TAA: TAA (100 mg/kg BW, i.p.) and pure water (gavage); 3) OSML: TAA (100 mg/kg BW, i.p.) and OSM (280.8 mg TCM-808FB /kg BW, gavage); 4) OSMH: TAA (100 mg/kg BW, i.p.) and OSM (1404 mg TCM-808FB /kg BW, gavage). TAA and OSM treatments were both given three times per week during a persistent 8-week period. At the end of the treatment period, rats were fasted, and sacrificed. Immediately, blood and tissue samples were harvested for further analyses. Animal use and protocol were reviewed and approved

by the National Taiwan University Institution Animal Care and Use Committee  
(IACUU No.: 100-015).





Figure III-1. Experimental design of this study

### 3.3 Sample collection

During the experimental period, food and water intakes, and body weight were recorded weekly. At the end of experiment, rats were fasted overnight. Then they were euthanized by ethoxyethane (Sigma-Aldrich, St. Louis, MO, USA), and harvested blood samples by abdominal aorta puncture. The liver, heart, and kidney from each rat was removed and weighted individually. Liver was cut off two or three one cubic millimeter soaking with 10% formalin (Sigma-Aldrich, St. Louis,

MO, USA) for histopathological section, and the others were placed into liquid N<sub>2</sub> for further analysis. Finally, all the samples but the aforementioned samples for section were stored at -80 °C for subsequent analyses.



### **3.4 Serum biochemical value analyses**

Blood samples were collected from the abdominal aorta and placed for 1 hour at room temperature to allow clotting. Then the serum were collected by a centrifugation at 3,000 x g for 15 min (Model 3740; KUBOTA, Tokyo, Japan) and then stored at -80 °C for subsequent analyses. The serum alanine aminotransferase (ALT; GPT), aspartate aminotransferase (AST; GOT), triglyceride (TG), and cholesterol (TC) levels were assayed by using an ARKRAY SPOTCHEM SP-4410 automatic dry chemistry analyzer (ARKRAY, Kyoto, Japan) with respective kits.


### **3.5 Preparation of liver homogenate**

A 0.5 g amount of liver was homogenized on ice in 4.5 mL of phosphate buffer saline (PBS, pH 7.0, containing 0.25 M sucrose) and centrifuged at 12,000 x g for 30 min (Model 3740; KUBOTA, Tokyo, Japan). The supernatant was collected for further analyses. The protein content in the supernatant was measured according to the procedures of a Bio-Rad protein assay kit (catalog #500-0006; Bio-Rad Laboratories, Inc., Hercules, CA, USA) using bovine serine albumin as a standard.

### **3.6 Liver lipid analyses**

Liver triglyceride and cholesterol concentrations were measured according to the procedures (Yang *et al.*, 2010). Briefly, liver lipid was extracted by chloroform and methanol (2:1, v/v). The extract was dried under N<sub>2</sub> and resuspended in

isopropanol via an ultrasonic cleaner (Model: DC150H, Taiwan Delta New Instrument, TW). Triglyceride (TAG), cholesterol (TC), and bile acid concentrations were measured by using commercial kits (Randox Laboratories Ltd., Lodon, United Kingdom).



The former two commercial kits were both developed and based on the methods from Trinder (1969). The triglycerides of samples were hydrolysed into glycerols and fatty acids, and the glycerols may be phosphorylated to glycerol-3-phosphate via glycerol kinase, consequently, forming the dihydroxyacetone, phosphate, and H<sub>2</sub>O<sub>2</sub> by glycerol-3-phosphate oxidase. Last, the end products transformed into light-pink-targets, quinoneimine, by peroxidase. Reading the O.D. values under 500nm wavelength and calculating by following formula:

The triglycerides of sample (*mg/dL*)

$$= \frac{O.D. \text{ value}_{500nm} \text{ of sample}}{O.D. \text{ value}_{500nm} \text{ of standard}} \times \text{the concentration of standard}$$

The method of cholesterol analysis was quite similar. Cholesterol esters of sample were hydrolysed into cholesterol and fatty acids via cholesterol esterase, oxidizing into cholestene-3-one and H<sub>2</sub>O<sub>2</sub> by cholesterol oxidase. Similarly, the end products and additive 4-aminoantipyrine reacted and formed the quinoneimine. After all, reading the O.D. values under 500nm wavelength and calculating by following formula:

The cholesterol of sample (*mg/dL*)

$$= \frac{O.D. \text{ value}_{500nm} \text{ of sample}}{O.D. \text{ value}_{500nm} \text{ of standard}} \times \text{the concentration of standard}$$



### 3.7 Antioxidative capability analyses


#### 3.7.1 Thiobarbituric acid reactive substances (TBARS)

MDA, by-product of lipid peroxidation, which binds to thiobarbituric acid (TBA, J. T. Baker; Malinckrodt Baker, Inc., Philipburg, NJ, USA) undergoes color reaction to pink. Both MDA and GSH content were performed according to procedures by Yang *et al.* (2009a). Liver homogenate or PBS for blank was added 1 mL into pre-mix solution that contained 1.5 mL TBA and 8.5 mL Trichloroacetic acid-hydroxyl chloride reagent (TCA-HCL; Sigma-Aldrich, St. Louis, MO, USA). The samples were heated in 95 °C water-bath for 30 min, cooling on ice for 10 min, centrifuging in 4 °C 9170 x g for 5 min (Model 3740; KUBOTA, Tokyo, Japan), last, the supernatant will measure under 535 nm wavelength.

$$\begin{aligned} \text{TBARS of liver tissue} & \left( \frac{\text{nmole MDA}}{\text{mg protein}} \right) \\ & = \text{sample } O.D_{.535\text{nm}} \times \frac{705.15}{\text{protein Con. of liver tissue}} \end{aligned}$$

#### 3.7.2 Glutathione (GSH)

Basically, the cysteine among GSH binds to 5,5'-dithiobis (2-nitrobenzoic acid, DTNB; Sigma-Aldrich, St. Louis, MO, USA) and undergoes color reaction into yellow (thio-2-nitrobenzoic acid). Before the analysis, 0.5 mL 10% tissue sample was added into 0.5 mL 10% Trichloroacetic acid (TCA; Sigma-Aldrich, St. Louis, MO, USA), mixing, reacting for 5 min at room temperature and centrifugated (2290 x g, 10 min, 4 °C; Model 3740; KUBOTA, Tokyo, Japan). Then the 50 µL supernatant was added into the tube with 1 mL Tris base (Apolo,



TW) - EDTA (ethylenediaminetetraacetic acid, J. T. Baker; Malinckrodt Baker, Inc., Philipburg, NJ, USA) buffer (20mM) and read for value A1 under 412 nm wavelength. The 20  $\mu$ L DTNB was added into the former interacting buffer, and incubating for 5 min. Last, the optical density value of each well was measured by the Synergy H1 hybrid reader (Bio-Tech Instruments, Inc., Wooski, VT, USA) as value A2. Importantly, the values were calibrated with the blank (value B), whose sample was replaced by water in final reacting buffer, due to the background color of DTNB.

$$\text{GSH content of liver (nmole/mg protein)} = \frac{(A_2 - A_1 - B) \times 15.7 \times 20 \times 10^3}{\text{protein Con. of liver tissue}}$$

### 3.7.3 Trolox equivalent antioxidant capacity (TEAC)

The TEAC value was analyzed according to a method described by Hung *et al.* (2006). A free radical, ABTS<sup>+</sup>, can be generated by mixing ABTS (100  $\mu$ M; Sigma-Aldrich, St. Louis, MO, USA) with H<sub>2</sub>O<sub>2</sub> (50  $\mu$ M; Sigma-Aldrich, St. Louis, MO, USA) and peroxidase (4.4 U/mL; Sigma-Aldrich, St. Louis, MO, USA). The TEAC value was expressed as a scavenging capacity against ABTS<sup>+</sup>. Briefly, a 0.25mL mixture of ABTS, H<sub>2</sub>O<sub>2</sub>, peroxidase, and 1.5 mL of dd H<sub>2</sub>O were mixed well, consequently, it was placed under a dark room. After 30 min, 0.25 mL of diluted liver homogenate (1%, v/v) was then added. The absorbance was measured at 734 nm wavelength after the interaction of sample solution for 10 min. The decrease in absorption at 734 nm after the addition of reactant was used to calculate the TEAC value. A standard curve was plotted for Trolox on scavenging ABTS<sup>+</sup> capacity and was used for calculation for TEAC of samples. The higher TEAC value of a sample results in the stronger antioxidant activity.





### 3.7.4 Superoxide dismutase (SOD)

The SOD was measured by the inhibitory effect of SOD on pyrogallol autoxidation (Mueller *et al.*, 2009). Under the condition of pH 7, pyrogallol undergone auto-oxidation and formed the anion free radicals, purporalin, which turned into yellow. Therefore, the tissue origin SOD could retard the pyrogallol auto-oxidation and reduce the formation of purporgalin.

Briefly, 100  $\mu$ L of 10% liver homogenate was mixed well with 650  $\mu$ L of PBS (pH 7.0; Bio-kit, Inc., Maoli, Taiwan). After centrifugation at 6000 x g for 10 min under 4 °C (Model 3740; KUBOTA, Tokyo, Japan), 10  $\mu$ L of supernatant was mixed with 3 mL of Tri-HCl buffer (50mM, pH 8.2; APOLO, Taipei, Taiwan) and 15  $\mu$ L of pyrogallol (0.2 mM; Riedel-de Haën; Sigma-Aldrich, St. Louis, MO, USA). The absorbance change caused by the formation of the yellow pyrogallol oxidation product, purpurogallin, was recorded at 420 nm wavelength in 3 min. One unit of SOD activity was defined as the amount of enzyme that inhibited the autoxidation of pyrogallol by 50%. The hepatic SOD activity was expressed by unit/mg protein.

$$\text{Activity of SOD} \left( \frac{\text{unit}}{\text{mg protein}} \right) = \frac{(\text{standard } O.D._{.60s} - \text{standard } O.D._{\text{initail}}) - (\text{sample } O.D._{.60s} - \text{sample } O.D._{\text{initial}})}{(\text{standard } O.D._{.60s} - \text{standard } O.D._{\text{initail}}) \times 50\% \times \text{protein Con. of liver tissue}}$$

### 3.7.5 Catalase (CAT)

The CAT activity was performed according to the procedure as described by Hong and Lee (2009) with a slight modification. Briefly, 450  $\mu$ L of liver homogenate was mixed well with 50  $\mu$ L of triton X-100 (10% v/v; AMRESCO,

Solon, OH, USA). After centrifugation at 6000 x g for 10 min under 4 °C, a mixture of 10 µL of supernatant and 990 µL of PBS (pH 7.0; Bio-kit, Inc., Maoli, Taiwan) was reacted with 0.5 mL of H<sub>2</sub>O<sub>2</sub> (30 mM; Sigma-Aldrich, St. Louis, MO, USA). The difference in absorbance between initial and 3 min incubation was measured at 240 nm wavelength. The hepatic CAT activity was calculated by taking the extinction coefficient of H<sub>2</sub>O<sub>2</sub> to be 0.0395 mM<sup>-1</sup>cm<sup>-1</sup>. One unit of CAT was expressed as the amount of enzyme that decomposes 1 µmole H<sub>2</sub>O<sub>2</sub> per min at 25 °C. The hepatic CAT activity was expressed by unit/mg protein.

Activity of CAT (*unit/mg protein*)

$$= \frac{\left\{ \frac{(sample\ O.D._{initial} - sample\ O.D._{60s})}{0.0395\ (mM^{-1}cm^{-1}) \times 1\ (cm)} \times 0.75\ (mL) \right\}}{0.75\ (mL) \times protein\ Con.\ of\ liver\ tissue\ (mg/mL)} \Big/ 1(min)$$

### 3.7.6 Glutathione peroxidase (GPx)

The GPx activity was measured according to the procedure as described by Hong and Lee (2009) with a slight modification. Briefly, 2 µL of liver homogenate was mixed with 988 µL of reaction solution containing 100 mM PBS (pH 7.0; Bio-kit, Inc., Maoli, Taiwan), 10 mM EDTA (J. T. Baker; Malinckrodt Baker, Inc., Philipburg, NJ, USA), 10 mM NaN<sub>3</sub> (Sigma-Aldrich, St. Louis, MO, USA), 2 mM NADPH (Sigma-Aldrich, St. Louis, MO, USA), 10 mM GSH (L- Glutathione reduced; Sigma-Aldrich, St. Louis, MO, USA), and 1 U/mL GSH reductase (from Bakers yeast; Sigma-Aldrich, St. Louis, MO, USA). After 3 min, 100 µL of H<sub>2</sub>O<sub>2</sub> (2.5 mM; Sigma-Aldrich, St. Louis, MO, USA) was then added. The difference of absorbance between 0 and 3 min was measured at 340 nm wavelength.

$$\text{Activity of GPx} \left( \frac{\text{nmole NADPH}}{\text{min} \times \text{mg protein}} \right) = \frac{(\text{sample } O.D._{60s} - \text{sample } O.D._{\text{initial}}) - (\text{standard } O.D._{60s} - \text{standard } O.D._{\text{initial}})}{622 \times 10^6 \times 2 \times \text{protein Con. of liver tissue}}$$




### 3.8 Inflammatory cytokine analyses

Hepatic tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) (Quantikine Rat TNF- $\alpha$  immunoassay, CAT: RTA00) and interleukin-1 $\beta$  (IL-1 $\beta$ ) (Quantikine Rat IL-1 $\beta$ /IL-1F2 immunoassay, CAT: RLB00) content were measured by sandwich enzyme-linked immunosorbent assay (ELISA) and the procedures were followed according to the commercial manufacturer's instructions (R&D system, Inc., Minneapolis, MN, USA).

First, 10% liver homogenous, control buffer, washing buffer, standard solution, and substrate solution were prepared before the experiments. 50 $\mu$ L of assay diluent (TNF- $\alpha$ : RD-1-41; IL-1 $\beta$ : RD1-21) were added into 96-well plate, then 50 $\mu$ L standard and samples were added into plate and incubated for 2 hours at room temperature. Then the plate was washed by washing buffer and then conjugate was added 100  $\mu$ L into plate which next incubated for 2 hours at room temperature, and repeated the washing processing. Finally, 100 $\mu$ L substrate solution was added into plate then incubated for 30 min at room temperature in the dark room, and then 100 $\mu$ L of stop solution was added into each well. After 30 min reaction, immediately, the optical density value of each well was measured in an ELISA reader. Hepatic TNF- $\alpha$  and IL-1 $\beta$  levels were both expressed by pg/mg protein.

### 3.9 Histopathological sections and staining


For a histopathological study, liver tissues were placed in formalin



(Sigma-Aldrich, St. Louis, MO, USA) up to 24 hours, and all samples were fixed in a new neutral-buffered formalin solution again. Consequently, they were dehydrated in graded alcohol (ECHO chemical, Taipei, Taiwan), cleared in xylene (Merck Millipore, Darmstadt, Germany), and embedded in paraffin wax (Leica Microsystems, Singapore) by embedding plate (Electron Microscopy Sciences, Hatfield, USA) and plastic ware (Simport, Beloeil, Canada) under the Hybridization Oven (RH-800; YIH DER, Taipei, Taiwan) and Digital Dry Bath h Incubator (Genepure Technology, Taipei, Taiwan). These blockers were later sectioned using a HM315R microtome (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Moreover, the paraffin-embedded sections were put in water bath (WB100, Taiwan) for spreading out, and dried by electronic heating plate (HP1200, Taiwan). All sections were dehydrated in graded alcohol, embedded in paraffin section, and stained with hematoxylin (Merck Millipore, Darmstadt, Germany) and eosin (Merck Millipore, Darmstadt, Germany). The Masson's trichrome method is a specific staining for collagen. The commercial kit was purchased from Sigma-Aldrich Co. (Product No. HT15). All the fixed, dehydrated, embedded and hematoxylin staining processing is same to the preceding paragraph, but the sections were stained with Biebrich-scarlet-acid fuchsin solution, hosphomolybdic- phosphotungstic acid solution, aniline blue solution and acetic acid solution.

The values of fibrosis and inflammation were given by trained observers in double blind assay. The former one was following the METAVIR fibrosis staging system (Figure III-2) that was usually for clinical diagnosis. The samples were categorized into 5 levels depend on the severity. Finally, the different scores were given to each group for analysis. Whereas the later one followed the general international standards, histology activity index score (HAI score; Table II-1). The

activity of inflammatory level was valuing according to area condition such as portal inflammation, intralobular degeneration and periportal-bridging necrosis.







Figure III-2. The criteria of METAVIR fibrosis staging system (Brunt, 2000)



Table III-1. International histology activity index (HAI) score

EVENT	OBSERVED DETAIL	SCORE
Portal inflammation	No inflammation	0
	Slight inflammation (less than 1/3)	1
	Middle inflammation (about 1/3 to 2/3)	3
	Sever inflammation (more than 2/3)	4
Intralobular inflammation	No inflammation	0
	Slight inflammation (less than 1/3)	1
	Middle inflammation (about 1/3 to 2/3)	3
	Sever inflammation (more than 2/3)	4
Periportal degeneration	No periportal degeneration	0
	Slight focal necrosis (less than 10%)	1
	Middle focal necrosis (less than 50%)	3
	Sever focal necrosis (more than 50%)	4
	Middle focal and bridging necrosis	5
	Sever focal and bridging necrosis	6
	Multi-lobe necrosis	10

(Brunt, 2000)



### 3.10 Collagen assay

The collagen assay was performed according to the procedure as described by Reddy and Enwemeka (1996) with a slight modification. The concentration of hydroxyproline (Sigma-Aldrich, St. Louis, MO, USA) is representative value for collagen because every 7.46 g collagen contains 1 g hydroxyproline.


Before analysis, there were three essential buffers required, and all the chemicals in this analysis were purchased from Sigma-Aldrich, Inc. First, the acetate-citrate buffer (pH=6.5) which contains 120 g sodium acetate trihydrate, 46 g citric acid, 12 mL acetic acid, and 34 g sodium hydroxide in 1 L deionized water. Second, Chloramine-T (0.056 M) contains 1.27 g chloramine-T, 20 mL 50% N-propanol in 1 L deionized water. The last, Ehrlich's reagent required 15 g dimethylaminobenzaldehyde in 100 mL solvent that was consisted of N-propanol and perchloric acid (2:1 in volume).

Briefly, the serial dilution of hydroxyproline stock was added into 96-well plate as standard, and the sample were added into plate too, but they were required to be autoclaved at 120 °C for 20 min before use. First, hydroxyproline was oxidized into pyrrole by chloramine-T, and reacted with Erlich's reagent for color reaction.

$$\text{Con. of tissue collagen} \left( \frac{g}{g \text{ liver}} \right) = \text{Con. of hydroxyproline} \times 7.46$$



### 3.11 Real-time polymerase chain reaction (Realtime-PCR)



After sacrificing the experimental mice, 0.1 g liver tissue in 0.5 mL RNA later (Qiagen, Valencia, CA, USA) at room temperature overnight, and then stored at -80 °C until analysis. A commercial kit (E.Z.N.Z™ Tissue RNA kit, Omega Bio-Tek, Norcross, GA, USA) was applied to extract the mRNA from liver tissues, and the cDNA was synthesized from mRNA by the reverse transcriptional reaction according to the manufacturer's protocol offered by ImProm-II™ Reverse Transcriptase (Promega, Madison, WI, USA). According to the principle of quantitative real time PCR, all the primers (Table III-2) were designed for the specific gene sequences in order to amplify the specific cDNA fragments. Two μL cDNA (50 ng/μL), 5 μL SYBR Green (Fast SYBR® Green Master Mix, Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 2 μL RNase free water, and 1 μL primer were mixed together. After a centrifugation (KUBOTA8700, KUBOTA, Tokyo, Japan; Rotor RS-3000/6 053-5930), the remnant was spun down by 1350 x g for 3 min. the fluorescence signals of each target gene were detected by using the StepOne Real time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). GAPDH was used as an internal control, and the values of all genes in TAA, OSML, and OSMH rats were expressed relatively to the average value of Control rats, which was set to 1.0.

Table III-2. Primer sequences and PCR product size for quantitative real time PCR

Gene	Size	Accession number	Primer sequence (5'-3')
Gapdh	264	NM_017008.4	F: GACCCCTTCATTGACCTCAAC R: GGAGATGATGACCCTTTTGGC
Tgfb1	86	NM_021578.2	F: CCTGAAAGGGCTCAACACC R: CAGTTCTTCTCTGTGGAGCTGA
Tgfb1	159	NM_012775.2	F: TCCAAACCACAGAGTAGGCAC R: TGGATTCCGCCAATGGAACA
Tgfb2	78	NM_031132.3	F: CCGTGTGGAGGAAGAACGAC R: TGAAGCCGTGGTAGGTGAAC
Tlr4	165	NM_019178.1	F: CTACCTCGAGTGGGAGGACA R: TGGGTTTTAGGCGCAGAGTT
Myd88	118	NM_198130.1	F: CTCGCAGTTTGTGGATGCC R: TCGATGCGGTCCTTCAGTTC
Trif/Rnf138	95	NM_053588.2	F: CCTATGTCGCGGAAGTGTGA R: TGCAGCTACCAGAAACCCTC
Akt	178	NM_033230.2	F: GAAGTCTGAGCCCACCTTTCA R: CCACTGGCTGAGTAGGAGAAC
Nfkb1	145	NM_001276711.1	F: TGGGGCCTGCAAAGGTTATC R: TTTGCAAAGCCAACCACCAT
Cox2	94	NM_017232.3	F: TGTATGCTACCATCTGGCT R: GTTTGGAACAGTCGCTCGTCATC
Col1a1	102	NM_053304.1	F: GACTGTCCCAACCCCAAAA R: CTTGGGTCCCTCGACTCCTA
Acta2/ $\alpha$ SMA	200	NM_031004.2	F: TTCGTTACTACTGCTGAGCGTGAGA R: AAAGATGGCTGGAAGAGGGTC

### 3.12 Immunohistochemical analysis (IHC)

The commercial kit of immunohistochemistry assay was purchase from VECTOR Laboratories (Mouse IgG, PK-6102; Rabbit IgG, PK-6101). The procedure was according to the instructions manual.



Before the immunochemical reaction, all sections should be deparaffinized and hydrated through xylene, graded alcohol, and tap water. Consequently, antigen retrieval was necessary step for antigen presenting, all the sections were sunk into sodium-citrate buffer which contain 2.581 g citric acid (Sigma-Aldrich, St. Louis, MO, USA) and 500  $\mu$ L Tween-20 (Chumeia chemical Inc.) in 1 L deionized water; the sections were heated by microwave for 10 min three times. After cooling, blocking procedure were taken via biotin/avidin blocking kit (SP-2001; VECTOR Laboratories, Inc., Burlingame, CA, USA) and H<sub>2</sub>O<sub>2</sub> (Sigma-Aldrich, St. Louis, MO, USA)/methanol (Sigma-Aldrich, St. Louis, MO, USA) buffer 30 min each step, which would eliminate the endogenous noise from peroxidase, biotin, and avidin. Finally, blocking buffer which contained the animal serum was added upon the tissue area for 20 min. PBS was added to wash the sections 5 min four times between the different buffers.

Sections were incubated with primary antibody (Table III-3) that diluted to optimal concentration, and they were washed and added the diluted biotinylated secondary antibody solution for optimal reacting time. Next, all samples were incubated with VECTASTAIN<sup>®</sup> Elite ABC Reagent for 30 min each buffer. Last, slides were hybridized with DAB peroxidase substrate (Cat. No. SK-4100, VECTOR Laboratory, CA, USA) until desired stain intensity develops. After all, we rinsed sections in tap water, and it gone to counterstain, clean, and mount. When the sections were completely dry, the Axioskop microscope (ZEISS, Oberkochen,

Germany) was used to observe the tissue section. The microphotography was taken through commercial program, AxioVision Rel. 4.8, from ZEISS.





Table III-3. Product sheets of primary antibody for IHC

Primary Antibody	Cat. number	Company
NFkappaB/p65	PA5-16545	Thermo Fisher Scientific, Inc., Waltham, MA, USA
Anti-Actin, Smooth muscle, clone ASM-1	CBL171	Merck Millipore, Darmstadt, Germany

## IV. RESULTS




### 4.1 Effects of OS mycelium on growth performance of rats

The growth performance is an important factor of liver injury, and the body weight is the representative value for metabolic efficiency. At the end of 8-weeks experiment, the body weight of control group was heavier ( $p < 0.05$ ) than TAA-treated group (Figure IV-1), but there were not ( $p > 0.05$ ) difference on body weight among TAA-treated groups (TAA, OSML, and OSMH). During the experimental period, the food intakes were not different ( $p > 0.05$ ) (Table IV-1), but water intakes of TAA-treated groups (43.24~45.51 mL/rat/day) were less ( $p < 0.05$ ) than that of Control group (54.29 mL/rat/day) (Table IV-1). Regarding to organ sizes, there was no ( $p > 0.05$ ) different on heart size among groups, but liver and kidney sizes were increased ( $p < 0.05$ ) in TAA-treated groups compared to those of Control group. The liver size of TAA group was 3093.84 mg/100g BW, but control group is only 2459.16 mg/100g BW (Table IV-1). It may be due to the hepatic hypertrophy and inflammation induced by TAA. As this observation, it was speculated that OS mycelium treatment could alleviate the TAA-induced damage for liver and kidney.

### 4.2 Effects of OS mycelium on serum and liver lipids

According to the data from National Laboratory Animal Center, Taiwan, the rat's TG and TC levels in this study coincide to their normal physiological ranges. At the end of experiment, while lower serum lipids (TG and TC) occurred in TAA-treated groups, OS mycelium supplementation increased ( $p > 0.05$ ) serum lipids, especially TC which normalized to the level of Control groups (Figure IV-2;

C and D). In liver lipids, it showed opposite results to serum lipid results. The liver lipids of TAA-treated groups are higher ( $p > 0.05$ ) than those of Control group, but OS mycelium supplementation reduced ( $p < 0.05$ ) them (Table IV-1). These results imply that OS mycelium can reduce lipid accumulation in livers.




#### **4.3 Effects of OS mycelium on antioxidative capacity of livers**

The liver antioxidant capacities are shown on Table IV-2. It was reported that a raising intrahepatic oxidative stress easily results in the liver injuries (Kaplowitz, 2002). The MDA, a by-product of polyunsaturated fatty acid peroxidation, increased ( $p < 0.05$ ) in TAA-treated groups (Table IV-2), but decreased ( $p < 0.05$ ) when supplemented with OS mycelium (Table IV-2). Although there was no ( $p > 0.05$ ) differences on liver GSH contents among groups, rats injected by TAA without OS mycelium had lower ( $p < 0.05$ ) liver TEAC value than Control rats but OS mycelium supplementation normalized ( $p < 0.05$ ) liver TEAC values to the Control group (Table IV-2). Similarly, the activities of liver antioxidative enzymes including SOD, CAT, and GPx were decreased ( $p < 0.05$ ) by TAA treatment, but OS mycelium supplementation increased ( $p < 0.05$ ) them (Table IV-2).

#### **4.4 Effects of OS mycelium on liver damage**

Serum AST (GOT) and ALT (GPT) values are often used as biochemical markers for liver injury. As expected, while TAA group had higher ( $p < 0.05$ ) values than Control group, but OS mycelium supplementation decreased AST and ALT values ( $p < 0.05$ ) (Figure IV-2; A and B). For another, inflammatory cytokine such as TNF- $\alpha$  and IL-1 $\beta$  were determined in this study. Based on the results, the TAA treatments indeed raised ( $p < 0.05$ ) hepatic TNF- $\alpha$  and IL-1 $\beta$  values (Figure IV-3),



and OS mycelium supplementation decreased ( $p < 0.05$ ) them (Table IV-3). Similarly, the hepatic collagen content was increased ( $p < 0.05$ ) by TAA compared to that of Control group but decreased ( $p < 0.05$ ) by OS mycelium (Table IV-3). Regarding to histopathological analyses, the visible signs of fibrosis and intrahepatotic inflammation were directly observable (Figure IV-3 & Figure IV-4). By microscopic images and double-blind experimental design the results show that OS mycelium supplementation alleviated ( $p < 0.05$ ) the processing of liver damages (Figure IV-3 & Figure IV-4). In the microscopic image of trichrome staining, visible fibrotic scar and collagen is strong evident for fibrosis in TAA group, and those observations of TAA-treated groups were reduced ( $p < 0.05$ ) by OS mycelium supplementation (Figure IV-3) which is corresponding to the results of hepatic collagen assay (Table IV-3). For H&E staining, the values determined with the size of monocyte- aggregated area (black arrow), the amount of cell under necrosis (black triangle), the morphology of portal area and intralobular area. The results were also similar as the results I Masson's trichrome staining (Figure IV-4). In Figure IV-5, arrow heads indicated  $\alpha$ SMA positive areas. Apparently, TAA group had larger those areas than Control group. OSM supplementation significant reduced them wich is corresponding to the observation of Masson's trichrome (fibrotic scars in Figure IV-3).


#### **4.5 Protective mechanism by OSM supplementation**

According to the mRMA expressions of NF $\kappa$ B induction pathways, the TGF- $\beta$  (Figure IV-6) and TLR4 pathway (Figure IV-7), TAA treatment significantly induced ( $p < 0.05$ ) TGF- $\beta$ , TGFBR1, and TGFBR2, as well as TRIF and Akt, respectively, while TLR4 and MyD88 gene expressions were not influenced ( $p > 0.05$ ).

Regarding to the fibrosis related gene expressions (Figure IV-8),  $\alpha$ SMA, Col1 $\alpha$ , NF $\kappa$ B, and COX2 were upregulated ( $p < 0.05$ ) by TAA intoxication. Those changed patterns of gene expressions were downregulated ( $p < 0.05$ ) by OSM supplementation, especially a high dosage of OSM. In the immunohistochemical analysis of NF $\kappa$ B protein (Figure IV-9), there were several NF $\kappa$ B positive cells (dash circles) in liver tissues of TAA treated groups. However, an inflammation was induced only by the entrance of NF $\kappa$ B subunit (p65) into nuclei (arrow head). In a comparison of NF $\kappa$ B p65 entrances, liver sections in TAA treated mice without OSM supplementation showed more positive nuclei than those with OSM supplementation.



## V. DISCUSSION



Ljubuncic *et al.* (2005) reported that liver hepatic hypertrophy and lighter body weight are observed on TAA treated Sprague-Dawley rats where the results were also observed in our experiment (Figure IV-1 & Table IV-1). Meanwhile, it has also proclaimed that these symptoms are caused by toxic metabolite of TAA, which differs from high-fat diet animal model, non-alcohol fatty liver animal model and other inducing factors related with obesity (Yang *et al.*, 2009b). A recent report from our team also showed the lower body weight and larger liver size of mice treated with TAA but co-treatment of silymarin reversed these observations (Chen *et al.*, 2011). Based on our data, it is speculated that OS mycelium is potentially hepatoprotective. Otherwise, TAA often causes kidney damage with chronic liver damage both in human clinical and animal researches (Water *et al.*, 2005). The reason is that liver fibrogenesis forms the intrahepatic nodules which press the portal vein and cause portal hypertension during the pathological processing. The efficiency for filter and sodium re-absorption was decreased in glomerulus that decreases the effective blood volume (Natarajan *et al.*, 2006; Hocher *et al.*, 2011), so it is reasonable to explain the increased kidney size and decreased water intake presented in this study (Table IV-1).

Synder *et al.* (2012) proclaimed the relation between serum albumin and muscle mass changes. According to our results, serum albumin levels were consistent among all treating groups (Table IV-2), and it may indicate that decreasing of body weights in this study did not comprise of muscle mass changes. Precisely, under same daily food intake, the body weights of TAA treating rats were decreased due to liver-related metabolic dysfunction, the lipid tended to accumulate in liver (Table IV-2) rather than circulation system (Figure IV-2). Although OSM supplementation could attenuate those levels significantly, the lipid homeostasis was not rebuilt completely.

In many pharmacological cases, there were not dose-dependent. According to the results of this study (Table V-1), it seems to be dose-independent. Although results of OSMH may not effective as those of OSML, the hepatoprotective effects of it still presented compared to TAA group. Incidentally, OS was classified to “mild” herbal materials by Chinese ancient records, it means there may not be acute toxicity.





Table V-1. The hepatoprotective effects in different treatments


	TAA-induced	Hepatoprotective effects	
		OSML	OSMH
Body weight	Decreased	-	-
Liver size	Increased	●	-
Albumin	No change	-	-
Liver TG, TC	Increased	●	●
Serum TG, TC	Decreased	●	●
Serum AST	Increased	●	●
Serum ALT	Increased	●●	●
TBARS	Increased	●	●
GSH	No change	-	-
TEAC	Decreased	●	●
SOD, CAT, GPx	Decreased	●	●
IL-1 $\beta$ & TNF $\alpha$	Increased	●	●
HAI score	Increased	●	-
Fibrotic score	Increased	●●	●

Literatures reported that the metabolites of TAA can form a covalent binding to intracellular molecules such as membrane protein which causes nuclear stress, ER stress, mitochondria stress and oxidative stress (Pumford *et al.*, 1997; James *et al.*, 2003; Kaplowitz, 2004). Oxidative stress is defined as the exposures of the cell to an




excessive level of oxidants, free radicals, superoxide or hydroxyl radicals, which commonly refer to as reactive oxygen species (ROS). The major site of production of ROS is the mitochondria so the high oxidative stress affects many cellular functions and leads to severe adverse effects of target cells including lipid peroxidation and protein thiol oxidation (Dai *et al.*, 2014). The consequences of these effects are as following: 1) The covalent binding leads to membrane destruction of hepatic cell, and the target cells will go under necrosis (Singh and Handa, 1995) (Figure IV-4B), and then AST and ALT will release into outer space and diffused into blood with extracellular liquid (Figure IV-2A & B); 2) Because of irregular protein thiol oxidation, Golgi structure and ER stress, the production and delivery efficiency of apoprotein B, and low-density lipoprotein (VLDL) are decreased (Sabesin *et al.*, 1977), and causes lower serum lipids but higher liver lipid accumulation (Table IV-1 & Figure IV-2); 3) The lipid peroxidation by-products, i.e. MDA increase, while the quantity and activity of antioxidants and relative enzymes, respectively, decrease under the oxidative stress state (Sanz *et al.*, 1995; Dai *et al.*, 2005) (Table IV-2); 4) The mitochondria is also an important site of the cell death (Kaplowitz and Tsukamoto, 1996; Czaja, 2002). While TAA induces the ROS productions, the apoptotic messengers are activated indirectly to lead to hepatic parenchymal cells going under mitochondria-dependent apoptosis pathway (intrinsic pathway).

The study on hepatoprotection of OSM against carbon tetrachloride indicated decreases of serum AST and ALT values; meanwhile, increased anti-oxidative capabilities by OSM supplementation were also observed (Ko *et al.*, 2010). Several previous studies had proclaimed *Cordyceps sinensis* can inhibit the formation of MDA, delay the peroxidation of VLDL and reduce the accumulation of esterified cholesterol in microphage (Shin *et al.*, 2001; Tsai *et al.*, 2001; Wang *et al.*, 2004).



Although bioactive compounds are not the major concerns in this study, the OSM powder (TCM-808FB), which contains 10% polysaccharide and 0.25% adenosine (offered from TCM Biotech International Corp., Taipei, Taiwan). Adenosine was proved to inhibit the macrophage-origin cytokine production and reversed the immune reaction (Hasko *et al.*, 1996), which was similar to the hepatoprotective effect in results. Moreover, the previous research that hepatoprotection of polysaccharides extracted from *Lucium barbarum* against alcohol in rats was attributed to decreased serum lipid levels, oxidative stress, and liver damage (Cheng and Kong, 2011). Our previous studies also indicated that amelioration of noni juice on serum lipids, oxidative status, and inflammatory responses in high-cholesterol/fat dietary hamsters or alcohol-treated mice is related to the phytochemicals in noni juice (Lin *et al.*, 2012&2013; Chang *et al.*, 2013). In addition, Cordycepin modulated the NF $\kappa$ B activation and the expression of apoptotic proteins (Jeong *et al.*, 2010; Ren *et al.*, 2012). Ko *et al.*, (2010) indicated that OSM decreases of serum AST and ALT values in carbon tetrachloride treated rats; meanwhile, increased anti-oxidative capabilities were also observed. Several previous studies had proclaimed *Cordyceps sinensis* can inhibit the formation of MDA, delay the peroxidation of VLDL and reduce the accumulation of esterified cholesterol in macrophage (Shin *et al.*, 2001; Tsai *et al.*, 2001; Wang *et al.*, 2004).


The oxidative stress and cell death signals in direct damage are the trigger of many signal transductions such as fibrogenesis, immune response, inflammatory response etc. (Losser & Payen, 1996; Jaeschke *et al.*, 2002). The ROS which stimulated by injury and inflammation will directly activate hepatic stellate cells (Robino *et al.*, 2000), and then upregulate the expressions of fibrosis related genes (Parola and Robino, 2001; Bataller and Brenner, 2005; Novo *et al.*, 2006). The active HSCs are known as initiator of liver fibrosis because they are main secretors of ECM such as collagen, and in this study the



scoring of Metavir was the same as the expectation (Figure IV-3). It has been demonstrated that the mitochondria damage and lipid peroxidation stimulate Kupffer cells or adjacent sinusoidal endothelial cells to secrete cytokines, including TNF- $\alpha$  and IL-1 $\beta$ , the main cytokines in hepatotoxin related inflammation (Michie *et al.*, 1988; Holst *et al.*, 1996; Laskin and Laskin, 2001), which lead to severe inflammation (Shakibaei *et al.*, 2005) and apoptosis (Chou *et al.*, 1999; Meier and Silke, 2003) (Table IV-3), and the scoring of inflammation by HAI is also support the this estimation (Figure IV-4).

Crucial concern in this thesis is screening the molecular pathway for OSM-preventing effect of the liver fibrosis. As aforementioned, TGF- $\beta$  relative pathway is classic fibrotic signaling cascade in various tissues, and it is proved to be necessary factor in HSCs activation (Saile *et al.*, 2001; Liu *et al.*, 2003). Although the activation mechanism of TGF- $\beta$  may be tissue specific, but it is acceptable that pro- and activated-TGF- $\beta$  molecule are released from ECM via immune cells, such as T-cell, Kuffer cell, etc. (Annes *et al.*, 2003; Taylor, 2009). The OSM supplement could be effective to avoid the inflammation (Table IV-3; Figure IV-4), even though the type of immune cells are not identified respectively, so that it disrupts the downstream signal of TGF- $\beta$  (Figure IV-6) and attenuates the activation of HSCs (Figure IV-3, Figure IV-5, & Figure IV-7). Yang *et al.* (2008) proclaimed that HSCs were activated by ROS and calcium flux which is induced by TGF- $\beta$  signal cascade; meanwhile, OSM supplement also hold the antioxidative system obviously (Table IV-2) that could scavenge the ROS efficiently (Figure II-13), possibly, the modulation may be attributed to the phytosterol content (Wong *et al.*, 2013).

NF $\kappa$ B, a key player in inflammatory pathway, was found an apoptotic modulator in liver (Sonenshein, 1997). Although, the general function had been revealed, the specific



function in liver fibrosis is uncertain due to the complicated cell composition in liver. In fibroblast, NF $\kappa$ B is an upstream suppressor of apoptotic signal from extracellular TGF- $\beta$  through enhancing expression of Smad7 protein (Bitzer *et al.*, 2000). In the activated HSCs, the driving force of fibrogenesis, apoptotic signal from TGF- $\beta$  and TNF- $\alpha$  also involves the downstream NF $\kappa$ B (Saile *et al.*, 2001). In our data, the expression pattern of NF $\kappa$ B was changed in OSM supplement *in vivo* (Figure IV-8 & Figure IV-9), and the transcription pattern of downstream molecules (i.e., COX2, TNF- $\alpha$ , IL-1 $\beta$ ) are also similar (Table IV-3 & Figure IV-8), but it need *in vitro* data to further clarify the critical role of NF $\kappa$ B in different hepatic cells. Incidentally, the NF $\kappa$ B-related immuno-modulated ability of cordycepin may share the above bioactivity (Jeong *et al.*, 2010; Ren *et al.*, 2012).

Overall, inflammatory signal is highly influence progressing of liver fibrosis through TGF- $\beta$  pathway. Recently, many researches indicate that TLR4 signaling participates in chronic liver diseases including hepatic fibrosis (Soare *et al.*, 2010; Guo *et al.*, 2010). In addition, TLR4 signaling is upstream factor that affect the activation of NF $\kappa$ B, and Seki *et al.* (2007) proved it will mediate the regulation of TGF- $\beta$  pseudoreceptor in HSCs, so it is reasonable to involve this targeting beneficial effect. In this thesis, although the receptor is not responsive to TAA-intoxification in mRNA level, the downstream signals (i.e., TRIF, Akt) are decreased slightly (Figure IV-7). In spite of lacking of confirmation in protein level, it is difficult to ignore the connection between these two vital pathways.

## VI. Conclusion



According to the results from this study, the hepatoprotective effects of OSM against the TAA treatment are due to reducing hepatic lipid accumulation, increasing antioxidative capabilities, and decreasing hepatic cytokine secretion and collagen accumulation. All beneficial effect may involve the NF $\kappa$ B induction pathway including TGF- $\beta$  and TLR4 related pathway. In addition, not only observation of physiological values but also investigation of antioxidant and anti-inflammatory/anti-fibrotic mechanisms on OS mycelium against TAA induced liver fibrosis were indicated (Figure VI-1). Furthermore, we sincerely hope that the research frame in this study could offer future workers an original thinking and strategy of hepatoprotective researches.




Figure VI-1. Conclusive illustration for this study. In this study, it showed the evidences from bio-molecular signal cascade to pathophysiological events.






Figure IV-1. Body weight changes of experimental rats during the feeding period. The data are given as means + SEM (n=12). Different letters on data points in each feeding period indicate significant differences ( $p < 0.05$ ).



Table IV-1. Average food and water intakes, organ sizes, serum albumin and liver lipids

Parameter	Treatment			
	Control	TAA	OSML	OSMH
Food intake (g/rat/day)	26.77±0.69a	24.31±1.32a	24.81±0.73a	26.46±1.36a
Water intake (mL/rat/day)	54.29±1.94a	43.24±1.95b	45.51±1.57b	43.89±1.65b
Organ size (mg/100g BW)				
Heart	297.38±6.83a	311.47±9.80a	322.78±8.30a	316.82±9.66a
Liver	2459.16±61.59c	3093.84±76.10a	2855.06±48.00b	2914.79±107.01ab
Kidney	557.86±17.06c	654.01±19.27a	604.47±12.95bc	627.93±18.36ab
Serum albumin (g/dL)	4.00±0.10a	4.10±0.10a	4.10±0.10a	4.30±0.10a
Liver lipid (mg/g liver)				
Triglyceride	10.29±0.07b	11.56±0.29a	10.12±0.15b	10.06±0.28b
Cholesterol	2.44±0.07c	4.51±0.08a	2.76±0.11b	2.70±0.09b

\* The data are given as means ± SEM (n=12). Mean values with different letters in each testing parameter were significantly different ( $p < 0.05$ ).

Table IV-2. Antioxidative capacity and enzymatic activities of liver tissues

Parameter	Treatment			
	Control	TAA	OSML	OSMH
MDA (nmol/mg protein)	0.45±0.02c	2.38±0.04a	1.62±0.05b	1.63±0.06b
GSH (nmol/mg protein)	60.67±1.87a	60.55±1.62a	60.91±1.36a	63.44±1.37a
TEAC (nmol/mg protein)	100.18±3.11a	83.51±3.04b	108.87±3.66a	109.36±4.98a
SOD (unit/mg protein)	11.12±0.41b	4.35±0.09c	14.15±0.19a	10.64±0.26b
CAT (unit/mg protein)	19.72±0.39b	17.38±0.36c	20.83±0.43ab	20.97±0.38a
GPx (nmol NADPH oxidized/min/mg protein)	36.16±0.79a	23.54±0.54d	28.21±0.55c	30.71±0.59b

\* The data are given as means ± SEM (n=12). Mean values with different letters in each testing parameter were significantly different ( $p < 0.05$ ).





Figure IV-2. Serum triglyceride (A), cholesterol (B), AST (C), and ALT (D) levels of serum. The data are given as means  $\pm$  SEM (n=12). Different letters on data points in each feeding period indicate significant differences ( $p < 0.05$ ).

Table IV-3. Liver collagen and cytokine contents

Parameter	Treatment			
	Control	TAA	OSML	OSMH
<i>Cytokine (pg/mg protein)</i>				
Interleukin-1 $\beta$	3.28 $\pm$ 0.12b	5.03 $\pm$ 0.12a	3.68 $\pm$ 0.20b	3.73 $\pm$ 0.19b
Tumor necrosis factor- $\alpha$	18.40 $\pm$ 0.98c	26.00 $\pm$ 0.85a	22.72 $\pm$ 0.84b	22.02 $\pm$ 0.71b
<i>Liver collagen content (g/g liver)</i>				
	0.29 $\pm$ 0.14c	0.43 $\pm$ 0.01a	0.36 $\pm$ 0.01b	0.35 $\pm$ 0.01b

\* The data are given as means  $\pm$  SEM (n=12). Mean values with different letters in each testing parameter were significantly different ( $p < 0.05$ ).







Figure IV-3. Masson's trichrome staining for liver tissues. (A) The gross appearance of representative liver in animals. The scale is shown in 200 (100X) and 100 (200X)  $\mu\text{m}$ . CV is abbreviated names of central vein, and the black arrows were toward to the collagen fibers. (B) The score of liver fibrosis. Values were expressed as means  $\pm$  SEM.







Figure IV-4. HE staining for liver tissues. (A) The scale is shown in 200 (100X) and 100 (200X)  $\mu\text{m}$ . CV and P are abbreviated names of central vein and portal tracts; the black arrows and triangles are toward to inflammation area and necrotic cells. (B) The score of HAI values were expressed as mean  $\pm$  SEM.








Figure IV-5. Immunohistochemical analysis:  $\alpha$ SMA protein expression. The scale is shown in 100 (200X, first column in left hand) and 50  $\mu$ m (400X, second column), and the right one demonstrated the expression area (arrowhead) and cell type (circle in dotted line; long spindle shape). Slide was stained with primary antibody and hematoxylin. The positive are in brown color, which may indicate to myofibroblast-like cells.






Figure IV-6. TGF-β related gene expressions. mRNA expression of (A) TGF-β, (B) TGFBR1, and (C) TGFBR2 were detected by SYBR Green system . The data are given as means ± SEM (n=12). Different letters on data bars indicate significant differences ( $p < 0.05$ ).




Figure IV-7. TLR4 related gene expressions. mRNA expression of (A) TLR4, (B) TRIF, (C) MyD88, and (D) Akt were detected by SYBR Green system . The data are given as means  $\pm$  SEM (n=12). Different letters on data bars indicate significant differences ( $p < 0.05$ ).




Figure IV-8. Hepatic fibrosis related gene expressions. mRNA expression of (A)  $\alpha$ SMA, (B) Col1 $\alpha$ , (C) NF $\kappa$ B and (D) COX2 were detected by SYBR Green system. The data are given as means  $\pm$  SEM (n=12). Different letters on data bars indicate significant differences ( $p < 0.05$ ).








Figure IV-9. Pathway detection by Immunohistochemistry analysis: NFκB protein expression. The scale is shown in 100 (200X, first column in left hand) and 50 μm (400X, second column), and the right one demonstrated the expression area (arrowhead) and cell type (circle in dash-line; round with pig nuclei). NFκB is a key transcription factor of this study, and the entrance of nuclei means the activation of it.


## REFERENCE



- Adhirai, M. and Selvam, R. (1997). Protection of cyclosporin A-induced biochemical changes by vitamin E pretreatment in hyperoxaluric rat kidney. *Nutritional Biochemistry*, 8, 32-37.
- Ahn, Y. J., Park, S. J., Lee, S. G., Shin, S. C., & Choi, D. H. (2000). Cordycepin: selective growth inhibitor derived from liquid culture of *Cordyceps militaris* against *Clostridium* spp. *Journal of Agricultural and Food Chemistry*, 48, 2744-2748.
- Allen, K., Jaeschke, H., & Copple, B. L. (2011). Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. *American Journal of Pathology*, 178, 175-86.
- Ando, K., Moriyama, T., Guidotti, L. G., Wirth, S., Schreiber, R. D., Schlicht, H. J., Huang, S. N., & Chisari, F. V. (1993). Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. *Journal of Experimental Medicine*, 178, 1541-1554.
- Annes, J. P., Munger, J. S., & Rifkin, D. B. (2003). Making sense of latent TGF $\beta$  activation. *Journal of Cell Science*, 116, 217-224.
- Arai, C., Arai, N., Mizote, A., Kohno, K., Iwaki, K., Hanaya, T., Arai, S., Ushio, S., & Fukuda, S. (2010). Trehalose prevents adipocyte hypertrophy and mitigates insulin resistance. *Nutrition Research*, 30, 840-848.
- Arends, M. J., McGregor, A. H., & Wyllie, A. H. (1994). Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. *American Journal of Pathology*, 144, 1045-1057.
- Awad, A. B., Barta, S. L., Fink, C. S., & Bradford, P. G. (2008). Beta-sitosterol enhances tamoxifen effectiveness on breast cancer cells by affecting ceramide metabolism. *Molecular Nutrition & Food Research*, 52, 419-426.
- Awad, A. B., Chen, Y. C., Fink, C. S., & Hennessey, T. (1996). Beta-sitosterol inhibits HT-29 human colon cancer cell growth and alters membrane lipids. *Anticancer Research*, 16, 2797-2804.
- Bataller, R. and Brenner, D. A. (2005). Liver fibrosis. *Journal of Clinical Investigation*, 115, 209-218
- Bernardi, P., Petronilli, V., Di Lisa, F., & Forte, M. (2001). A mitochondrial perspective on cell death. *Trends in Biochemical Sciences*, 26, 112-117.


- 
- Berkeley M. J. (1843). On some entomogenous Sphaeriae. *London Journal of Botany*, 2, 205-211.
- Bizter, M., Gersdorff, G. V., Liang, D., Dominguez-Rosales, A., Beg, A. A., Rojkind, M., & Böttinger, E. P. (2000). A mechanism of suppression of TGF- $\beta$ /SMAD signaling by NF $\kappa$ B/RelA. *Genes & Development*, 14, 187-197.
- Boldyrev, A. A. (2009). Molecular mechanisms of homocysteine toxicity. *Biochemistry (Moscow)*, 74, 589-598.
- Bolsoni-Lopes, A., Festuccia, W. T., Farias, T. S. M., Chimin, P., Torres-Leal, F. L., Derogis, P. B. M., Andrade, P. B., Miyamoto, S., Lima, F. B., Curi, R., & Alonso-Vale, M. I. C. (2013). Palmitoleic acid (n-7) increases white adipocyte lipolysis and lipase content in a PPAR $\alpha$ -dependent manner. *American Journal of Physiology - Endocrinology and Metabolism*, 305, E1093-E1102.
- Bosy-Westphal, A., Ruschmeyer, M., Czech, N., Oehler, G., Hinrichsen, H., Plauth, M., Lotterer, E., Fleig, W., & Müller, M. J. (2003). Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. *American Journal of Clinical Nutrition*, 77, 1269-1277.
- Brandl, M., Seidler, B., Haller, F., Adamski, J., Schmid, R. M., Saur, D., & Schneider, G. (2013). IKK $\alpha$  controls canonical TGF $\beta$ -SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in Panc1 cells. *Journal of Cell Science*, 123, 4231-4239.
- Brennan, L., Shine, A., Hewage, C., Maithous, J. P., Brinkle, K. M., McClenaghan, N., Flatt, P. R., & Newsholme, P. (2002). Anuclear magnetic resonance-based demonstration of substantial oxidative L-alanine metabolism and L-alanine is important to the regulation of insulin secretion. *Diabetes*, 51, 1714-1721.
- Brookes, P. S., Yoon, Y., Robotham, J. L., Anders, M. W., & Sheu, S. S. (2004). Calcium, ATP, and ROS: a mitochondrial love-hate triangle. *American Journal of Physiology - Cell Physiology*, 287, C817-C833.
- Bruck, R., Aeed, H., Avni, Y., Shirin, H., Matas, Z., Shahmurov, M., Avinoach, I., Zozulya, G., Weizman, N., & Hochman, A. (2004). Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. *Journal of Hepatology*, 40, 86-93.
- Brunn, G. J., Bungum, M. K., Johnson, G. B., & Platt, J. L. (2005). Conditional signaling by Toll-like receptor 4. *FASEB Journal*, 19, 872-874.


- 
- Brunt, E. M. (2000). Grading and Staging the Histopathological Lesions of Chronic Hepatitis: The Knodell Histology Activity Index and Beyond. *Hepatology*, *31*, 241-246.
- Buenz, E. J., Bauer, B. A., Osmundaon, T. W., & Motley, T. J. (2005). The traditional Chinese medicine Cordyceps sinensis and its effects on apoptotic homeostasis. *Journal of Ethnopharmacology*, *96*, 19-29.
- Buenz, E. J., Weaver, J. G., Bauer, B. A., Chalpin, S. D., & Badley, A. D. (2004). Cordyceps sinensis extracts do not prevent Fas-receptor and hydrogen peroxide-induced T-cell apoptosis. *Journal of Ethnopharmacology*, *90*, 57-62.
- Cansev, M. (2006). Uridine and cytidine in the brain: Their transport and utilization. *Brain Research Reviews*, *52*, 389-397.
- Castillo, T., Koop, D. R., Kamimura, S., Triadafilopoulos, G., & Tsukamoto, H. (1992). Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid peroxidation. *Hepatology*, *16*, 992-996.
- Cha, J. Y., Ahn, H. Y., Cho, Y. S., & Je, J. Y. (2013). Protective effect of cordycepin-enriched Cordyceps militaris on alcoholic hepatotoxicity in Sprague-Dawley rats. *Food and Chemical Toxicology*, *60*, 52-57.
- Chan, C. C., Hwang, S. J., Lee, F. Y., Wang, S. S., Chang, F. Y., Li, C. P., Chu, C. J., Lu, R. H., & Lee, S. D. (1997). Prognostic value of plasma endotoxin levels in patients with cirrhosis. *Scandinavian Journal of Gastroenterology*, *32*, 942-946.
- Chang, Y. Y., Lin, Y. L., Yang, D. J., Liu, C. W., Hsu, C. L., Tzang, B. S., & Chen, Y. C. (2013). Hepatoprotection of noni juice against chronic alcohol consumption: lipid homeostasis, antioxidation, alcohol clearance, and anti-inflammation. *Journal of Agricultural and Food Chemistry*, *46*, 11016-11024.
- Chen, I. S., Chen, Y. C., Chou, C. H., Chuang, R. F., Sheen, L. Y. & Chiu, C. H. (2011). Hepatoprotection of silymarin against thioacetamide-induced chronic liver fibrosis. *Journal of the Science of Food and Agriculture*, *92*, 1441-1447.
- Chen, X., Sun, Z., Du, X., Liu, C., Liu, Y., & Wu, L. (2004). Study on the relationship between heat shock protein 70 and Toll like receptor-4 of monocytes. *Journal of Huazhong University Science and Technology*, *24*, 560-562.
- Cheng, D. and Kong, H. (2011). The effect of *Lycium barbarum* polysaccharide on alcohol-induced oxidative stress in rats. *Molecules*, *16*, 2542-2550.
- Cheung, J. K. H., Li, J., Cheung, A. W. H., Zhu, Y., Zheng, K. Y. Z., Bi, C. W. C.,


- 
- Duan, R., Choi, R. C., Lau, D. T., Dong, T. T., Lau, B. W., & Tsim, K. W. (2009). Cordysinocan, a polysaccharide isolated from cultured Cordyceps, activates immune responses in cultured T-lymphocytes and macrophages: Signaling cascade and induction of cytokines. *Journal of Ethnopharmacology*, *124*, 61-68.
- Chiang, D. J., Roychowdhury, S., Bush, K., McMullen, M. R., Pisano, S., Niese, K., Oلمان, M. A., Pritchard, M. T., & Nagy, L. E. (2013). Adenosine 2A Receptor Antagonist Prevented and Reversed Liver Fibrosis in a Mouse Model of Ethanol-Exacerbated Liver Fibrosis. *PLoS One*, *8*, e69114.
- Chilakapati, J., Shankar, K., Korrapati, M. C., Hill, R. A., & Mehendale, H. M. (2005). Saturation toxicokinetics of thioacetamide: role in initiation of liver injury. *Drug Metabolism and Disposition*, *33*, 1877-1885.
- Chitturi, S. and Farrell, G. C. (2001). Etiopathogenesis of nonalcoholic steatohepatitis. *Seminars in Liver Disease*, *21*, 27-41.
- Chiou, W. F., Chang, P. C., Chou, C. J., & Chen, C. F. (2000). Protein constituent contributes to the hypotensive and vasorelaxant activities of Cordyceps sinensis. *Life Sciences*, *66*, 1369-1376.
- Chiou, Y. L. and Lin, C. Y. (2012). The extract of Cordyceps sinensis inhibited airway inflammation by blocking NF- $\kappa$ B activity. *Inflammation*, *35*, 985-993.
- Choi, J. W., Yoo, B. K., Shin, C. Y., Ryn, M. K., Ryn, J. H., Kouni, M. H., Lee, J. C., Kim, W. K., & Ko, K. H. (2006). Uridine prevents the glucose deprivation-induced death of immunostimulated astrocytes via the action of uridine phosphorylase. *Neuroscience Research*, *56*, 111-118.
- Chou, J. J., Li, H., Salvesen, G. S., Yuan, J., & Wagner, G. (1999). Solution structure of BID, an intracellular amplifier of apoptotic signaling. *Cell*, *96*, 615-624.
- Cooper, R. and Chang, J. (2001). Asian herbals: opportunities for marketing traditional Chinese medicines in the west. *Journal of Nutraceuticals, Functional & Medical foods*, *3*, 25-37.
- Czaja, M. J. (2002). Induction and regulation of hepatocyte apoptosis by oxidative stress. *Antioxidants and Redox Signaling*, *4*, 759-767.
- Dai, D. F., Chiao, Y. A., Marcinek, D. J., Szeto, H. H., & Rabinovitch, P. S. (2014). Mitochondrial oxidative stress in aging and healthspan. *Longevity and Healthspan*, *3*, 6.
- Dai, K., Qi, J. Y., & Tian, D. Y. (2005). Leptin administration exacerbates





- thioacetamide-induced liver fibrosis in mice. *World Journal of Gastroenterology*, *11*, 4822-4826.
- Dal-Cim, T., Molz, S., Egea, J., Parada, E., Romero, A., Budni, J., Saavedra, M. D. M., Barrio, L. D., Tasca, C. I., & Lopez, M. (2012). Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxygenase-1 via PI3K/Akt/GSK-3 $\beta$  pathway. *Neurochemistry International*, *61*, 397-404.
- De Creus, A., Abe, M., Lau, A. H., Hackstein, H., Raimondi, G., & Thomson, A. W. (2005). Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin. *Journal of Immunology*, *174*, 2037-2045.
- De David, C., Rodrigues, G., Bona, S., Meurer, L., González-Gallego, J., Tuñón, M. J., & Marroni, N. P. (2011). Role of quercetin in preventing thioacetamide-induced liver injury in rats. *Toxicologic Pathology*, *39*, 949-957.
- Diez-Fernandez, C., Sanz, N., & Cascales, M. (1996). Intracellular calcium concentration impairment in hepatocytes from thioacetamide-treated rats. Implications for the activity of Ca(2+)-dependent enzymes. *Journal of Hepatology*, *24*, 460-467.
- Ding, J. W., Ning, Q., Liu, M. F., Lai, A., Leibowitz, J., Peltekian, K. M., Cole, E. H., Fung, L. S., Holloway, C., Marsden, P. A., Yeger, H., Phillips, M. J., & Levy, G. A. (1997). Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase. *Journal of Virology*, *71*, 9223-9230.
- Dong, C. H. and Yao, Y. J. (2008). In vitro evaluation of antioxidant activities of aqueous extracts from natural and cultured mycelia of *Cordyceps sinensis*. *LWT - Food Science and Technology*, *41*, 669-677.
- Dyroff, M. C. and Neal, R. A. (1981). Identification of the major protein adduct formed in rat liver after thioacetamide administration. *Cancer Research*, *41*, 3430-3435.
- Eguchi, S., Lilja, H., Hewitt, W. R., Middleton, Y., Demetriou, A. A., & Rozga, J. (1997). Loss and recovery of liver regeneration in rats with fulminant hepatic failure. *Journal of Surgical Research*, *72*, 112-122.
- Engelbrecht, T. N., Schroeter, A., Hauß, T., & Neubert, R. H. H. (2011). Lipophilic penetration enhancers and their impact to the bilayer structure of stratum corneum


- 
- lipid model membranes: neutron diffraction studies based on the example oleic acid. *Biochimica et Biophysica Acta*, 1808, 2798-2806.
- Evaldsson, C., Ryden, I., & Uppugunduri, S. (2007). Anti-inflammatory effects of exogenous uridine in an animal model of lung inflammation. *International Immunopharmacology*, 7, 1025-1032.
- Fracchia, K. M., Pai, C. Y., & Walsh, C. M. (2013). Modulation of T Cell Metabolism and Function through Calcium Signaling. *Frontiers in Immunology*, 4, 324.
- Friedman, S. L. (2008). Mechanisms of hepatic fibrogenesis. *Gastroenterology*, 134, 1655-69.
- Fullerton, M. D. and Steinberg, G. R. (2010). SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. *Diabetes*, 59, 551-553.
- Galloway, E., Shin, T., Huber, N., Eismann, T., Kuboki, S., Schuster, R., Blanchard, J., Wong, H. R., & Lentsch, A. B. (2008). Activation of hepatocytes by extracellular heat shock protein 72. *American Journal of Physiology - Cell Physiology*, 295, C514-C520.
- Gaspers, L. D. and Thomas, A. P. (2005). Calcium signaling in liver. *Cell Calcium*, 38, 329-342.
- Gentle, E. M., Shi, S., Daehn, I., Zhang, T., Qi, H., Yu, L., D'Agati, V. D., Schlondorff, D. O., & Bottinger, E. P. (2013). Epithelial cell TGF $\beta$  signaling induces acute tubular injury and interstitial inflammation. *Journal of American Society of Nephrology*, 24, 787-799.
- Gingery, A., Bradley, E. W., Pederson, L., Ruan, M., Horwood, N. J., & Oursler, M. J. (2008). TGF- $\beta$  coordinately activates TAK1/MEK/AKT/NF $\kappa$ B and SMAD pathways to promote osteoclast survival. *Experimental Cell Research*, 314, 2725-2738.
- Gokce, N. (2004). L-arginine and hypertension. *Journal of Nutrition*, 134, 2807S-2811S.
- Gong, H. Y., Wang, K. Q., & Tang, B. (2000). Effects of Cordyceps sinensis on T lymphocyte subsets and hepatofibrosis in patients with chronic hepatitis B. *Hunan Yi Ke Da Xue Xue Bao*, 25, 248-250.
- Grau, A. M., Datta, P. K., Zi, J., Halder, S. K., & Beauchamp, R. D. (2006). Role of Smad proteins in the regulation of NF- $\kappa$ B by TGF- $\beta$  in colon cancer cells. *Cellular Signalling*, 18, 1041-1050.
- Greenfield, J. R., Farooqi, I. S., Keogh, J. M., Henning, E., Habib, A. M., Blackwood,

- 
- A., Reimann, F., Holst, J. J., & Gribble, F. M. (2009). Oral glutamine increases circulation glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. *American Journal of Clinical Nutrition*, 89, 106-113.
- Guo, J. and Friedman, S.L. (2010). Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. *Fibrogenesis Tissue Repair*, 3, 21.
- Guo, P., Kai, Q., Gao, J., Lian, Z. Q., Wu, C. M., Wu, C. A., & Zhu, H. B. (2010). Cordycepin Prevents Hyperlipidemia in Hamsters Fed a High-Fat Diet via Activation of AMP-Activated Protein Kinase. *Journal of Pharmacological Sciences*, 113, 395-403.
- Guo, J. S. L. J., Zheng, F., Hong, F., Yea, S., Fugita, M., Tarocchi, M., Abar, O. T., Huang, H. J., Sninsky, J. J., & Friedman, S. L. (2009). Functional Linkage of Cirrhosis-Predictive Single Nucleotide Polymorphisms of Toll-like Receptor 4 to Hepatic Stellate Cell Responses. *Hepatology*, 49, 960-968.
- Hajovsky, H., Hu, G., Koen, Y., Sarma, D., Cui, W., Moore, D. S., Staudinger, J. L., & Hanzlik, R. P. (2012). Metabolism and toxicity of thioacetamide and thioacetamide S-oxide in rat hepatocytes. *Chemical Research in Toxicology*, 25, 1955-1963.
- Haskó, G., Szabo, C., Nemeth, Z. H., Kvetan, V., Pastores, S. M., & Vizi, E. S. (1996). Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. *Journal of Immunology*, 157, 4634-4640.
- He, Y., Zhou, J., Dou, K. F., & Chen, Y. (2003). A rat model for acute hepatic failure. *Hepatobiliary & Pancreatic Diseases International*, 2, 423-425.
- Henderson, N. C. and Iredale, J. P. (2007). Liver fibrosis: cellular mechanisms of progression and resolution. *Clinical Science*, 112, 265-280.
- Ho, C. J. S., Rydström, A., Trullsson, M., Bålfors, J., Storm, P., Puthia, M., Nadeem, A., & Svanborg, C. (2012). HAMLET: functional properties and therapeutic potential. *Future Oncology*, 8, 1301-1333.
- Hofer, B., Heiden, S., von Websky, K., Arafat, A. M., Rahnenfuhrer, J., Alter, M., Kalk, P., Ziegler, D., Fischer, Y., & Pfab, T. (2011). Renal effects of the novel selective adenosine A1 receptor blocker SLV329 in experimental liver cirrhosis in rats. *PLoS One*, 6, e17891.
- Holst, O., Ulmer, A. J., Brade, H., Flad, H. D., & Rietschel, E. T. (1996). Biochemistry

- 
- and cell biology of bacterial endotoxins. *FEMS Immunology and Medical Microbiology*, 16, 83-104.
- Hong, J. H. and Lee, I. S. (2009). Effects of *Artemisia capillaris* ethyl acetate fraction on oxidative stress and antioxidant enzyme in high-fat diet induced obese mice. *Chemico-Biological Interactions*, 179, 88-93.
- Houseknecht, K. L., Vanden Heuvel, J. P., Moya-Camarena, S. Y., Por-tocarrero, C. P., Peck, L. W., Nickel, K. P., & Belury, M. A. (1998). Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. *Biochemical and Biophysical Research Communications*, 244, 678-682.
- Hozumi, Y., Imaizumi, T., & Kondo, S. (1994). Effect of cyclosporin on hair-existing area of nude mice. *Journal of Dermatological Science*, 7, S33-S38.
- Hsieh, H. L., Wang, H. H., Wu, W. B., Chu, P. J., & Yang, C. M. (2010). Transforming growth factor- $\beta$ 1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK- NF- $\kappa$ B pathway. *Journal of Neuroinflammation*, 7, 88.
- Hsu, T. H., Shiao, L. H., Hsieh, C., & Chang, D. M. (2002). A comparison of the chemical composition and bioactive ingredients of the Chinese medicinal mushroom *DongChongXiaCao*, its counterfeit and mimic, and fermented mycelium of *Cordyceps sinensis*. *Food Chemistry*, 78, 463-469.
- Hua, J., Qiu de, K., Li, J. Q., Li, E. L., Chen, X. Y., & Peng, Y. S. (2007). Expression of Toll-like receptor 4 in rat liver during the course of carbon tetrachloride-induced liver injury. *Journal of Gastroenterology and Hepatology*, 22, 862-869.
- Huang, Y. L., Leu, S. F., Liu, B. C., Sheu, C. C., & Huang, B. M. (2004). In vivo stimulatory effect of *Cordyceps sinensis* mycelium and its fractions on reproductive functions in male mouse. *Life Sciences*, 75, 1051-1062.
- Hui, M. Y., Wang, B. S., Shiow, C.H., & Duh, P. D. (2006). Comparison of protective effects between cultured *Cordyceps militaris* and natural *Cordyceps sinensis* against oxidative damage. *Journal of Agricultural and Food Chemistry*, 54, 3132-3138.
- Hung, M. Y., Fu, T. Y., Shih, P. H., Lee, C. P. & Yen, G. C. (2006). *Du-Zhong* (*Eucommia ulmoides* Oliv.) leaves inhibits CCl<sub>4</sub>-induced hepatic damage in rats. *Food and Chemical Toxicology*, 44, 1424-1431.


- 
- Hutterer, F. E. Rubin, E., and Popper, H. (1964). Mechanism of Collagen Resorption in Reversible Hepatic Fibrosis. *Experimental and Molecular Pathology*, 86, 215-223.
- IARC (International Agency for Research on Cancer, World Health Organization). GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012, 2012. URL [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx?cancer=liver](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=liver). Accessed 15.06.14.
- Ikeda, M., Tsuru, S., Ohmori, T., Kitahara, S., Inouye, T., & Healy, G. B. (1993). CO-N reaction a new serological activity index on Wegener's granulomatosis. *Journal of Laryngology & Otolaryngology*, 107, 607-610.
- Inoue, N., Nagao, K., Hirata, J., Wang, Y. M., & Yanagita, T. (2004). Conjugated linoleic acid prevents the development of essential hypertension in spontaneously hypertensive rats. *Biochemical and Biophysical Research Communications*, 323, 679-684.
- Inoue, N., Nagao, K., Wang, Y. M., Noguchi, H., Shirouchi, B., & Yanagita, T. (2006). Dietary conjugated linoleic acid lowered tumor necrosis factor- $\alpha$  content and altered expression of genes related to lipid metabolism and insulin sensitivity in the skeletal muscle of Zucker rats. *Journal of Agriculture and Food Chemistry*, 54, 7935-7939.
- Ip, C., Chin, S. F., Scimeca, J. A., & Pariza, M. W. (1991). Mammary cancer prevention by conjugated dienoic derivatives of linoleic acid. *Cancer Research*, 51, 6118-6124.
- Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., & Leclercq, I. (2003). Central role of PPAR  $\alpha$ -dependent hepatic lipid turnover in dietary steatohepatitis in mice. *Hepatology*, 38, 123-132.
- Ip, C., Scimeca, J. A., & Thompson, H. J. (1994). Conjugated linoleic acid: a powerful anticarcinogen from animal fat sources. *Cancer*, 74, 1050-1054.
- Itagaki, H., Shimizu, K., Morikawa, S., Ogawa, K., & Ezaki, T. (2013). Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. *International Journal of Clinical and Experimental Pathology*, 6, 2683-2696.
- Jaeschke, H. (2002). Inflammation in response to hepatocellular apoptosis. *Hepatology*, 35, 964-966.

- 
- Jaeschke, H. (2006). Mechanisms of liver injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. *American Journal of Physiology*, 290, G1083-G1088.
- Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., & Lemasters, J. J. (2002). Mechanisms of hepatotoxicity. *Toxicological Sciences*, 65, 166-176.
- Jaeschke, H., Knight, T. R., & Bajt, M. L. (2003). The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. *Toxicology Letters*, 144, 279-288.
- James, L. P., Mayeux, P. R. & Hinson, J. A. (2003). Acetaminophen-induced hepatotoxicity. *Drug Metabolism and Disposition*, 31, 1499-1506.
- Jeong, J. W., Jin, C. Y., Kim, G. Y., Lee, J. D., Park, C., Kim, G. D., Kim, W. J., Jung, W. K., Seo, S. K., Choi, I. W., & Choi, Y. H. (2010). Anti-inflammatory effects of cordycepin via suppression of inflammatory mediators in BV2 microglial cells. *International Immunopharmacology*, 10, 1580-1586.
- Jiang, D., Liang, J., Fan, J., Yu, S., Chen, S., Luo, Y., Prestwich, G. D., Mascarenhas, M. M., Garg, H. G., Quinn, D. A., Homer, R.J., Goldstein, D. R., Bucala, R., Lee, P. J., Medzhitov, R., & Noble, P. W. (2005). Regulation of lung injury and repair by Toll-like receptors and hyaluronan. *Nature Medicine*, 11, 1173-1179.
- Jin, D. Q., Park, B. C., Lee, J. S., Choi, H. D., Lee, Y. S., Yang, J. H., & Kim, J. A. (2004). Mycelial extract of *Cordyceps ophioglossoides* prevents neuronal cell death and ameliorates beta-amyloid peptide-induced memory deficits in rats. *Biological & Pharmaceutical Bulletin*, 27, 1126-1129.
- Jorgacevic, B., Mladenovic, D., Ninkovic, M., Prokic, V., Stankovic, M., Aleksic, V., Cerovic, I., Vukicevic, R. J., Vucevic, D., Stankovic, M., & Radosavljevic, T. (2013). Dynamics of oxidative/nitrosative stress in mice with methionine-choline-deficient diet-induced nonalcoholic fatty liver disease. *Human & Experimental Toxicology*, 33, 701-709.
- Jung, E. C., Kim, K. D., Bae, C. H., Kim, J. C., Kim, D. K., & Kim, H. H. (2007). A mushroom lectin from ascomycete *Cordyceps militaris*. *Biochimica et Biophysica Acta*, 1770, 833-838.
- Jung, W. K., Seo, S. K., Choi, I. W., & Choi, Y. H. (2010). Anti-inflammatory effects of cordycepin via suppression of inflammatory mediators in BV2 microglial cells. *International Immunopharmacology*, 10, 1580-1586.

- 
- Kang, K. H., Qian, Z. J., Ryu, B., Kim, D., & Kim, S. K. (2012). Protective effects of protein hydrolysates from marine microalgae *Navicula incerta* on ethanol-induced toxicity in HepG2/CYP2E1 cells. *Food Chemistry*, *132*, 677-685.
- Kang, J. S., Wanibuchi, H., Morimura, K., Wongpoomchai, R., Chusiri, Y., Gonzalez, F. J., & Fukushima, S. (2008). Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. *Toxicology and Applied Pharmacology*, *228*, 295-300.
- Kaplowitz, N. (2002). Biochemical and cellular mechanisms of toxic liver injury. *Seminars in Liver Disease*, *22*, 137-144.
- Kaplowitz, N. (2004). Drug-induced liver injury. *Clinical Infectious Diseases*, *38*, S44-48.
- Kaplowitz, N. and Tsukamoto, H. (1996). Oxidative stress and liver disease. *Progress in Liver Disease*, *14*, 131-159.
- Kass, G. E. (2006). Mitochondrial involvement in drug-induced hepatic injury. *Chemico-Biological Interactions*, *163*, 145-159.
- Kennedy, E. M., and Weiss, S. B. (1956). The function of cytidine coenzymes in the biosynthesis of phospholipids. *Journal of Biological Chemistry*, *222*, 193-214.
- Kim, K. M., Kwon, Y. G., Chung, H. T., Yun, Y. G., Pae, H. O., Han, J. A., Ha, K. S., Kim, T. W., & Kim, Y. M. (2003). Methanol extract of *Cordyceps pruinosa* inhibits in vitro and in vivo inflammatory mediators by suppressing NF-kappaB activation. *Toxicology and Applied Pharmacology*, *190*, 1-8.
- Kireev, R., Bitoun, S., Cuesta, S., Tejerina, A., Ibarrola, C., Moreno, E., Vara, E., & Tresguerres, J. A. (2013). Melatonin treatment protects liver of Zucker rats after ischemia/reperfusion by diminishing oxidative stress and apoptosis. *European Journal of Pharmacology*, *701*, 185-193.
- Kneifel, H., Konig, W. A., Loeffler, W., & Muller, R. (1977). Ophiocordin, an antifungal antibiotic of *Cordyceps ophioglossoides*. *Archives of Microbiology*, *113*, 121-130.
- Ko, W. S., Hsu, S. L., Chyau, C. C., Chen, K. C., & Peng, R. Y. (2010). Compound *Cordyceps* TCM-700C exhibits potent hepatoprotective capability in animal model. *Fitoterapia*, *81*, 1-7.
- Koba, K. and Yanagita, T. (2013). Health benefits of conjugated linoleic acid (CLA). *Obesity Research & Clinical Practice*,


<http://dx.doi.org/10.1016/j.orcp.2013.10.001>.


- Kobayashi, H., Hirabayashi, Y., Murakami, H., & Ueda, T. (2009). Anti-obesity effects of amino acid in high-fat diet induced obese mice. *Journal of the federation of American Societies for Experimental Biology*, *23*, 227-231.
- Koek, G. H., Liedorp, P. R., & Bast, A. (2011). The role of oxidative stress in non-alcoholic steatohepatitis. *Clinica Chimica Acta*, *412*, 1297-1305.
- Kosters, A. and Karpen, S. J. (2010). The role of inflammation in cholestasis: clinical and basic aspects. *Seminars in Liver Disease*, *30*, 186-194.
- Köhler, C., Gogvadze, V., Håkansson, A., Svanborg, C., Orrenius, S., & Zhivotovsky, B. (2001). A folding variant of human  $\alpha$ -lactalbumin induces mitochondrial permeability transition in isolated mitochondria. *European Journal of Biochemistry*, *268*, 186-191.
- Kubo, E., Yoshikawa, N., Kunitomo, M., Kagota, S., Shinozuka, K., & Nakamura, K. (2010). Inhibitory effect of *Cordyceps sinensis* on experimental hepatic metastasis of melanoma by suppressing tumor cell invasion. *Anticancer Research*, *30*, 3429-3433.
- Kuo, C. F., Chen, C. C., Luo, Y. H., Huang, R. Y., Chuang, W. J., Sheu, C. C., & Lin, Y. S. (2005). *Cordyceps sinensis* mycelium protects mice from group a streptococcal infection. *Journal of Medical Microbiology*, *54*, 795-802.
- Kumar, R., Negi, P.S., Singh, B., Ilavazhagan, G., Bhargava, K., & Sethy, N. K. (2011). *Cordyceps sinensis* promotes exercise endurance capacity of rats by activating skeletal muscle metabolic regulators. *Journal of Ethnopharmacology*, *136*, 260-266.
- Laleman, W., Vander Elst, I., Zeegers, M., Servaes, R., Libbrecht, L., Roskams, T., Fevery, J., & Nevens, F. (2006). A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. *European Journal of Clinical Investigation*, *36*, 242-249.
- Laskin, D. L. and Laskin, J. D. (2001). Role of macrophages and inflammatory mediators in chemically induced toxicity. *Toxicology*, *160*, 111-118.
- Lee, S. Y., Debnath, T., Kim, S. K., & Lim, B. O. (2013). Anti-cancer effect and apoptosis induction of cordycepin through DR3 pathway in the human colonic cancer cell HT-29. *Food and Chemical Toxicology*, *60*, 439-447.
- Lee, Y. and Friedman, S. L. (2010). Fibrosis in the liver: acute protection and chronic








- disease. *Progress in Molecular Biology and Translational Science*, 97, 151-200.
- Lee, J. Y., Sohn, K. H., Rhee, S. H., & Hwang, D. (2001). Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. *Journal of Biological Chemistry*, 276, 16683-16689.
- Lee, B., Park, J. B., Park, J. H., Shin, H. J., Kwon, S., Yeom, M. J., Sur, B. J., Kim, S. H., Kim, M. H., Lee, H. J., Yoon, S. H., & Hahm, D. H. (2011). Cordyceps *militaris* improves neurite outgrowth in Neuro2A cells and reverses memory impairment in rats. *Food Science and Biotechnology*, 20, 1599-1608.
- Leist, M., Single, B., Castoldi, A. F., Kühnle, S., & Nicotera, P. (1997). Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. *Journal of Experimental Medicine*, 185, 1481-1486.
- Ledda-Columbano, G. M., Coni, P., Curto, M., Giacomini, L., Faa, G., Oliverio, S., Piacentini, M., & Columbano, A. (1991). Induction of two different modes of cell death, apoptosis and necrosis, in rat liver after a single dose of thioacetamide. *American Journal of Pathology*, 139, 1099-1109.
- Li, S. P., Zhang, G. H., Zeng, Q., Huang, Z. G., Wang, Y. T., Dong, T. T. X., & Tsim, K. W. K. (2006). Hypoglycemic activity of polysaccharide, with antioxidation, isolated from cultured Cordyceps mycelia. *Phytomedicine*, 13, 428-433.
- Li, Y., Wang, X. L., Jiao, L., Jiang, Y., Li, H., Jiang, S. P., Lhosumtseiring, N., Fu, S. Z., Dong, C. H., Zhan, Y., & Yao, Y. J. (2011). A Survey of the geographic distribution of *Ophiocordyceps sinensis*. *Microbiological Society of Korea*, 49, 913-919.
- Lin, Y. W. and Chiang, B. H. (2008). Anti-tumor activity of the fermentation broth of *Cordyceps militaris* cultured in the medium of *Radix astragali*. *Process Biochemistry*, 43, 244-250.
- Lin, Y. L., Chou, C. H., Yang, D. J., Chen, J. W., Tzang, B. S., & Chen, Y. C. (2012). Hypolipidemic and antioxidative effects of noni (*Morinda citrifolia* L.) juice on high-fat/cholesterol-dietary hamsters. *Plant Foods for Human Nutrition*, 67, 294-302.
- Lin, Y. L., Chang, Y. Y., Yang, D. J., Tzang, B. S., & Chen, Y. C. (2013). Beneficial effects of noni (*Morinda citrifolia* L.) juice on livers of high-fat dietary hamsters. *Food Chemistry*, 140, 31-38.
- Lin, C. Y., Ku, F. M., Kuo, Y. C., Chen, C. F., Chen, W. P., Chen, A., & Shiao, M. S.


- 
- (1999). Inhibition of activated human mesangial cell proliferation by the natural product of *Cordyceps sinensis* (H1-1): an implication for treatment of IGA mesangial nephropathy. *Journal of Laboratory and Clinical Medicine*, 133, 55-63.
- Liu, C., Gaca, M. D. A., Swenson, E. S., Vellucci, V. F., Reiss, M., & Wells, R. G. (2003). Smads 2 and 3 are differentially activated by transforming growth factor- $\beta$  (TGF- $\beta$ ) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF- $\beta$  independent. *Journal of Biological Chemistry*, 278, 11721-11728.
- Liu, Z., Li, P., Zhao, D., Tang, H., & Guo, J. (2011). Anti-inflammation effects of *Cordyceps sinensis* mycelium in focal cerebral ischemic injury rats. *Inflammation*, 34, 639-644.
- Liu, Y. K. and Shen, W. (2003). Inhibitive effect of *Cordyceps sinensis* on experimental hepatic fibrosis and its possible mechanism. *World Journal of Gastroenterology*, 9, 529-533.
- Ljubuncic, P., Song, H., Cogan, U., Azaizeh, H., & Bomzon, A. (2005). The effects of aqueous extracts prepared from the leaves of *Pistacia lentiscus* in experimental liver disease. *Journal of Ethnopharmacology*, 100, 198-204.
- Lo, H. C., Hsu, T. H., Tu, S. T., & Lin, K. C. (2006). Anti-hyperglycemic activity of natural and fermented *Cordyceps sinensis* in rats with diabetes induced by nicotinamide and streptozotocin. *American Journal of Chinese Medicine*, 5, 819-832.
- Losser, M. R. and Payen, D. (1996). Mechanism of liver damage. *Seminars in Liver Disease*, 16, 357-367.
- Makino, H., Togo, S., Kubota, T., Morioka, D., Morita, T., Kobayashi, T., Tanaka, K., Shimizu, T., Matsuo, K., Nagashima, Y., & Shimada, H. (2005). A good model of hepatic failure after excessive hepatectomy in mice. *Journal of Surgical Research*, 127, 171-176
- Manabe, N., Azuma, Y., Sugimoto, M., Uchio, K., Miyamoto, M., Taketomo, N., Tsuchita, H., & Miyamoto, H. (2000). Effects of the mycelial extract of cultured *Cordyceps sinensis* on in vivo hepatic energy metabolism and blood flow in dietary hypoferric anaemic mice. *British Journal of Nutrition*, 83, 197-204.
- Manabe, N., Sugimoto, M., Azuma, Y., Taketomo, N., Yamashita, A., Tsuboi, H., Tsunoo, A., Kinjo, N., Nian-Lai, H., & Miyamoto, H. (1996). Effects of the mycelial extract


- 
- of cultured *Cordyceps sinensis* on in vivo hepatic energy metabolism in the mouse. *Japanese Journal of Pharmacology*, 70, 85-88.
- Mangipudy, R. S., Chanda, S., & Mehendale, H. M. (1995). Tissue repair response as a function of dose in thioacetamide hepatotoxicity. *Environmental Health Perspectives*, 103, 260-267.
- Mann, F. C. (1921). Studies in the physiology of the liver: I. Technique and general effects of removal. *The American Journal of the Medical Sciences*, 161, 37-42.
- Maris, M., Waelkens, E., Cnop, M., D'Hertog, W., Cunha, D. A., Korf, H., Koike, T., Overbergh, L., & Mathieu, C. (2011). Oleate-induced beta cell dysfunction and apoptosis: a proteomic approach to glucolipotoxicity by an unsaturated fatty acid. *Journal of Proteome Research*, 10, 3372-3385.
- Meier, P. and Silke, J. (2003). Programmed cell death: Superman meets Dr Death. *Nat The Journal of Cell Biology*, 5, 1035-1038.
- Meimei, H., Dejin, M., Erzhen, C., Minmin, S., Songyao, J., Jianfang, L., & Hao, C. (2014). Inhibiting the Toll-Like Receptor 4 Toll/Interleukin-1 Receptor Domain Protects Against Hepatic Warm Ischemia and Reperfusion Injury in Mice. *Critical Care Medicine*, 42, e123-e131.
- Melton, A. C., Soon, R. K. Jr., Park, J. G., Martinez, L., Dehart, G. W., & Yee, H. F. Jr. (2007). Focal adhesion disassembly is an essential early event in hepatic stellate cell chemotaxis. *American Journal of Physiology*, 293, G1272-G128
- Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., & Wilmore, D. W. (1988). Detection of circulating tumor necrosis factor after endotoxin administration. *New England Journal of Medicine*, 318, 1481-1486.
- MOHW (Department of Statistics, Ministry of Health and Welfare, R.O.C.). The statistics analysis of cause of death in 2012, 2013. URL [http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f\\_list\\_no=312&fod\\_list\\_no=2747](http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2747). Accessed 21.12.13. [Chinese]
- Mossberg, A. K., Mok, K. H., Morozova-Roche, L. A., & Svanborg, C. (2010). Structure and function of human  $\alpha$ -lactalbumin made lethal to tumor cells (HAMLET)-type complexes. *FEBS Journal*, 277, 4614-4625.
- Moya-Camarena, S. Y., Vanden Heuvel, J. P., Blanchard, S. G., Leesnitzer, L. A., & Belury, M. A. (1999). Conjugated linoleic acid is a potent naturally occurring ligand

- 
- and activator of PPAR. *Journal of Lipid Research*, *40*, 1426-1433.
- Mu, Y. P., Ogawa, T., & Kawada, N. (2010). Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine-choline-deficient diet. *Laboratory Investigation*, *90*, 245-256.
- Mueller, A. S., Bosse, A. C., Most, E., Klomann, S. D., Schneider, S., & Pallauf, J. (2009). Regulation of the insulin antagonistic protein tyrosine phosphatase 1B by dietary Se studied in growing rats. *Journal of Nutritional Biochemistry*, *20*, 235-247.
- Mueller, W. E. G., Weiler, B. E., Charubala, R., Pfleiderer, W., Leserman, L., Sobol, R. W., Suhadolnik, R. J., & Schroeder, H. C. (1991). Cordycepin analogs of 2',5'-oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase. *Biochemistry*, *30*, 2027-2033.
- Nakamura, H., Nakamura, K., & Yodoi, J. (1997). Redox regulation of cellular activation. *Annual Review of Immunology*, *15*, 351-369.
- Nakayasu, H., Ota, K., Tanaka, H., Irie, H., & Takahashi, K. (1990). Suppression of actively induced and passively transferred experimental allergic neuritis by cyclosporin A. *Journal of Neuroimmunology*, *26*, 219-27.
- Nakazawa, K., Ijima, H., Fukuda, J., Sakiyama, R., Yamashita, Y., Shimada, M., Shirabe, K., Tsujita, E., Sugimachi, K., & Funatsu, K. (2002). Development of a hybrid artificial liver using polyurethane foam/hepatocyte spheroid culture in a preclinical pig experiment. *International Journal of Artificial Organs*, *25*, 51-60.
- Nan, J. X., Park, E. J., Yang, B. K., Song, C. H., Ko, G., & Sohn, D. H. (2001). Antifibrotic effect of extracellular biopolymer from submerged mycelial cultures of *Cordyceps militaris* on liver fibrosis induced by bile duct ligation and scission in rats. *Archives of Pharmacal Research*, *24*, 327-332.
- Natarajan, S. K., Basivireddy, J., Ramachandran, A., Thomas, S., Ramamoorthy, P., Pulimood, A. B., Jacob, M., & Balasubramanian, K. A. (2006). Renal damage in experimentally-induced cirrhosis in rats: Role of oxygen free radicals. *Hepatology*, *43*, 1248-1256.
- National Toxicology Program, 2000. Report on Carcinogens, ninth ed., Department of Health and Human Service.
- Newsome, P. N., Plevris, J. N., Nelson, L. J., & Hayes, P. C. (2000). Animal models of fulminant hepatic failure: a critical evaluation. *Liver Transplantation*, *6*, 21-31.

- 
- Niazy, E. M., (1997). Influence of oleic-acid and other permeation promoters on transdermal delivery of dihydroergotamine through rabbit skin. *International Journal of Pharmaceutics*, 67, 97-100.
- Nicotera, P. and Melino, G. (2004). Regulation of the apoptosis/necrosis switch. *Oncogene*, 23, 2757-2765.
- Novo, E., Marra, F., Zamara, E., Valfre di Bonzo, L., Caligiuri, A., Cannito, S., Antonaci, C., Colombatto, S., Pinzani, M., & Parola, M. (2006). Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. *Gut*, 55, 90-97.
- O'Brien, K. M., Allen, K. M., Rockwell, C. E., Towery, K., Luyendyk, J. P., & Copple, B. L. (2013). IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis. *American Journal of Pathology*, 183, 1498-507.
- Ohashi, K., Burkart, V., Flohe, S., & Kolb, H. (2000). Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll like receptor-4 complex. *Journal of Immunology*, 164, 558-561.
- Ohmori, T., Tamura, K., Tsuru, S., & Nomoto, K. (1986). Antitumor activity of protein-bound polysaccharide from *Cordyceps ophioglossoides* in mice. *Japanese Journal of Cancer Research*, 77, 1256-1263.
- Okamura, Y., Watari, M., Jerud, E. S., Young, D. W., Ishizaka, S. T., Rose, J., Chow, J. C., & Strauss, J. F. (2001). The extra domain A of fibronectin activates Toll-like receptor 4. *Journal of Biological Chemistry*, 276, 10229-10233.
- Okuyama, H., Nakamura, H., Shimahara, Y., Araya, S., Kawada, N., Yamaoka, Y., & Yodoi, J. (2003). Overexpression of thioredoxin prevents acute hepatitis caused by thioacetamide or lipopolysaccharide in mice. *Hepatology*, 37, 1015-1025.
- Okuyama, H., Son, A., Ahsan, M. K., Masutani, H., Nakamura, H., & Yodoi, J. (2008). Thioredoxin and thioredoxin binding protein 2 in the liver. *IUBMB Life*, 60, 656-60.
- Oleskovicz, S. P. B., Martins, W. C., Leal, R. B., & Tasca, C. I. (2008). Mechanism of guanosine-induced neuroprotection in rat hippocampal slices submitted to oxygen-glucose deprivation. *Neurochemistry International*, 52, 411-418.
- Olsson, R. A. and Pearson, J. D. (1990). Cardiovascular purinoceptors. *Physiological Reviews*, 70, 761-845.
- Orrenius, S., Zhivotovsky, B., & Nicotera, P. (2003). Regulation of cell death: the


- 
- calcium-apoptosis link. *Nature Reviews Molecular Cell Biology*, 4, 552-565.
- Pan, M. M., Zhang, M. H., Ni, H. F., Chen, J. F., Xu, M., & Phillips, A. O. (2013). Inhibition of TGF- $\beta$ 1/Smad signal pathway is involved in the effect of Cordyceps sinensis against renal fibrosis in 5/6 nephrectomy rats. *Food and Chemical Toxicology*, 58, 487-494.
- Paik, Y. H., Schwabe, R. F., Bataller, R., Russo, M. P., Jobin, C., & Brenner, D. A. (2003). Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. *Hepatology*, 37, 1043-1055.
- Pallottini, V., Martini, C., Bassi, A. M., Romano, P., Nanni, G., & Trentalance, A. (2006). Rat HMGCoA reductase activation in thioacetamide-induced liver injury is related to an increased reactive oxygen species content. *Journal of Hepatology*, 44, 368-374.
- Pan, M. M., Zhang, M. H., Ni, H. F., Chen, J. F., Xu, M., & Phillips, A. O. (2013). Inhibition of TGF- $\beta$ 1/Smad signal pathway is involved in the effect of Cordyceps sinensis against renal fibrosis in 5/6 nephrectomy rats. *Food and Chemical Toxicology*, 58, 487-494.
- Pariza, M. W., Park, Y., & Cook, M. E. (2001). The biologically active isomers of conjugated linoleic acid. *Progress in Lipid Research*, 40, 283-298.
- Park, J. S., Svetkauskaite, D., He, Q., Kim, J. Y., Strassheim, D., Ishizaka, A., & Abraham, E. (2004). Involvement of Toll like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. *Journal of Biological Chemistry*, 279, 7370-7377.
- Park, Y., Albright, K. J., Liu, W., Strokson, J. M., Cook, M. E., & Pariza, M. W. (1997). Effect of conjugated linoleic acid on body composition in mice. *Lipids*, 32, 853-858.
- Parola, M. and Robino, G. (2001). Oxidative stress-related molecules and liver fibrosis. *Journal of Hepatology*, 35, 297-306.
- Peng, J. H., Li, X. M., Feng, Q., Chen, L. L., Xu, L., & Hu, Y. Y. (2013). Anti-fibrotic effect of Cordyceps sinensis polysaccharide: inhibiting HSC activation, TGF- $\beta$ 1/Smad signalling, MMPs and TIMPs. *Experimental Biology and Medicine*, 238, 668-677.
- Pérez, M. J., Suárez, A., Gómez-Capilla, J. A., Sánchez-Medina, F., & Gil, A. (2002). Dietary nucleotide supplementation reduces thioacetamide-induced liver fibrosis in


- 
- rats. *Journal of Nutrition*, 132, 652-657.
- Pooler, A. M., Guez, D. H., Benedictus, R., & Wurtman, R. J. (2005). Uridine enhances neurite outgrowth in nerve growth factor-differentiated pheochromocytoma cells. *Neuroscience*, 134, 207-214.
- Popvic, P. J., Zeh, H. J., & Ochoa, J. B. (2007). Arginine and immunity. *The Journal of Nutrition*, 137, 1681S-1686S.
- Porter, W. R., Gudzinowicz, M. J., & Neal, R. A. (1979). Thioacetamide-induced hepatic necrosis. II. Pharmacokinetics of thioacetamide and thioacetamide-S-oxide in the rat. *Journal of Pharmacology and Experimental Therapeutics*, 208, 386-391.
- Porter, W. R. and Neal, R. A. (1978). Metabolism of thioacetamide and thioacetamide S-oxide by rat liver microsomes. *Drug Metabolism and Disposition*, 6, 379-388.
- Poulsen, L., Siersbaek, M., & Mandrup, S. (2012). PPARs: fatty acid sensors controlling metabolism. *Seminars in Cell & Developmental Biology*, 23, 631-639.
- Povero, D., Busletta, C., Novo, E., di Bonzo, L. V., Cannito, S., Paternostro, C., & Parola, M. (2010). Liver fibrosis: a dynamic and potentially reversible process. *Histology and Histopathology*, 25, 1075-1091.
- Proskuryakov, S. Y., Konoplyannikov, A.G., & Gabai, V. L. (2003). Necrosis: a specific form of programmed cell death. *Experimental Cell Research*, 283, 1-16.
- Pumford, N. R., Halmes, N. C., & Hinson, J. A. (1997). Covalent binding of xenobiotics to specific proteins in the liver. *Drug Metabolism Reviews*, 29, 39-57.
- Qi, W., Zhang, Y., Yan, Y. B., Lei, W., Wu, Z. X., Liu, N., Liu, S., Shi, L., & Fan, Y. (*In press*). The protective effect of cordymin, a peptide purified from the medicinal mushroom *Cordyceps sinensis*, on diabetic osteopenia in alloxan-induced diabetic rats. *Evidence-Based Complementary and Alternative Medicine*, <http://dx.doi.org/10.1155/2013/985636>.
- Rahman, T. M. and Hodgson, H. J. (2000). Animal models of acute hepatic failure. *International Journal of Experimental Pathology*, 81, 145-157.
- Ramesh, T., Yoo, S. K., Kim, S. W., Hwang, S. Y., Sohn, S. H., Kim, I. W., & Kim, S. K. (2012). Cordycepin (3'-deoxyadenosine) attenuates age-related oxidative stress and ameliorates antioxidant capacity in rats. *Experimental Gerontology*, 47, 979-987.
- Reddy, J. K. and Rao, M. S. (2006). Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. *American Journal of Physiology*.


- 
- Gastrointestinal and Liver Physiology*, 290, G852-858.
- Reddy, G. K. and Enwemeka, C. S. (1996). A simplified method for the analysis of hydroxyproline in biological tissues. *Clinical Biochemistry*, 29, 225-229.
- Ren, Z., Cui, J., Huo, Z., Xue, J., Cui, H. C., Luo, B., Jiang, L., & Yang, R. (2012). Cordycepin suppresses TNF- $\alpha$ -induced NF- $\kappa$ B activation by reducing p65 transcriptional activity, inhibiting I $\kappa$ B $\alpha$  phosphorylation, and blocking IKK $\gamma$  ubiquitination. *International Immunopharmacology*, 14, 698-703.
- Rinella, M. E. and Green, R. M. (2004). The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. *Journal of Hepatology*, 40, 47-51.
- Rinella, M. E., Elias, M. S., Smolak, R. R., Fu, T., Borensztajn, J., & Green, R. M. (2008). Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. *Journal of Lipid Research*, 49, 1068-1076.
- Robino, G., Parola, M., Marra, F., Caligiuri, A., De Franco, R. M., Zamara, E., Bellomo, G., Gentilini, P., Pinzani, M., & Dianzani, M. U. (2000). Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor. Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells. *Journal of Biological Chemistry*, 275, 40561-40567.
- Rodríguez-Navarro, J. A., Rodríguez, J., Casarejos, M. J., Solano, R. M., Gómez, A., Perucho, J., Cuervo, A. M., Yébenes, J. G., & Mena, M. A. (2010). Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. *Neurobiology of Disease*, 39, 423-438.
- Russo, A., Cardile, V., Piovano, M., Caggia, S., Espinoza, C. L., & Garbarino, J. A. (2010). Pro-apoptotic activity of ergosterol peroxide and (22E)-ergosta-7,22-dien-5 $\alpha$ -hydroxy-3,6-dione in human prostate cancer cells. *Chemico-Biological Interactions*, 184, 352-358.
- Sabesin, S. M., Frase, S., & Ragland, J. B. (1977). Accumulation of nascent lipoproteins in rat hepatic golgi during induction of fatty liver by orotic acid. *Laboratory Investigation*, 37, 127-135.
- Saccardo, P. A. (1878). Enumeratio Pyrenomycetum Hypocreaceorum hucusque cognitorum systemate carpologico dispositurum. *Michelia*, 1, 277-325.
- Saiga, A., Tanabe, S., & Nishimura, T. (2003). Antioxidant activity of peptides obtained from porcine myofibrillar proteins by protease treatment. *Journal of Agricultural*





- and Food Chemistry*, 51, 3661-3667.
- Saile, B., Matthes, N., Armouche, H. E., Neubauer, K., & Ramadori, G. (2001). The bcl, NFκB and p53/p21<sup>WAF1</sup> systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-β or TNF-α on activated hepatic stellate cells. *European Journal of Cell Biology*, 80, 554-561.
- Sakai, H., Park, S. S., & Kikkawa, Y. (1992). Differential oxidase activity of hepatic and pulmonary microsomal cytochrome P-450 isozymes after treatment with cytochrome P-450 inducers. *Biochemical and Biophysical Research Communications*, 187, 1262-1269.
- Salama, S. M., Abdulla, M. A., AlRashdi, A. S., & Hadi, A. H. A. (2013). Mechanism of hepatoprotective effect of *Boesenbergia rotunda* in thioacetamide-induced liver damage in rats. *Evidence-Based Complementary and Alternative Medicine*, doi: 10.1155/2013/157456. (有頁碼??，沒有頁碼為什麼有年份??)
- Sánchez-Campos, S., Alvarez, M., Culebras, J. M., Gonzalez-Gallego, J., & Tuñón, M. J. (2004). Pathogenic molecular mechanisms in an animal model of fulminant hepatic failure: rabbit hemorrhagic viral disease. *Journal of Laboratory and Clinical Medicine*, 144, 215-222.
- Sanz, N., Diez-Fernandez, C., Fernandez-Simon, L., Alvarez, A., & Cascales, M. (1995). Relationship between antioxidant systems, intracellular thiols and DNA ploidy in liver of rats during experimental cirrhogenesis. *Carcinogenesis*, 16, 1585-1593.
- Sanz, N., Diez-Fernandez, C., Andres, D., & Cascales, M. (2002). Hepatotoxicity and aging: endogenous antioxidant systems in hepatocytes from 2-, 6-, 12-, 18- and 30-month-old rats following a necrogenic dose of thioacetamide, *Biochimica et Biophysica Acta*, 1587, 12-20.
- Schupp, M. and Lazar, M. A. (2010). Endogenous ligands for nuclear receptors: digging deeper. *Journal of Biological Chemistry*, 285, 40409-40415.
- Schuppan, D. and Afdhal, N. H. (2008). Liver cirrhosis, *Lancet*, 371, 838-851.
- Schuppan, D., Ruehl, M., Somasundaram, R., & Hahn, E. G. (2001). Matrix as a modulator of hepatic fibrogenesis. *Seminars in Liver Disease*, 21, 351-372.
- Schuppan, D., Schmid, M., Somasundaram, R., Ackermann, R., Ruehl, M., Nakamura, T., & Riecken, E. O. (1998). Collagens in the liver extracellular matrix bind hepatocyte growth factor. *Gastroenterology*, 114, 139-152.
- Schwabe, R. F., Seki, E., & Brenner, D. A. (2006). Toll-like receptor signaling in the


- 
- liver. *Gastroenterology*, *130*, 1886-1900.
- Scott, M. J. and Billiar, T. R. (2008). Beta2-integrin-induced p38 MAPK activation is a key mediator in the CD14/TLR4/MD2-dependent uptake of lipopolysaccharide by hepatocytes. *Journal of Biological Chemistry*, *283*, 29433-29446.
- Scott, M. J., Liu, S., Shapiro, R. A., Vodovotz, Y., & Billiar, T. R. (2009). Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1-dependent mechanism. *Hepatology*, *49*, 1695-1708.
- Seki, E., De Minicis, S., Osterreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nature Medicine*, *13*, 1324-1332.
- Shakibaei, M., Schulze-Tanzil, G., Takada, Y., & Aggarwal, B. B. (2005). Redox regulation of apoptosis by members of the TNF superfamily. *Antioxid Redox Signal*, *7*, 482-496.
- Sharma, S. (2004). Trade of *Cordyceps sinensis* from high altitudes of the Indian Himalaya: conservation and biotechnological priorities. *Current Science*, *86*, 1614-1619.
- Shashidhar, M. G., Giridhar, P., Sankar, K. U., & Manohar, B. (2013). Bioactive principles from *Cordyceps sinensis*: a potent food supplement - a review. *Journal of Functional Foods*, *5*, 1013-1030.
- Sheng, L., Chen, J. P., Li, J., & Zhang, W. Y. (2011). An exopolysaccharide from cultivated *Cordyceps sinensis* and its effects on cytokine expressions of immunocytes. *Applied Biochemistry and Biotechnology*, *163*, 669-678.
- Shin, K. H., Lim, S. S., Lee, S. H., Lee, Y. S., & Cho, S. Y. (2001). Antioxidant and immunostimulating activities of the fruiting bodies of *Paecilomyces japonica*, a new type of *Cordyceps* sp. *Annals of the New York Academy of Sciences*, *928*, 261-273.
- Shirai, M., Arakawa, S., Miida, H., Matsuyama, T., Kinoshita, J., Makino, T., Kai, K., & Teranishi, M. (2013). Thioacetamide-induced Hepatocellular Necrosis Is Attenuated in Diet-induced Obese Mice. *Journal of Toxicologic Pathology*, *26*, 175-186.
- Shryock, J. C. and Belardinelli, L. (1997). Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. *American Journal of Cardiology*, *79*, 2-10.
- Singh, A. and Handa, S. S. (1995). Hepatoprotective activity of *Apium graveolens* and

- 
- Hygrophila auriculata against paracetamol and thioacetamide intoxication in rats. *Journal of Ethnopharmacology*, 49, 119-126.
- Slater, T. F. (1981). Activation of carbon tetrachloride: chemical principles and biological significance. In D. C. H. McBrien, T. F. Slater (Eds.), *Free Radicals, Lipid Peroxidation and Cancer* (pp. 243-270). London: Academic Press.
- Smiley, S. T., King, J. A., & Hancock, W. W. (2001). Fibrinogen stimulates macrophage chemokine secretion through Toll like receptor 4. *Journal of Immunology*, 167, 2887-2894.
- Soares, J. B., Pimentel-Nunes, P., Roncon-Albuquerque, R., & Leite-Moreira, A. (2010). The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. *Hepatology International*, 4, 659-672.
- Soares, F. A., Schmidt, A. P., Farina, M., Frizzo, E. S., Tavares, R. G., Portela, L. V. C., Lara, D. R., & Souza, D. O. (2004). Anticonvulsant effect of GMP depends on its conversion to guanosine. *Brain Research*, 1005, 182-186.
- Sone, Y., Reiko, O., Noriko, W., Etsu, K., & Akira, M. (1985). Structures and antitumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. *Agricultural and Biological Chemistry*, 49, 2641-2653.
- Sonenshein, G. E. (1997). Rel/NF-kappaB transcription factors and the control of apoptosis. *Seminars in Cancer Biology*, 8, 113-119.
- Spolaore, B., Pinato, O., Canton, M., Zamboni, M., Polverino de Laureto, P., & Fontana, A. (2010).  $\alpha$ -Lactalbumin forms with oleic acid a high molecular weight complex displaying cytotoxic activity. *Biochemistry*, 49, 8658-8667.
- Sriwijitkamol, A., Ivy, J. L., Christ-Roberts, C., DeFronzo, R. A., Mandarino, L. J., & Musi, N. (2006). LKB1-AMPK signaling in muscle from obese insulin-resistant Zucker rats and effects of training. *American Journal of Physiology - Endocrinology and Metabolism*, 290, E925-E932.
- Stewart, J. M. and Blakely, J. A. (2000). Long chain fatty acids inhibit and medium chain fatty acids activate mammalian cardiac hexokinase. *Biochimica et Biophysica Acta*, 1484, 278-286.
- Sung, G. H., Hywel-Jones, N. L., Sung, J. M., Luangsaard, J. J., Shrestha, B., & Spatafora, J. W. (2007). Phylogenetic classification of Cordyceps and the clavicipitaceous fungi. *Studies in Mycology*, 57, 5-59.

- 
- Tanaka, T., Katsuma, S., Adachi, T., Koshimizu, T. A., Hirasawa, A., & Tsujimoto, G. (2008). Free fatty acids induce cholecystokinin secretion through GPR120. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 377, 523-527.
- Taylor, A. W. (2009). Review of the activation of TGF- $\beta$  in immunity. *Journal of Leukocyte Biology*, 85, 29-33.
- Taylor, K. R., Trowbridge, J. M., Rudisill, J. A., Termeer, C. C., Simon, J. C., & Gallo, R. L. (2004). Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. *Journal of Biological Chemistry*, 279, 17079-17084.
- Terblanche, J. and Hickman, R. (1991). Animal models of fulminant hepatic failure. *Digestive Diseases and Sciences*, 36, 770-774.
- Trinder, P. (1969). Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. *Annals of clinical Biochemistry*, 6, 24-27.
- Trulsson, M., Yu, H., Gisselsson, L., Chao, Y., Urbano, A., Aits, S., Mossberg, A. K., & Svanborg, C. (2011). HAMLET binding to  $\alpha$ -actinin facilitates tumor cell detachment. *PLoS One*, 6, e17179.
- Tsai, C. H., Stern, A., Chiou, J. F., Chern, C. L., & Liu, T. Z. (2001). Rapid and specific detection of hydroxyl radical using an ultraweak chemiluminescence analyzer and a low-level chemiluminescence emitter: application to hydroxyl radical-scavenging ability of aqueous extracts of food constituents. *Journal of Agricultural and Food Chemistry*, 49, 2137-2141.
- Túnez, I., Muñoz, M. C., Villavicencio, M. A., Medina, F. J., de Prado, E. P., Espejo, I., Barcos, M., Salcedo, M., Feijóo, M., & Montilla, P. (2005). Hepato- and neurotoxicity induced by thioacetamide: protective effects of melatonin and dimethylsulfoxide. *Pharmacological Research*, 52, 223-228.
- Tuñón, M. J., San Miguel, B., Crespo, I., Jorquera, F., Santamaría, E., Alvarez, M., Prieto, J., & González-Gallego, J. (2011). Melatonin attenuates apoptotic liver damage in fulminant hepatic failure induced by the rabbit hemorrhagic disease virus. *Journal of Pineal Research*, 50, 38-45.
- Tuñón, M. J., Alvarez, M., Culebras, J. M., & González-Gallego, J. (2009). An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure. *World Journal of Gastroenterology*, 15, 3086-3098.
- Tuñón, M. J., Sanchez-Campos, S., Garcia-Ferreras, J., Alvarez, M., Jorquera, F., & Gonzalez-Gallego, J. (2003). Rabbit hemorrhagic viral disease: characterization of

- 
- a new animal model of fulminant liver failure. *Journal of Laboratory and Clinical Medicine*, 141, 272-278.
- Valerio, M. S., Minderman, H., Mace, T., & Awad, A. B. (2013).  $\beta$ -Sitosterol modulates TLR4 receptor expression and intracellular MyD88-dependent pathway activation in J774A.1 murine macrophages. *Cellular Immunology*, 285, 76-83.
- Van de Kerkhove, M. P., Hoekstra, R., van Gulik, T. M., & Chamuleau, R. A. (2004). Large animal models of fulminant hepatic failure in artificial and bioartificial liver support research. *Biomaterials*, 25, 1613-1625.
- Van Golen, R. F., van Gulik, T. M., & Heger, M. (2012). The sterile immune response during hepatic ischemia/reperfusion. *Cytokine and Growth Factor Reviews*, 23, 69-84.
- Van Golen, R. F., Reiniers, M. J., Olthof, P. B., van Gulik, T. M., & Heger, M. (2013). Sterile inflammation in hepatic ischemia/reperfusion injury: present concepts and potential therapeutics. *Journal of Gastroenterology and Hepatology*, 28, 394-400.
- Vinadé, E. R., Izquierdo, I., Lara, D. R., Schmidt, A. P., & Souza, D. O. (2004). Oral administration of guanosine impairs inhibitory avoidance performance in rats and mice. *Neurobiology of Learning and Memory*, 81, 137-143.
- Wang, J., Liu, Y. M., Cao, W., Yao, K. W., Liu, Z. Q., & Guo, J. Y. (2012). Anti-inflammation and antioxidant effect of Cordymin, a peptide purified from the medicinal mushroom *Cordyceps sinensis*, in middle cerebral artery occlusion-induced focal cerebral ischemia in rats. *Metabolic Brain Disease*, 27, 159-165.
- Wang, Y. H., Ye, J., Li, C. L., Cai, S. Q., Ishizaki, M., & Katada, M. (2004). An experimental study on anti-aging action of Cordyceps extract. *Zhongguo Zhong Yao Za Zhi*, 29, 773-776.
- Wang, Y. M., Nagao, K., Inoue, N., Ujino, Y., Shimada, Y., Nagao, T., Iwata, T., Kamegai, T., Yamauchi-Sato, Y., & Yanagita, T. (2006). Isomer-specific anti-obese and hypolipidemic properties of conjugated linoleic acid in obese OLETF rats. *Bioscience, Biotechnology, and Biochemistry*, 70, 355-362.
- Wang, L., Pooler, A. M., Albrecht, M. A., & Wurtman, R. J. (2005). Dietary uridine-5'-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats. *Journal of Molecular Neuroscience*, 27, 137-145.

- 
- Wang, X. L. and Yao, Y. J. (2011). Host insect species of *Ophiocordyceps sinensis*: a review. *ZooKeys*, 127, 43-59.
- Wani, A. A., Ramzan, A. U., Nizami, F., Malik, N. K., Kirmani, A. R., Bhatt, A. R., & Singh, S. (2008). Controversy in use of mannitol in head injury. *Indian Journal of Neurotrauma*, 5, 11-13.
- Water, N. J., Waterfield, C. J., Farrant, R. D., Holmes, E., & Nicholson, J. K. (2005). Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. *Chemical Research in Toxicology*, 18, 639-654.
- Weber, L. W., Boll, M., & Stampfl, A. (2003). Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. *Critical Reviews in Toxicology*, 33, 105-136.
- Wells, R. G. (2008). The role of matrix stiffness in regulating cell behavior. *Hepatology*, 47, 1394-1400.
- Wiest, R. and Garcia-Tsao, G. (2005). Bacterial translocation (BT) in cirrhosis. *Hepatology*, 41, 422-433.
- Wilson, J.E. (2003). Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. *Journal of Experimental Biology*, 206, 2049-2057.
- Witzmann, F. A., Fultz, C. D., Mangipudy, R. S., & Mehendale, H. M. (1996). Two dimensional electrophoretic analysis of compartment-specific hepatic protein charge modification induced by thioacetamide exposure in rats. *Fundamental and Applied Toxicology: Official Journal of the Society of Toxicology*, 31, 124-132.
- Wong, H. S., Chen, N., Leong, P. K., & Ko, K. M. (2013).  $\beta$ -sitosterol enhances cellular glutathione redox cycling by reactive oxygen species generated from mitochondrial respiration: protection against oxidant injury in h9c2 cells and rat hearts. *Phytotherapy Research*, 28, 999-1006
- Wu, Z. L., Wang, X. X., & Cheng, W. Y. (2000). Inhibitory effect of *Cordyceps sinensis* and *Cordyceps militaris* on human glomerular mesangial cell proliferation induced by native LDL. *Cell Biochemistry and Function*, 18, 93-97.
- Wu, C., Guo, Y., Su, Y., Zhang, X., Luan, H., Zhang, X., Zhu, H., He, H., Wang, X., Sun, G., Sun, X., Guo, P., & Zhu, P. (2014). Cordycepin activates AMP-activated protein kinase (AMPK) via interaction with the  $\gamma$ 1 subunit. *Journal of Cellular and Molecular Medicine*, 18, 293-304.

- 
- Xiao, J., Li, X., Min, X., & Sakaguchi, E. (2013). Mannitol improves absorption and retention of calcium and magnesium in growing rats. *Nutrition*, 29, 325-331.
- Yamaguchi, Y., Kagota, S., Nakamura, K., Shinozuka, K., & Kunitomo, M., (2000). Inhibitory effects of water extracts from fruiting bodies of cultured *Cordyceps sinensis* on raised serum lipid peroxide levels and aortic cholesterol deposition in atherosclerotic mice. *Phytotherapy Research*, 14, 650-652.
- Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X. X., Pandey, S. K., Bhanot, S., Monia, B. P., Li, Y. X., & Diehl, A. M. (2007). Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. *Hepatology*. 45, 1366-1374.
- Yan, X. F., Zhang, Z. M., Yao, H. Y., Guan, Y., Zhu, J. P., Zhang, L. H., Jia, Y. L., & Wang, R. W. (2013). Cardiovascular protection and antioxidant activity of the extracts from the mycelia of *Cordyceps sinensis* act partially via adenosine receptors. *Phytotherapy Research*, 27, 1597-1604.
- Yang, D. J., Chang, Y. Y., Hsu, C. L., Liu, C. W., Lin, Y. L., Lin, Y. H., Liu, K. C., & Chen, Y. C. (2010). Antiobesity and hypolipidemic effects of polyphenol-rich longan (*Dimocarpus longans* Lour.) flower water extract in hypercaloric-dietary rats. *Journal of Agricultural and Food Chemistry*, 58, 2020-2027.
- Yang, F. Q., Feng, K., Zhao, J., & Li, S. P. (2009a). Analysis of sterols and fatty acids in natural and cultured *Cordyceps* by one-step derivatization followed with gas chromatography-mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis*, 49, 1172-1178.
- Yang, F. Q. and Li, S. P. (2008). Effects of sample preparation methods on the quantification of nucleosides in natural and cultured *Cordyceps*. *Journal of Pharmaceutical and Biomedical Analysis*, 48, 231-235.
- Yang, K. L., Chang, W. T., Chuang, C. C., Hung, K. C., & Li, E. I. C. (2008). Antagonizing TGF- $\beta$ -induced liver fibrosis by a retinoic acid derivative through regulation of ROS and calcium influx. *Biochemical and Biophysical Research Communications*, 365, 484-489.
- Yang, Z. H., Takeo, J., & Katayama, M. (2013). Oral administration of omega-7 palmitoleic acid induces satiety and the release of appetite-related hormones in male rats. *Appetite*, 65, 1-7.
- Yang, S. F., Tseng, J. K., Chang, Y. Y., & Chen, Y. C. (2009b). Flaxseed oil attenuates

- nonalcoholic fatty liver of hyperlipidemic hamsters. *Journal of Agricultural and Food Chemistry*, 57, 5078-5083.
- Yang, C., Zeisberg, M., Mosterman, B., Sudhakar, A., Yerramalla, U., Holthaus, K., Xu, L., Eng, F., Afdhal, N., & Kalluri, R. (2003). Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. *Gastroenterology*, 124, 147-159.
- Yang, J., Zhang, W., Shi, P., Chen, J., Han, X., & Wang, Y. (2005). Effects of exopolysaccharide fraction (EPSF) from a cultivated *Cordyceps sinensis* fungus on c-Myc, c-Fos, and VEGF expression in B16 melanoma-bearing mice. *Pathology - Research and Practice*, 201, 745-750.
- Yogalakshmi, B., Viswanathan, P., & Anuradha, C. V. (2010). Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats. *Toxicology*, 268, 204-212.
- Young, M.K., Su, M.C., Jee, H.K., Jae, H.L., Yeon, A.L., Seung, J.L., & Min, W.L. (2001). Hypoglycemic effect of *Cordyceps militaris*. *Korean Journal of Pharmacognosy*, 32, 327-329.
- Yu, R., Song, L., Zhao, Y., Bin, W., Wang, L., Zhang, H., Wu, Y., Ye, W., & Yao, X. (2004). Isolation and biological properties of polysaccharide CPS-1 from cultured *Cordyceps militaris*. *Fitoterapia*, 75, 465-472.
- Yu, R. M., Yang, W., Song, L., Yan, C. Y., Zhang, Z., & Zhao, Y. (2007). Structural characterization and antioxidant activity of a polysaccharide from the fruiting bodies of cultured *Cordyceps militaris*. *Carbohydrate Polymers*, 70, 430-436.
- Yu, F., Lu, S., Yu, F., Shi, J., McGuire, P. M., & Wang, R. (2008). Cytotoxic activity of an octadecenoic acid extract from *Euphorbia kansui* (Euphorbiaceae) on human tumour cell strains. *Journal of Pharmacy and Pharmacology*, 60, 253-259.
- Yue, K., Ye, M., Zhou, Z., Sun, W., & Lin, X. (2012). The genus *Cordyceps*: a chemical and pharmacological review. *Pharmacy and Pharmacology*, 65, 474-493.
- Ytrebø, L. M., Nedredal, G. I., Langbakk, B., & Revhaug, A. (2002). An experimental large animal model for the assessment of bioartificial liver support systems in fulminant hepatic failure. *Scandinavian Journal of Gastroenterology*, 37, 1077-1088.
- Zarembek, K. A. and Godowski, P. J. (2002). Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in



response to microbes, their products, and cytokines. *Journal of Immunology*, 168, 554-561.

Zeisel, S. H., Costa, K. D., Franklin, P. D., Alexander, E. A., Lamont, J. T., Sheard, N. F., & Beiser, A. (1991). Choline, an essential nutrient for humans. *FASEB Journal*, 5, 2093-2098.

Zhang, W., Yang, J., Chen, J., Hou, Y., & Han, X. (2005). Immunomodulatory and antitumour effects of an exopolysaccharide fraction from cultivated *Cordyceps sinensis* (Chinese caterpillar fungus) on tumour-bearing mice. *Biotechnology and Applied Biochemistry*, 42, 9-15.
















Zhao, J., Xie, J., Wang, L. Y., & Li, S. P. (2013). Advanced development in chemical analysis of *Cordyceps*. *Journal of Pharmaceutical and Biomedical Analysis*, <http://dx.doi.org/10.1016/j.jpba.2013.04.025>.

Zhu, R., Zheng, R., Deng, Y., Chen, Y., & Zhang, S. (2014). Ergosterol peroxide from *Cordyceps cicadae* ameliorates TGF-1-induced activation of kidney fibroblasts. *Phytomedicine*, 21, 372-378.



## APPENDIX

Supplement 1. List of major chemicals and their structures found in OS (Zhao *et al.*, 2013)


No.	Structure	No.	Structure	No.	Structure			
<b>Nucleosides, bases and their analogues</b>								
1		Adenine	2		Cytosine	3-4		Guanine: R=NH <sub>2</sub> ; Hypoxanthine: R=H
5-6		Thymine: R=CH <sub>3</sub> ; Uracil: R=H	7-9		Uridine: R <sub>1</sub> =OH, R <sub>2</sub> =OH; 2'-deoxyuridine: R <sub>1</sub> =OH, R <sub>2</sub> =H; 3'-deoxyuridine: R <sub>1</sub> =H, R <sub>2</sub> =OH	10		Cytidine
11		Thymidine	12		Uridine-5' -monophosphate	13-15		Inosine: R <sub>1</sub> =H, R <sub>2</sub> =H; Guanosine: R <sub>1</sub> =NH <sub>2</sub> , R <sub>2</sub> =H; Guanosine-5' -monophosphate: R <sub>1</sub> =NH <sub>2</sub> , R <sub>2</sub> =HPO <sub>3</sub> <sup>-</sup>
16-19		Adenosine: R <sub>1</sub> =OH, R <sub>2</sub> =OH; 2'-deoxyadenosine: R <sub>1</sub> =OH, R <sub>2</sub> =H; 3'-deoxyadenosine: R <sub>1</sub> =H, R <sub>2</sub> =OH; 3'-amino-3' -deoxyadenosine: R <sub>1</sub> =NH <sub>2</sub> , R <sub>2</sub> =OH	20-21		N <sup>6</sup> -hydroxyethyl -adenosine: R=CH <sub>2</sub> OH N <sup>6</sup> -methyladenosine: R=CH <sub>3</sub>	22-23		Adenosine-5' -monophosphate: R=HPO <sub>3</sub> <sup>-</sup> ; O <sup>3</sup> -acetyl cordycepin: R=COCH <sub>3</sub>
24		3'-homocitrullyl-amino-3'-deoxyadenosine	25		N <sup>6</sup> -[β-(acetylcarmoyloxy)ethyl] adenosine	26		Ophicordin



**No. Structure**


**Sterols and their analogues**

1-2




Ergosterol: R=H  
Ergosteryl-3-O-β-D-glucopyranoside: R=glu

7




Ergosta-4,6,8(14),22-tetraen-3-one (ergone)

10




5α, 8α-epidioxy-22E-ergosta-6,9(11),22-trien-3β-ol

13



Ergosterol peroxide


16-17



Campesterol: R<sub>1</sub>=CH<sub>3</sub>, R<sub>2</sub>=H  
Dihydrobrassicasterol: R<sub>1</sub>=H, R<sub>2</sub>=CH<sub>3</sub>


**No. Structure**

3-4




β-sitosterol: R=H  
Daucosterol: R=Glu

8




5α,6α-epoxy-24(R)-methylcholesta-7,22-dien-3β-ol

11




5α,6α-epoxy-5α-ergosta-7,22-dien-3β-ol

14



Ergosta-7,22-diene-3,5,6-triol


18-19



5,8-epidioxyergosta-6,22-dien-3-ol : R=H  
5,8-epidioxyergosta-6,22-dien-3-O-β-D-glucopyranoside: R=glu


**No. Structure**

5-6




Cholesterol: R=H  
Cholesteryl palmitate: R=CO(CH<sub>2</sub>)<sub>14</sub>CH<sub>3</sub>

9




22-dihydroergosteryl-3-O-β-D-glucopyranoside

12





δ-3-Ergosterol


15



5,6-epoxyergosta-7,22-dien-3-ol

No.	Structure
<b>Carbohydrates</b>	
1	 <p>Cordycepic acid: Mannitol</p>
4	SCP-I: (1→4)- $\alpha$ -D-glucan backbone
7	WIPS: (1→4)- $\alpha$ -D-Glcp backbone
10	EPS-1A: (1→6)- $\alpha$ -D-glucose and (1→6)- $\alpha$ -D-mannose backbone
13	CPS-2: (1→4)- $\alpha$ -D-glucose and (1→3)- $\alpha$ -D-mannose backbone
16	CBP-1: (1→4)- $\alpha$ -D-mannose backbone
19	P70-1: (1→6)- $\beta$ -D-mannopyranosyl backbone
22	CT-4N: (1→6) - and (1→2)- $\alpha$ -D-mannopyranosyl backbone
25	CPS-2: Unknown
28	CI-P, CI-A: (1→6)- $\alpha$ -D-mannose backbone
31	CS-F10: $\alpha$ -D-glucopyranosyl backbone
34	PCB I: 1, 4-mannopyranosyl
37	CPSN: (1→2)-D-mannopyran

No.	Structure
2	 <p>Glucose</p>
5	CPS : (1→4)- and (1→3)- $\alpha$ -D-glucan backbone
8	AIPS: Linear D-glucans with a backbone of (1→4)- $\alpha$ -D-Glcp (>60%).
11	CBHP: (1→4)- and (1→3)- $\alpha$ -D-Glcp backbone
14	CPMN Fr III: $\beta$ -(1→6)-galactoglucomannan.
17	CPS1: (1→2) and (1→4)-mannose, (1→3)-galactose and (1→) and (1→3, 6)-glucose backbone
20	Mannoglucan: (1→4)- and (1→3)- $\alpha$ -D-glucan backbone
23	CMB: (1→6)-Man, (1→6)-Glc, (1→4)-Glc and (1→4)-Gal backbone
26	CPS-3: $\alpha$ -D-glucan
29	C-3: (1→2)- and (1→6) - $\alpha$ -D- mannopyranosyl backbone
32	PCA I: 1,4-mannopyranosyl backbone
35	PCB II: Unknown
38	EPS: (1→3)- $\beta$ -D-glucan backbone






No.	Structure
3	 <p>Trehalose</p>
6	CPS50-I: (1→3)-xylose and (1→2)-mannose and galactose backbone
9	AEPS-1: (1→3)- $\alpha$ -D-Glcp backbone
12	O-linked heterogalactomannans: $\alpha$ -(1→6)-mannose backbone.
15	CM-hs-CPS2: $\alpha$ -glucan.
18	CS-Pp: 1, 3- $\beta$ -D-glucan backbone
21	APS: $\alpha$ -(1→, →5) - $\alpha$ -(1→, →4)-Galp-(1→ and →4)-GalAp-(1→ backbone
24	CPS-1: (1→2) mannose, (1→4) xylose and (1→2) or (1→3) galactose backbone
27	CO-1: (1→3)- $\beta$ -D-glucopyranosyl backbone
30	EPS: $\beta$ -D-glucan backbone
33	PCA II: Nonlinear linked heterogeneous oligosaccharide
36	CS- I: 1, 2-D-mannofuranosyl











No.	Structure
<b>Miscellaneous</b>	
1-2	<p>Cordyheptapeptide A: R=OH Cordyheptapeptide B: R=H</p>
6-8	<p>Cyclo-(L-glycyl-L-prolyl): R=H Cyclo-(L-leucyl-L-prolyl): R=CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub> Cyclo-(L-valyl-L-prolyl): R=CH(CH<sub>3</sub>)<sub>2</sub></p>
19-21	<p>(C) (E) (F)</p> <p>Cepharosporolides C-F</p>
27	<p>Putrescine</p>
30	<p>Cadaverine</p>

No.	Structure
3-4	<p>Cicadpeptin I: R<sub>1</sub>=CH, R<sub>2</sub>=H Cicadpeptin II: R<sub>1</sub>=H, R<sub>2</sub>=CH<sub>3</sub></p>
9-13	<p>Cordycedipeptide A: R<sub>1</sub>=CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, R<sub>2</sub>=CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>; Cyclo-(L-threonyl-L-leucyl): R<sub>1</sub>=CH(OH)CH<sub>3</sub>, R<sub>2</sub>=CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>; Cyclo-(L-alacyl-L-leucyl): R<sub>1</sub>=CH<sub>3</sub>, R<sub>2</sub>=CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>; Cyclo-(L-alacyl-L-valyl): R<sub>1</sub>=CH<sub>3</sub>, R<sub>2</sub>=CH(CH<sub>3</sub>)<sub>2</sub>; 3,6-di(4-hydroxy)benzyl-2,5-dioxopiperazine: R<sub>1</sub>=R<sub>2</sub>=4-hydroxybenzyl</p>
22-24	<p>10-membered macrolides 1: R<sub>1</sub>=H R<sub>2</sub>=OMe; 10-membered macrolides 2: R<sub>1</sub>=OMe R<sub>2</sub>=H; 10-membered macrolides 3: R<sub>1</sub>=H R<sub>2</sub>=OH</p>
28	<p>Spermine</p>
31	<p>Cordymin: The N-terminal sequence is AMAPPYGYRTPDAAQ</p>

No.	Structure
5	<p>Cyclosporin</p>
14-18	<p>(A) (B) (C) (D) (E)</p> <p>Cordysinins A-E</p>
25-26	<p>Cordyanhydride A Cordyanhydride B</p>
29	<p>1,3-diaminopropane</p>
32	<p>γ-aminobutyric acid</p>

No.	Structure
60	 <p>2-carboxymethyl-4-(3'-hydroxybutyl)-furan</p>
63	 <p>Cerebroside B</p>
66	 <p>Pyridine-2,6-dicarboxylic acid</p>
70	 <p>Cordypyridones A</p>
73	 <p>1-deoxo-cordytropolone</p>

No.	Structure
61	 <p>Caffeine</p>
64	 <p>7,8-dimethyl-iso-alloxazine</p>
67-68	 <p>Monomers 1: R=H Monomers 2: R=OH</p>
71	 <p>Cordypyridones B</p>
74	Fatty acids and their esters

No.	Structure
62	 <p>N-(2'-hydroxy-tetracosanoyl)-2-amino-1,3,4-trihydroxy-octadec-8E-ene</p>
65	 <p>D-allol</p>
69	 <p>4-(2-hydroxyethyl) phenol</p>
72	 <p>Cordypyridones C: R=H Cordypyridones D: R=OH</p>
75	Amino acids